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Controlled drug delivery has become a research focus in view of many of the drawbacks of 
conventional drug delivery including increased biodistribution and lack of target specificity, 
resulting side effects, and thus decreased patient compliance. Controlled delivery is the 
sustained administration of therapeutic agents, keeping dosage fluctuations within the 
therapeutic window. Controlled drug delivery relies on the design and modification of 
specialised drug delivery systems (DDS) for encapsulating and delivering therapeutic 
agents. Biodegradable polymers have been exploited extensively for this purpose, since 
post-administrative procedures for removal of these systems from the body is not a 
requisite, because their degradation can be catalysed by physiological enzymes and 
autocatalytic hydrolysis. Particulate DDS such as microspheres and nanospheres have 
gained prominence in this context, and the optimisation of these to cater to the type of 
target, therapeutic agent to be encapsulated and the mode of delivery is a growing need. 
Polyhydroxyalkanoates (PHAs) are a class of natural polyesters that are receiving great 
attention in many biomedical applications such as tissue regeneration, synthesis of medical 
devices and drug delivery. Poly(3-hydroxybutyrate), P(3HB), is a short chain length variety 
of this polymer which has specifically been recognised for its potential to form DDS. In the 
first part of this study the solid-in-oil-in-water technique was used to optimise production 
of P(3HB) microspheres. The optimization process used a response surface methodology 
based on the Box Behnken design. The effect of process parameters such as polymer 
concentration, surfactant concentration and stirrer speed on microsphere size was 
analysed. The results of these optimisation experiments were used to tailor micro and 
  
nanospheres of different size ranges and these were characterised for their size 
distribution, porosity, amount of surface residual surfactant and hydrophobicity. 
The second part of this study focused on developing micro and nanospheres with 
encapsulated therapeutic agents relevant in cardiovascular diseases. Encapsulation of two 
antiproliferative drugs namely rapamycin and tacrolimus were studied in the context of 
their application in drug eluting stents. Rapamycin encapsulated P(3HB) and PLLA 
microspheres were compared for their physical properties and drug release kinetics and 
their release kinetics were found to be comparable. However, P(3HB) microspheres were 
more suitable for applications as their degradation products were found to be less acidic 
than that of PLLA microspheres. Tacrolimus encapsulated micro and nanospheres of P(3HB) 
were compared, to analyse drug encapsulation and release kinetics with respect to size of 
the spheres. Microspheres were found to have increased encapsulation efficiency, with a 
slower drug release rate, in comparison with nanospheres. Vascular Endothelial Growth 
Factor (VEGF), commonly used in the context of cardiovascular regeneration, was 
encapsulated within P(3HB) micro and nanospheres and were embedded in collagen 
scaffolds. The differences in release of VEGF from spheres embedded and not embedded 
in the collagen scaffold were quantified and it was established that embedding in the 
scaffolds reduced burst release.  
In the next stage of this study, P(3HB) microspheres were developed as novel target specific 
photodynamic drug delivery systems, with potential anticancer therapy applications. Three 
derivatives of a commonly used photosensitiser, namely porphyrin, were encapsulated 
within P(3HB) microspheres. The reduction in cell viability of these with respect to drug 
loading was quantified. Encapsulation efficiency was found to increase with drug loading
  
and reduction in cell viability was found to be a direct reflection of this. These microspheres 
were made target specific by adsorbing an antibody ‘Anti- HER-2’, which specifically binds 
to HER2, a cancer marker overexpressed on breast cancer cells. The incorporation of the 
antibody was found to result in increased cytotoxicity of the formulations, for all three 
derivatives.  
P(3HB) is a crystalline, hydrophobic polymer and degrades through surface erosion. There 
are applications that necessitate drug delivery systems that can retain moisture (especially 
in the context of wound healing) and a quicker release of drug moieties. Bearing this 
requirement in mind, a conjugate of P(3HB) with hyaluronic acid (HA) was synthesised by 
Contipro a.s. and the final part of this study examined the optimisation of microsphere 
synthesis using these conjugates. As this conjugate was amphiphilic, a water in oil emulsion, 
coupled with crosslinking was employed for the synthesis process. Microspheres of ~20 m 
diameter were synthesised, and hydrophilic and hydrophobic drugs were encapsulated 
within them. The microspheres were found to be fast degrading, maintaining their 
structure up to a maximum of 11 days. The drug release kinetics from these showed an 
increased burst release compared to P(3HB) microspheres.
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1.0. Controlled drug delivery 
The process of drug formulation and commercialization is lengthy and extremely costly 
(Vilos and Velasquez, 2012).  Commercialization of a drug involves 3-5 years of preclinical 
development, 6-8 years of clinical trials and 2-3 years of market surveillance (Figure 1.1). 
Even after the lengthy process of the development of drug molecules, their successful 
commercialization is minimal (Vilos and Velasquez, 2012).  Between 2007 to 2016, only 134 
new drug molecules were approved worldwide of which, 30.6% was by the European 
Medicines Agency (EMA) (Zeukeng, Seoane-Vazquez and Bonnabry, 2018).  
 
Figure 1.1: A schematic representation of stages of commercialization of a new drug 
molecule, as required by European Medicines Agency (EMA) (adapted from Vilos and 
Velasquez, 2012). 
 
Apart from the time and economic constraints of the process of drug development, 
conventional therapeutics also suffers from its inability to often attain efficient disease 
management.  This is because of the fact that conventional modes of delivery, often fail in 
maintaining minimally fluctuating therapeutic dosage of drug molecules for a prolonged 
period of time in the blood stream (Mansour et al., 2010).   The drawbacks of conventional 
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therapeutics that are administered in the forms of oral (tablets and capsules), and 
intravenous injections are several. These include limited solubility of drug molecules in the 
blood stream, short half-lives that result in diminished or no delivery to the site of action, 
interaction with other molecules in the biological milieu, and increased biodistribution 
(Cullis, 2014). The low solubility and short half-live of molecules frequently imposed the 
need to have repeated administration protocols, which result in fluctuations that reach 
toxic blood levels of the administered molecules. Poor solubility of drugs can also result in 
precipitation of drugs in aqueous environment, which can again be toxic. Biodistribution of 
cytotoxic drugs such as doxorubicin can also cause necrosis and tissue damage, in the case 
of ‘free’ drugs (Cullis, 2014). Also, lack of target specificity of conventional administration 
often results in suboptimal bioavailability of drugs at the target site (Rabinow et al., 2004). 
All these impediments of conventional drug delivery necessitated the development for new 
therapeutic modes of applications for existing drug molecules.  
Controlled drug delivery is the sustained release of therapeutic agents, with time or stimuli, 
allowing for the maintenance of drug concentrations in the biological milieu within the 
therapeutic window (Yun et al., 2014). By using suitable drug delivery systems (DDS) such 
as lipid/ polymer particulates, implants, gastro-retentive and transdermal systems, the 
functionalities of ‘free’ therapeutic agents can be controlled and improved (Cullis 2014). 
These drug delivery systems can alter the pharmacokinetics and biodistribution in a 
desirable fashion and act as a reservoir for the agent being transported. Hence, the 
physicochemical properties and biocompatibility of the materials used as drug delivery 
systems are of huge significance.  The desirable properties of these materials would include 
increased circulation time within the body in comparison with drug molecules of low half-
life, low cytotoxicity, inertness to biological environment, and higher uptake at target sites 
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(Elzoghby et al., 2012). Various natural and synthetic materials have historically been used 
to formulate drug delivery systems. Although petro-chemically derived polymers such as 
plastics have been extensively used in pharmaceuticals, their non-biodegradability 
required post implant procedures to eliminate these systems from the body. A well-
designed DDS is identified as one that is capable of specific targeting, intracellular 
absorption, biocompatibility, along with responsive behaviour to physiological conditions. 
The most defined progress in modern drug delivery is the spatiotemporal release of 
therapeutics in both pulsatile dose delivery products and implanted reservoir systems, 
from polymeric drug delivery systems (Liechty et al., 2010). Controlled drug delivery is a 
dynamic research field which traces its history of 60 years from the macro to micro and 
nano eras, referring to the size range of DDS formulation, with new entrants of DDSs being 
formulated constantly ( Elzoghby et al., 2012).  
1.1. Micro and Nanospheres 
The applications of biodegradable and biocompatible polymers in biomedical applications 
have accelerated, and drug delivery systems based on these materials have received 
increased attention. The most prominent of these are micro and nanospheres 
formulations. Microparticles are drug delivery systems that range between 1-1000 m in 
size and nanoparticles are those that range between 1-1000 nm in size. These particulate 
DDS have reduced the administration frequency of existing therapeutic formulations, 
especially of proteins and nucleic acids (Mansour et al., 2010).  The manipulability of these 
particulate DDS is significant and hence, these are increasingly employed in delivery of a 
multitude of drug molecules; both of hydrophobic and hydrophilic nature; and of varying 
molecular size ranges. Although different classes of drugs such as opioids, growth 
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hormones, contraceptives and antibiotics come under the purview of controlled drug 
delivery using polymeric particulate DDS, the advancement of these in anticancer drug 
delivery is so promising. The technique followed for the synthesis of polymeric particulate 
DDS depends primarily on the therapeutic drug being incorporated, polymer used, size 
range of the anticipated spheres (<250 m, ideal for parenteral administration) and 
reproducibility (Park, Ye and Park, 2005). The most common methods employed are spray 
drying, supercritical fluid technology and the solvent evaporation method. 
1.1.1. Spray drying 
Spray drying involves spraying a solution or suspension of polymer and drug in a volatile 
organic solvent to a stream of heated air. The narrow tip of the nozzle used for spraying 
atomizes the solution/suspension droplets, and this process determines the size of the 
particles obtained. Atomization pressure, feed rate, airflow, inlet temperature, outlet 
temperature, and the size of nozzle orifice are the determinant variables for particle size 
range using this technique. Spray drying is a technique widely used in the food industry and 
pharmaceuticals and has several advantages such as good reproducibility, better control 
over particle size range and less dependency on organic solvents being used. Low process 
yield is one of the main disadvantages of this technique, since formation of large aggregates 
during the process can result in a lot of the material being lost ( Park, Ye and Park, 2005; 
Mansour et al., 2010).  
1.1.2. Supercritical fluid technology 
Substances are said to be at their supercritical fluid (SCF) state when they are exposed to 
pressure and temperature above their critical points. Supercritical fluid technology is said 
to be highly economical with low process operatives (maintenance of temperature and 
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pressure) (Thakkar et al., 2009). At SCF state, substances exhibit the solvent properties of 
a liquid and flow properties of gas. CO2 is a commonly used SCF solvent, due to its low 
critical temperature (Tc = 31.1 oC) and pressure (Pc = 73.8 bar).  
There are two main techniques of generating particles using SCF technology. The first 
technique to generate particles using SCF technology is rapid depressurization of the SCF 
in which the polymer and drug are dissolved. This rapid depressurization is achieved by 
Rapid Expansion of Supercritical Solutions (RESS) through fine nozzles at supersonic speeds 
resulting in the supersaturation of the solute and its precipitation (Thakkar et al., 2009). 
Polar high molecular weight molecules such as proteins are insoluble in supercritical CO2 
and in these instances, a suitable solvent in which the molecule is soluble is used, which is 
later impregnated with supercritical CO2, Producing a gas saturated solution (GSS). This will 
result in lowering of the solute concentration in the entire volume of the solution, and 
reduced viscosity. This solution is then subjected to rapid decompression, resulting in the 
precipitation of particles (Mansour et al., 2010). Often salting out of particles is preferred 
using an antisolvent technology, wherein a poor solvent of the solute is rapidly added to 
the SCF, which results in the rapid precipitation of the solutes. The main disadvantage of 
this technique is the poor control over size and morphology as crystallization need not 
always result in spherical moieties (Thakkar et al., 2009).  
1.1.3. Solvent evaporation method 
Although polymeric micro/nanospheres are prepared by various techniques such as spray 
drying, solvent evaporation of emulsions, phase separation coacervation, spray congealing, 
solvent extraction, and Quassi emulsion solvent diffusion, solvent evaporation for 
emulsions is the most extensively researched technique and is followed throughout this 
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project (Nigmatullin et al., 2015). Based on the type of the encapsulated drug, the nature 
of emulsions can vary; hydrophobic drugs can be better encapsulated in oil-in-water (o/w) 
emulsions and hydrophilic drugs in water-in-oil-in-water (w/o/w) emulsions. In the 
encapsulation of hydrophobic drugs, the drug and the polymer are dissolved and dispersed 
in an organic solvent (oil phase), which is then emulsified in an aqueous phase containing 
surfactants (water phase) as illustrated in Figure 1.2.  
 
Figure 1.2: Schematic representation of preparation of microspheres to encapsulate 
hydrophobic drugs, using water-in-oil emulsion technique. 
  
Emulsification can be achieved through different methods of agitation such as sonication, 
homogenisation, or mechanical/magnetic stirring, during which the oil phase is dispersed 
throughout the water phase. The agitation breaks down the emulsion droplets to smaller 
sizes, and this process can be optimised to get different size ranges.  
As the organic solvent evaporates, the polymer shrinks around the core, assuming spherical 
geometry, due to the circular nature of agitation. Hydrophobicity of the drug enables the 
drug to agglomerate towards the shrinking polymer as opposed to hydrophilic drugs, which 
might tend to remain in the aqueous phase.  
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 In the case of hydrophilic drug encapsulation, the drug is dissolved in a water phase and 
then dispersed in the organic phase as illustrated in Figure 1.3. This continuous phase is 
added to a water phase containing surfactants, to form an emulsion. During solvent 
evaporation, the polymer starts shrinking towards the core, also entrapping microdroplets 
of the emulsion which coalesce to form a honey comb structure with interconnecting water 
channels (Nigmatullin et al., 2015). 
 
Figure 1.3: Schematic representation of preparation of microspheres to encapsulate 
hydrophilic drugs, using double emulsion technique. 
 
The preparation of microspheres using solvent evaporation of emulsions considers a range 
of parameters such as material properties of the polymer, concentration of the polymer in 
the organic phase, chemical composition of organic phase, concentration of the surfactant 
in the water phase, rate of solvent evaporation which is governed by stirring speed and 
temperature (Nidhi et al., 2016). Material properties of the polymer such as molecular 
weight, crystallinity and hydrophobicity have a pronounced effect on the process. 
Molecular weight and concentration of the polymer is directly correlated with the viscosity 
of the organic phase. Hence, an increase in these parameters is expected to increase the 
viscous forces against which the shear forces of agitation must act. An increased viscosity 
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would mean a reduced distribution of shear forces, hence resulting in the formation of 
larger emulsion droplets. Therefore, keeping all the other variables stable, an increase in 
polymer concentration or use of a polymer of higher molecular weight is expected to 
produce spheres of larger sizes (Srivastava et al., 2016). Nature of the organic solvents used 
can also affect the process, since different solvents have different viscosity and miscibility 
with the aqueous phase and the rate of evaporation also can vary based on their surface 
tension.  
1.2. Effect of process parameters in the preparation of micro/ 
nanospheres using solvent evaporation technique 
1.2.1. Polymer 
The nature of the polymer, especially the molecular weight plays a significant role in 
determining the morphology and size of particles produced using solvent evaporation 
technique, and subsequent drug release. Mark-Houwink-Sakudara (MHS) equation states 
viscosity as a function of relative molecular weight of a polydispersed polymer (= KMw, 
where   is the viscosity, K is the MHS constant and Mw is the relative molecular weight) 
(Reis et al., 2007). Molecular weight of a polymer depends on its origin, and in the case of 
biopolymers, is influenced by production variables such as the microorganisms used and 
their amino acid pool, nutrients supplied, aeration, and the length of fermentation process. 
Weight fraction of the polymer used (concentration) is yet another parameter that 
influences viscosity. Viscosity of the dispersed phase can influence the disentanglement of 
polymeric chains and hence the higher the viscosity, the greater is the amount of energy 
required for this process.  Therefore, an increased viscosity can result in formation of larger 
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emulsion droplets which subsequently form larger spheres of increased wall thickness. A 
reduction in disentanglement due to increased viscosity would also result in closely packed 
matrices, which has a pronounced effect on the porosity of the microspheres formed 
(Subedi, Shrestha and Shakya, 2016).  
Ahmed et al., optimised a depot injectable atorvastatin biodegradable in situ gel using PLGA 
and PEG and the experimental design and analysis was carried out using a central 
composite design (Ahmed et al., 2016). Concentration of PLGA and molecular weight of 
PEG were amongst the independent variables analysed and were found to have 
pronounced effects on the synthesis process and release profile of the drug. It was found 
that high molecular weight formulations of PEG (PEG 4000) were difficult to inject as 
opposed to the low molecular weight ones (PEG 400).  The burst release after 2 hours was 
found to decrease from 30.79% to 17.24% when PEG4000 and PEG400 respectively, were 
used (Ahmed et al., 2016). 
Crystallinity of the polymer used is also known to influence drug release rate, since 
crystallinity can influence the rate of polymer degradation. Crystalline regions of a polymer 
are mechanically stronger than amorphous regions and less prone to hydrolytic 
degradation. Highly crystalline polymers with slower degradation rates are ideal for release 
of drugs that require a prolonged release kinetics (Akhtar et al., 1992).  
1.2.2. Surfactant 
Aggregation of the spheres formed is a major concern in any of the synthesis techniques 
employed to make micro/nanospheres. Surfactant such as PVA is used to circumvent this 
issue. Surfactants are amphiphilic moieties with a hydrophilic head and hydrophobic tail 
(Ansary et al., 2014). The nature and concentration of surfactant used have been reported 
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to affect morphology of spheres produced and drug release kinetics. Surfactants being 
amphiphilic, can increase the wettability and thereby the degradation rate of the polymer, 
resulting in a faster release of the incorporated drug. Increasing the surfactant 
concentration results in the lowering of interfacial energy between emulsion droplets, 
which causes in the formation of smaller particles. Increase in surfactant concentration is 
also known to affect extent of drug entrapment as a high concentration of surfactant in the 
dispersed phase can result in the drug molecules having a higher affinity to the surfactants, 
as opposed to the polymer matrix. Further to this, high amount of surface residual 
surfactant can result in high amount of surface residing drug molecules, and this is likely to 
cause a burst release (Shrestha and Shakya, 2016).  
1.2.3. Agitation 
Agitation or stirring in solvent evaporation technique is employed to ensure effective 
dispersion of the emulsion and reduction of emulsion droplet size. An agitation influences 
the extent to which the emulsion droplets are broken down, which subsequently translates 
to the size range of the spheres formed. Finer dispersions result in spheres of reduced 
porosity, and this can become a limiting factor in drug release. Therefore, increased 
agitation can be argued to bring about two antagonistic effects with respect to drug 
release; first one of which is smaller particle size- leading to increased surface area and 
therefore faster release, and the second is reduced porosity, which results in slower 
release. (Francis et al., 2011; Caetano, Almeida and Gonçalves, 2016) 
Francis et al., in their study on Polyhydroxybutyrate microsphere with encapsulated 
gentamycin that illustrates the effect of stirrer speed on the size range of microspheres. 
When all the other parameters were maintained constant, and the stirrer speed was 
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increased from 300 rpm to 800 rpm, microspheres size was observed to decrease from 2 
μm to 1.58 μm (Francis et al., 2011). 
1.3. Mechanisms of drug release  
Drug delivery systems are designed to attain optimal pharmacokinetic and 
pharmacodynamic profiles of a therapeutic agent in a temporally and spatially controlled 
manner.  The design of these systems is heavily dependent on the polymer’s 
biodegradability, biocompatibility, processability, and thermo-mechanical properties. Only 
polymers that are small enough (<50 kDa) to permeate through the renal globular 
membrane can be directly excreted from the body via renal excretion. This includes a very 
small window of non- biodegradable polymers and hence the need to consider other 
options. Controlled drug delivery systems cover a wide spectrum of structures or 
constructs, such as subcutaneous implants, compressed tablets for oral administration and 
micro-particulate carriers for subcutaneous and intravenous use. The type of drug delivery 
systems can influence the mechanism of drug release and hence pharmacokinetics, 
degradation profile and extent of entrapment. Mechanism of controlled release from these 
DDS varies depending on the type of polymer used, nature of encapsulated drug, and the 
physiological conditions they are exposed to. Different kinds of release mechanisms- 
dissolution followed by diffusion, partitioning, osmosis, swelling, erosion, and targeting- or 
one or more of their combinations usually affect drug release rate (Nigmatullin et al., 2015). 
1.3.1. Dissolution followed by diffusion 
Dissolution is the transfer of a substance from its solid phase to the surrounding liquid 
medium. Solubility in a given medium is defined as the concentration of any substance at 
its saturation. Drug delivery systems controlled by dissolution involve phase erosion of the 
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polymer carrier or drug that is associated with fast or slow dissolution of the 
macromolecular chains. This method is adopted in two kinds of devices- monolithic and 
reservoir. In monolithic devices, the therapeutic agents are entrapped homogeneously 
within the polymer matrix, whereas in a reservoir device a protective coating of polymer 
encloses the therapeutic agent in a core. The release rate of therapeutic agents 
encapsulated in a reservoir can be modulated by controlling dissolution parameters of the 
polymer or the coating of polymers. The thickness of the coating in this case can affect the 
rate of release (Shen et al., 2004). Polymer molecular weight, water, polymer and drug 
diffusion coefficients, equilibrium water concentration in the polymer, and water-polymer 
interaction are the parameters that control the mechanism and rate of drug release by 
dissolution, followed by diffusion (Narasimhan and Peppas, 1997). Diffusion and dissolution 
are interdependent as both are influenced by the concentration of the therapeutic agent 
in the surrounding medium.  
1.3.2. Partitioning 
Partition coefficient, which is the relative affinity of a substance to two different materials 
or phases, can be exploited to manipulate drug release kinetics. Hydrophilicity and 
hydrophobicity of drug molecules greatly affect the design of delivery systems.  
Hydrophobic drugs have been known to encapsulate in DDS with a hydrophobic core and 
hydrophilic corona to increase their uptake into the blood stream (Lao, Venkatraman and 
Peppas, 2008). PLA micelles as an excipient of Paclitaxel are such an example where the 
hydrophobic drug is partitioned into the core and can be retained until their delivery to the 
site of action (Kim et al., 2010).  
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1.3.3. Osmotic release 
This type of delivery depends on the availability of a semipermeable membrane protecting 
the hydrophilic therapeutic agent, allowing a controlled amount of water to enter the core 
and dissolve the therapeutic agent. The flux of water to the core is determined by the 
chemical potential of water or water potential on either side of the polymer membrane 
(Omidian et al., 2012).  Here, the pores or delivery orifices of the membrane are designed 
in such a manner that they coincide with a certain release rate. Therefore, with the water 
influx, the drug molecules either dissolve in the water or are released through these pores. 
Hydroxy ethyl cellulose, carboxy methylcellulose, hydroxy propyl methylcellulose, high-
molecular-weight poly(vinylpyrrolidone) are examples for the hydrophilic polymers and 
ethyl cellulose and wax materials are examples for the hydrophobic polymers used for this 
purpose. Sometime molecules known as osmogens are incorporated within the core, that 
would increase the osmotic pressure and expel the medicament faster. Sodium chloride, 
potassium chloride, and mannitol are such examples and various poorly soluble therapeutic 
agents are encapsulated as their salts to increase solubility. Another strategy is the use of 
wicking agents, which have the inherent ability to absorb water, on the polymeric 
membranes. Wicking agents form water channels between the outer and inner surfaces of 
the membrane. Colloidal silicon dioxide, PVP and Sodium lauryl sulphate are common 
examples of such agents that aid in forming such channels via physisorption of water 
(Keraliya et al., 2012).  
1.3.4. Swelling 
Swelling occurs when the polymeric matrix or shell takes up water and increases in volume, 
a common phenomenon that precedes dissolution. However, swelling does not necessarily 
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lead to dissolution, especially in the case of hydrogels. Swelling is often by virtue of large 
polymer chains or by the introduction of crosslinks forming networks that trap water. In 
polymers that swell rapidly, diffusion of the drug is controlled by the swelling rate. Swelling 
is dependent on parameters such as temperature and pH and therefore alternating these 
physiological conditions can result in reverse swelling, hence it is possible to create a DDS 
with a controllable drug diffusion (Omidian et al., 2012). 
1.3.5. Erosion 
Erosion is a very significant and rate-determining phenomenon in controlled drug delivery, 
especially with hydrolytically labile polymers. There are two mechanisms of erosion, bulk 
and surface erosion, which dictate the directionality of degradation. In bulk erosion, water 
penetrates the entire matrix of the polymer and initiates hydrolysis and chain scissions, 
across the matrix. The initial chain scissions would accelerate water diffusion into the core 
of the matrix and thereby degrade the whole matrix in a rapid fashion. This phenomenon 
can also be autocatalytic when the erosion products are acidic, and the hydrolysis of the 
polymer is acid catalysed (Omidian et al., 2012). In surface erosion, mass loss and 
degradation occur near the surface of the DDS, in a mechanism that is analogous to the 
peeling of an onion. This happens either due to slow penetration of water into the matrix 
where highly hydrophobic polymers are used. The water first hydrolyses the surface that it 
is in contact with, and this leads to the release of the therapeutic agent that is trapped in 
that layer. This process follows until the entire DDS has experienced mass loss, resulting in 
a progressive reduction in size of the DDS. Surface erosion brings about more linear 
changes in mechanical performance, drug release, and volume reduction, and hence is an 
attractive attribute in DDS.  Both surface and bulk erosion follow the same molecular 
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phenomenon of hydrolytic scission in the presence of water but are differentiated by how 
quickly the waterfront can penetrate through the matrix (Lyu and Untereker 2009). A 
matrix undergoes surface erosion, if the degradation of the surface polymer is faster than 
the rate of water penetration into the entire matrix. It is the difference in thickness of the 
diffusion zones that dictate whether a sample would undergo surface or bulk erosion. For 
example, for a PLA sphere to undergo surface erosion the sample size needs to be more 
than 40mm in diameter, which is a size that is unsuitable for drug delivery applications (Lyu 
and Untereker 2009).  
1.3.6. Targeting 
Targeting is a strategy to increase localization and therefore uptake of the therapeutic 
agents by designing DDS with materials that have an inherent affinity to the target site or 
incorporating adjuvants with affinity. Targeting is especially adopted in the case of micro 
and nano encapsulations, extensively in anti-cancer drug delivery.  Cancer drugs are 
generally highly cytotoxic and can adversely affect non-cancerous tissues and hence the 
preference of targeting anti-cancer drug delivery. Several targeting methods are currently 
in use, as described in the section below. 
I. Strategies for targeted anti- cancer therapy 
Cancer treatment necessitates the use of highly cytotoxic drugs, which can cause 
unacceptable side effects to normal tissues. Therefore, there is a preference for localization 
and delivery of the therapeutic agents precisely at the site of action as far as drug delivery 
of anticancer agents are concerned. Chemotherapy, which is the most common form of 
cancer intervention, has many drawbacks due to the low specificity and high toxicity of 
cancer drugs. Chemotherapeutic agents typically disrupt cell replication by inducing 
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apoptosis, and in most cases, this is not selective to cancer cells. Paclitaxel, doxorubicin, 
daunorubicin, cisplatin, and docetaxel are examples of some of the most commonly used 
anticancer drugs. These do not discriminate between cancer cells and healthy cells and 
highly proliferative tissues such as the hair, intestinal epithelial cells, and bone marrow 
become susceptible to their cytotoxic effect (Walker et al., 2009).  
Particulate DDS have the potential to decrease the side effects of anticancer agents, by 
improving target specificity and therapeutic efficacy (Walker et al., 2009).  These can be 
surface functionalised with cancer specific markers making them target specific. 
Encapsulating highly cytotoxic agents can reduce biodistribution, which ultimately 
translates to lower side effects and improved patience compliance. The design rationale of 
these systems increasingly depends on the tumour physiology, which is characterised by 
leaky vasculature, ill-defined lymphatic systems, and presence of growth factors such as 
Vascular Endothelial Growth Factors (VEGF) and several cancer specific markers. These 
physiological features render cancer tissues with Enhanced Permeability and Retention 
(EPR) of high molecular weight drug formulations, a phenomena DDS exploit.  
Zhang et al., illustrated the efficacy of PLGA microspheres encapsulated with the anticancer 
drug Temozolomide, in malignant glioma (Zhang et al., 2010). According to this study, a 
dual therapeutic agent system consisting of Temozolomide encapsulated microspheres in 
combination with Vatalanib; an anti- angiogenic drug was found to be more effective in 
inducing cytotoxicity. In another study, having identified degradation products of PLGA as 
highly acidic and inflammatory, nanoscale Hydroxyapatite (nHA) was used as an adjuvant, 
to increase biocompatibility of the degradation products (Zhang et al., 2012). This study 
compared two morphologies of DDS encapsulated with Temozolomide, the first one of 
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which was microspheres, and the second, rod shaped, for their ability for sustained drug 
release and cytotoxicity. The results showed that nHA addition had a significant effect in 
reducing burst control in both these structures.  
Cancer stem cells (CSC) are considered as potent targets for cancer treatments as they are 
significant in initiation, propagation and regeneration of cancer (Li et al., 2017). Cancer 
stem cell targeting is an accelerating area of research since the identification and 
characterization of cancer stem cells is rapidly advancing, providing a multitude of targeting 
strategies (Figure 1.4).  
 
Figure 1.4: strategies of CSC targeting (reproduced from li et al., 2017).  
Li et al., in their comprehensive review of cancer cell targeting mechanisms list six 
strategies for CSC targeting, as follows. A CSC niche supported by tumour 
microenvironment has an important role in multidrug resistance (MDR) and therefore, 
targeting elements such as vasculature and endothelial cells of this microenvironment and 
use of anti- inflammatory (IFN) drugs is the first strategy. A novel Rhodamine encapsulated 
integrin-targeted nanoparticle (ITNP) system was developed by Xie et al., with the prospect 
Chapter 1: Introduction 
  19 
 
of targeted drug delivery and imaging of cancer angiogenesis. Integrin αvβ3, a cell surface 
receptor overexpressed in cancer angiogenesis, was targeted, using a lipid-based integrin 
antagonist. The INTPs exhibited increased uptake in comparison with control nanoparticles, 
when administered in C3H, mice bearing murine squamous cell carcinoma (Xie et al., 2007). 
The second strategy is targeting signalling pathways involved in self-renewal (Notch), 
growth (Akt1 pathway) and apoptosis (Hedgehog). The other strategies include targeting 
markers such as CD33, CD44 and CD90, targeting cell differentiation, targeting immune 
system, and targeting metabolism. The targeting strategies that interfere with metabolism 
such as the limus family of drugs (everolimus, sirolimus and tacrolimus) that inhibit 
mammalian target of rapamycin (mTOR) are exclusively explored in cardiac stent 
applications.  
Published literature on micro and nano particulate structures for cancer DDS is exhaustive, 
with a plethora of synthetic and natural polymers, and comprehensive usage of most of the 
existing chemotherapeutic agents. Chemoembolization with microspheres is an alternative 
practice in certain cancers, wherein the microspheres of sufficient size range are used to 
aid in sustained drug release, as well as blocking arterial supply to tumours. These systems 
known as Drug Eluting Microsphere-Transarterial Chemoembolization (DEM-TACE) were 
first conceptualised by Hori and Osuga using Sodium acrylate polyvinyl (SAP). Their 
improvised versions namely CE-approved HepaSphere and FDA-approved QuadraSphere 
microspheres are in market, for the treatment of primary and metastatic liver tumours. 
These embolic agents provided in a variety of size ranges (200-800 m) have the capability 
to absorb 64 times their dry state volume and still maintain their spherical structure, 
thereby acting as arterial plugs (Rajput and Agrawal, 2010).  
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1.4. Theory of drug release 
Drug release is the process by which a pharmacologically active agent leaves a DDS and 
becomes available for pharmacological action. To understand the drug release profile from 
any DDS, it is important to know about the various mass transport phenomena involved, as 
explained in the above section. Rapid release dosage forms such as tablets eliminate the 
active agents from them rapidly, resulting in overexposure of the drug. As time proceeds, 
this would gradually become underexposure, until the next dosage. Controlled drug 
delivery systems work towards increasing the presence of drug molecules within the 
therapeutic window, for longer durations (Bruschi and Luciano 2015). In many controlled 
devices, when they are initially brought in contact with the release medium, an excess 
amount of drug is eluted out and this phenomenon is known as burst release (Huang and 
Brazel, 2001). It is often desirable where a rapid initial dosage of the drug is required. But 
in case of devices that are designed to deliver longer release profiles, burst release is 
considered to be undesirable.  
With the advances in formulation of various forms of DDS, mathematical modelling of drug 
delivery and release profile predictability is of huge commercial potential. In silico 
simulations to generate optimal designs by considering variables such as geometry and size 
of the DDS, solubility of the drug molecule incorporated, mode of erosion and degradation 
help increase predictability of temporal release profiles (Lao, Venkatraman and Peppas, 
2008; Dash et al., 2010). The parameters influencing release profiles vary, depending on 
the type of polymeric material used in DDS formulation, formulation technique, physiology, 
incorporated drug dose(s), types and amounts of excipients and degradation products 
(Siepmann and Siepmann, 2008).  Generating predictive models can not only increase 
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accuracy and easiness of application, but also ensure pharmacokinetic safety, especially in 
the case highly potent drugs with narrow therapeutic windows (Siepmann and Siepmann, 
2008).  However, as in the case of purely diffusion-, or diffusion- and swelling-controlled 
release devices, mathematical modelling of erodible systems are not as advanced since 
these systems are more complex and are influenced by physicochemical processes apart 
from mass transport phenomena (Faisant, Siepmann and Benoit, 2002). Since it is not 
practical to consider all the contributing factors, often models take the most dominating 
phenomena into account (Faisant, Siepmann and Benoit, 2002). To compare drug release 
profiles from various DDS, there are a number of models available, most of which represent 
the fractional drug release as a fucntion of time (ft). Many such models are based on Fick’s 
laws describing mass transport per unit area. Fick’s first law states that the amount of solid 
materials passing perpendicularly through a unit surface area per time from a DDS to its 
surrounding medium is directly proportion to the concentration gradient (Gouda, Baishya 
and Quing, 2017). According to this, a constant diffusion rate is achievable if the 
concentration gradient remains constant. Hick’s second law states that a rate of change of 
concentration at a region is proportional to change in concentration gradient at that point. 
Release mechanisms are categorized into four, based on the mode of mass transport 
(Maderuelo, Zarzuelo and Lanao, 2011). 
1). Fickian diffusion (type I): Drug release is dependent primarily upon diffusion 
2). Polymer swelling (type II): Drug release is a result of swelling of the polymer that makes 
up the DDS 
3). Anomalous / non Fickian diffusion: Drug release is dependent both on polymer swelling 
and diffusion 
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4). Super type II: Occurs in DDS where the surface gets hydrated and starts eroding. 
While he quantitative representation of release from simpler forms of DDS can be 
facilitated by using generic equations such as in zero order (explained in section 1.4.1), in 
most cases theoretical analysis of the process doesn not suffice for an accurate prediction 
(Costa and Sousa Lobo, 2001). Release kinetics can be predicted in roughly two different 
ways; Empirical models that usually unify all the contributive parameters to a single zero-
order process controlling the overall drug release rate, Mechanistic realistic mathematical 
models that consider diffusional mass transfer and/or chemical reactions (Faisant, 
Siepmann and Benoit, 2002). In the case of empirical models, the predictive power is 
considered to be low as the mathematical treatment is mostly descriptive, as opposed to 
the mechanistic models that take into account physical phenomena such as diffusion, 
dissolution, swelling, erosion, precipitation and/or degradation (Siepmann and Siepmann, 
2008). Zero- order kinetics, first- order, Higuchi, Hixson-Crowell and Korsmeyer-Peppas are 
examples of some of the popular approaches employed.  
1.4.1. Zero- order model  
In zero- order kinetics, the release of a drug from a DDS is directly proportional to time 
(Bruschi and Luciano 2015). Zero- order release kinetics is independent of the initial 
concentration. Constant release of active agent from the DDS is made possible along a 
concentration gradient and is mostly true for systems with a semipermeable coating. 
Osmosis property, dissolution, diffusion, and partition are identified as physical 
phenomena that can result in zero-order release of active agents from DDS (Bruschi and 
Luciano 2015). It is represented by the equation: 
Qt = Q0 + K0t  
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Where Q0 is the initial amount of drug in the solution it is being eluted to, Qt is the amount 
of drug dissolved in time t and K0 is the zero- order constant (Dash et al., 2010). Since for 
most systems K0= 0, Qt can be represented as a function of time (f(t)), whose slope () is 
the zero- order constant K0 (Figure 1.5). 
 
Figure 1.5: Graphical representation of drug release of zero- order release kinetics. 
 
By this method, it is possible to release the same amount of drug per unit time and hence 
is pharmacologically preferred. Zero- order release is observed in DDS that do not 
disaggregate and contain matrices with low soluble drugs or osmotic systems in which the 
drug is protected by semi- permeable membranes (Dash et al., 2010). 
1.4.2. First- order model 
In first- order kinetics, the change in concentration of the drug with time is dependent only 
on the concentration (Ramteke et al., 2014). The release of a drug obeying first- order 
kinetics can be represented by the equation: 
dC/ dT = -KC 
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where dC/ dT is the change in concentration of with respect to time, K is the first- order 
constant and C is the concentration. This equation can also be represented as:  
log C - log C0 = Kt / 2.303 
where C is the concentration of drug released at time t, and C0 is the initial amount of drug 
dissolved and K is the first- order constant. This means, a graph of log cumulative 
percentage of drug remaining vs. time will give a straight line with a slope of - K / 2.303, as 
given in figure 1.6. (Ramteke et al., 2014). 
 
Figure 1.6: Graphical representation of drug release of first- order release kinetics 
First- order release kinetics is observed in DDS that are formulated as porous matrices 
containing water soluble drugs (Dash et al., 2010). 
1.4.3. Higuchi model 
Higuchi can be considered as the pioneer of mathematical modelling in drug delivery, as he 
was the first scientist to propose a mathematical model, to describe the release of drugs 
from matrix systems in 1961 (Peppas and Narasimhan, 2014). Higuchi model was initially 
developed for planar systems such as ointments but was later extended to the release of 
soluble and partially soluble drug molecules from porous and matrix systems (Bruschi and 
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Luciano 2015). A simplified version of Higuchi model is represented by the following 
equation: 
Q= KH t1/2 
Where Q is the cumulative amount of drug released at time t and KH is the Higuchi constant. 
Higuchi model, considering DDS of varying geometry proposes that the cumulative 
percentage of drug release when plotted against square root of time gives a straight line, 
with a slope that is equal to Higuchi dissolution constant (Figure 1.7) (Gouda, Baishya and 
Quing, 2017).  
 
Figure 1.7: Graphical representation of drug release following Higuchi model 
The Higuchi model assumes the following: 1). The matrices contain drug in an amount that 
is much higher than its solubility, 2). Diffusion is one dimensional, 3) Swelling is negligible 
and 4). Drug molecules are much smaller in size than the matrices (Dash et al., 2010).  
1.4.4.  Hixson- Crowell model 
Hixson- Crowell model is applicable to DDS where the surface area reduces as a function of 
time, without altering the geometry. This model assumes that the rate of release is a 
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property of dissolution, rather than diffusion (Bruschi and Luciano 2015). According to this 
model,  
W01/3- Wt1/3 = t 
Where W0 is the initial amount of the drug, Wt is the remaining amount of drug at time ‘t’, 
and  is the Hixson- Crowell release constant incorporating the surface area and volume of 
the DDS (Gouda, Baishya and Quing, 2017). From the equation, it can be learned that a plot 
of cube root of percentage drug remaining unreleased vs. time would give a straight line 
with a slope ‘’ (Figure 1.8). 
 
Figure 1.8: Graphical representation of drug release following Hixson- Crowell model. 
While Higuchi model establishes diffusion as the prime mechanism of mass transfer, Hixson 
Crowell gives an insight into what kind of diffusion mechanism is involved.  
1.4.5. Korsmeyer-Peppas model 
Korsmeyer et al. (1983), developed a semi empirical model to describe drug release from 
polymeric systems. It is often used to linearize release data from microspheres and capsules 
(Bruschi and Luciano 2015). According to this model, the fraction of the drug released at 
any point is given by 
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Qt/Q0 = k tn 
Where Qt is the amount of drug released at time t, Q0 is the initial amount of drug and n is 
the release exponent. Therefore, a plot of log (Qt/Q0) vs log (t) should be able to provide 
the value of n from linear regression (Figure 1.9).  
 
Figure 1.9: Graphical representation of drug release following Korsmeyer-Peppas 
model. 
The n vale characterizes the type of mass transport mechanism for various geometries. For 
spheres, release mechanisms corresponding to different n values are given below in table 
1.1. 
Release exponent (n) Release mechanism 
0.43 Fickian diffusion 
0.43 < n < 0.85 Anomalous transport 
0.85 Type II transport 
Table 1.1: Correlation between release exponent ‘n’ and release mechanism in 
spherical DDS, following Korsmeyer-Peppas model (Carbinatto et al., 2014). 
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1.5. Biodegradable polymers in drug delivery 
1.5.1. Synthetic Polymers  
Although both naturally derived and synthetic polymers have been explored in the context 
of biomedical applications, associated disadvantages of naturally derived polymers such as 
immunogenicity, complexities associated with purification and sterilisation have triggered 
a new wave of synthetic polymer engineering (Lutolf and Hubbell, 2005). Synthetic 
polymers are broadly defined as man-made polymers from petroleum sources. These 
include polyesters, polyamides, polyurethanes, polyureas, poly(amide-enamines) and 
polyanhydrides (Vroman and Tighzert, 2009). Synthetic biomaterials have also been 
developed equipped with features that promote cell interactions and respond to molecular 
cues. The development of Molecular Imprinting technology has also made it possible to 
synthesise polymers with specific molecular recognition sites. Molecular Imprinted 
Polymers or MIPs are prepared by mixing the template molecules and monomers, followed 
by crosslinking and polymerisation. The template is then extracted out, resulting in MIPs 
that have memory of the template molecule, which can be used as effective tools for drug 
delivery (Yan and Ho Row, 2006). The main advantage of this technology is high selectivity 
and adaptability. The same material can be used to recognise a multitude of biomolecules 
such as DNA, antibodies, amino acids and drugs. MIPs made using methacrylic acid (MAA) 
as a functional monomer for the controlled release of Propranolol (a β-adrenergic 
antagonist), have exhibited prolonged release as opposed to non -MIPs (Vasapollo et al., 
2011). 
Synthetic polymers can be modified to have tailorable degradation rate, as in the case of 
Polylactic acid or PLA, usually obtained from polycondensation of D- or L-lactic acid or from 
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ring opening polymerization of lactide, a cyclic dimer of lactic acid (Vroman and Tighzert 
2009). Both the stereoisomeric forms of PLA namely PDLA and PLLA and their racemic 
mixture PDLLA have been used for biomedical applications. These have been used 
extensively as resorbable sutures, stents, artificial skin, staples, orthodontic implants, 
oriented and blown films and tissue regenerative scaffolds (Mallakpour and Zadehnazari, 
2011). However, drawbacks such as risk of toxicity due to acidic by-products have led 
researchers to consider alternatives.  
1.5.2. Natural polymers 
Natural polymers are naturally occurring macromolecules such as polysaccharides, starch, 
collagen, fibrinogen and elastin. The advantage of natural polymers in their inherent 
biological recognition, including presentation of receptor-binding ligands and susceptibility 
to cell-triggered proteolytic degradation and remodelling make them good candidates in 
biomedical applications (Lutolf and Hubbell 2005). Since natural polymers make up 
extracellular matrix, they have an inherent ability to communicate with other cellular 
components and assist in routine cellular processes (Sell et al., 2010). Cellulose, the most 
abundant material in nature, has been used as nanofillers for various polymers such as 
Polyvinyl alcohol (PVA), PLA and Polycaprolactone (PCL). Different aspect ratios of the fillers 
and different polymer/filler ratios have been evaluated and an improvement in the 
mechanical properties of the composites has been observed (Siqueira et al., 2010). Chitin, 
one of the most abundant natural polymers, has been used to produce hydrogels, powders, 
fibres and porous scaffolds. Porous chitosan scaffolds prepared by transferring a 
homogenised, air bubbled solution of chitosan into sodium hydroxide to facilitate liquid 
hardening, have been used to incorporate either bone morphogenic proteins (BMP-2) or 
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insulin- like growth factor (IGF-1). In vivo studies on these scaffolds revealed that the ones 
with IGF-1 exhibited increased osteoblastic differentiation (Sampath et al., 2016).  Starch is 
another natural polymer extensively researched in this context and has been so since early 
1970s. The applications of starch as biopolymers vary; the most prominent of them being 
in food industry. Corn starch and microcrystalline cellulose extrusions have been used to 
make edible films (Phan et al., 2009). They are also used in various medical applications 
such as starch based biodegradable bone regeneration scaffolds and as hydrogels and 
microspheres in drug delivery (Lu et al., 2009). Polyhydroxyalkanoates (PHAs), a group of 
naturally occurring biodegradable polyesters that are synthesised by microorganisms 
during unbalanced growth, have received much attention in the last decade, especially in 
biomedical applications. This is owing to their high biodegradability in varied environments 
and processing versatility (Bugnicourt et al., 2014). 
1.6. Polyhydroxyalkanoates (PHAs) 
PHAs are considered as potential alternatives for fossil fuel-based thermoplastics. These 
are bacterial storage polymers produced under nutrient limiting conditions such as 
nitrogen, phosphorous or potassium, but with excess carbon (Le Meur et al., 2012). These 
are water insoluble, biodegradable and biocompatible polymers and accumulate as 
cytoplasmic inclusions in both Gram positive and Gram-negative microorganisms. PHAs are 
polyesters of 3-, 4-, 5-, 6- hydroxyalkanoic acids and generally consist of 1000-10000 
monomer units (Figure 1.10). 
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Figure 1.10: General chemical structure of Polyhydroxyalkanoates (PHAs) (Nigmatullin 
et al., 2015). 
 
PHA producing microorganisms naturally occur in ecological niches where they are in 
communication with the biotic and abiotic environments. They have different survival 
adaptations and the accumulation of PHAs under nutrient stress is one such adaptation.  
The carbon source for PHA production can be from a wide spectrum of biomolecules. Over 
150 PHA monomer units have been identified (Nigmatullin et al., 2015). Lemoigne first 
identified the presence of PHAs as bacterial inclusions in 1926. Since then various 
microorganisms (over 300 different species) and various carbon sources such as 
carbohydrates, lipids, fatty acids, alkanes, alkenes, organic acids and aromatic compounds 
have been identified, for the synthesis of PHAs (Nigmatullin et al., 2015).  
Due to their varied monomer combinations, PHAs exhibit a wide range of mechanical, 
thermal, and physical properties.  PHAs are broadly classified into two groups depending 
on the number of carbon atoms present on their monomer units. Short chain length PHAs 
(SCL-PHAs) has 3-5 carbon atoms and medium chain length PHAs (MCL-PHAs) that have 6-
14 carbon atoms in their monomers. SCL-PHAs are in general brittle with a very high melting 
point and crystallinity (except for poly(4-hydroxybutyrate), P(4HB), and MCL-PHAs have a 
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low melting temperature, crystallinity, tensile strength and are extremely elastomeric in 
nature. The reason for the difference in crystallinity and melting point between SCL and 
MCL- PHAs could be the presence of larger pendant groups in MCL- PHAs that make the 
packing of polymer chains irregular. Crystallinity is a result of compact packing and SCL- 
PHAs with small regular pendant groups can pack in a more ordered manner, thus leading 
to increased crystallinity and melting point (Sánchez et al., 2013). Poly(3-hydroxybutyrate), 
P(3HB), poly(3-hydroxybutyrate-co-3-hydroxyvalerate), P(3HB-co-3HV), are some 
examples of SCL PHAs and poly(3-hydroxyhexanoate), P(3HHx), poly(3-hydroxyoctanoate), 
P(3HO), poly(3-hydroxydecanoate), P(3HD), poly(3-hydroxydodecanoate), P(3HDD) are 
some examples of MCL PHAs (Rai et al., 2011a).  
Homopolymers, block copolymers and random copolymers of PHAs are produced 
depending on the carbon source used, organism used and metabolic pathways. Sato et al., 
suggested that even the homopolymer P(3HB) consists of less than 1% monomer units of 
3-hydroxyvalerate (Sato et al., 2005). A few examples of diversities in mechanical and 
thermal properties of PHAs are tabulated below in Table 1.2. These properties vary from 
highly elastomeric to highly brittle. These varied properties imply their application in a 
variety of biomedical devices such as scaffolds for hard tissue regeneration (bone 
regeneration) and soft tissue regeneration (cardiac regeneration), cardiovascular stents 
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P(3HB) 175 40 3.5 5-6 
P(3HB-co-3HV) 137-170 20-25 0.7-2.9 50 
P(3HB-co-4HB) 152 26 - 444 
P(4HB) 53 36 0.23 1000 
P(3HHx-co-3HO) 61 9 0.008 380 
P(3HB-co-3HHx) 52 20 - 850 
P(3HO) 39-50 9.6 0.005 1300 
Polypropylene 170 38 1.7 400 
    Table 1.2: Thermal and mechanical properties of some PHAs (Valappil et al., 2006) 
 
These huge range of properties coupled with PHAs’ excellent biocompatibility has paved 
way to their use as a suitable material in various biomedical applications. They are natural 
storage polymers for microorganisms and are also ubiquitous in plants and animals and 
their degradation products are compatible with and similar to cell metabolic products, such 
as in fatty acid metabolism. Hence the metabolic pathway of PHAs and their removal from 
the body is well understood, which gives them a clear advantage over other biomaterials. 
TephaFLEX, an absorbable suture prepared from P(4HB) obtained FDA approval in 2007, a 
remarkable leap towards establishing PHAs as niche biomaterials in medical applications 
(Shrivastav et al., 2013). The list of these applications includes hard tissue and soft tissue 
regeneration scaffolds, wound healing, cardiac patches, nerve conduits, heart valve and 
therapeutic delivery (Table 1.3). Advancements in material processing techniques have 
enabled newer avenues for PHAs in biomedical applications.   
Chapter 1: Introduction 












Stomach wall patch 
Micro/ nanospheres Drug delivery, 
chemoembolization 
Implantable rods Peripheral nerve guide 
Fibronectin and alginate 
conjugated P3HB 








Film Drug delivery 
Design of a 3D 
microfibrous material-
formed by the blend and 















Porous tube form  Nerve conduit 
Human adipose tissue 
embedded scaffolds 
Cartilage proliferation 
Films Blood vessels 
3 D scaffolds Blood vessels 
Table 1.3: Biomedical applications of PHAs (Nigmatullin et al., 2015) 
 
Chapter 1: Introduction 
  35 
 
1.6.1. P(3HB) 
P(3HB), an SCL PHA is the best studied of PHAs, first discovered in Bacillus megaterium. 
P(3HB) is highly crystalline, hydrophobic, 100% biodegradable and, like most 
thermoplastics, can be processed by extrusion, injection, and melt press moulding, making 
it a suitable candidate for various processing methods (Pachekoski et al., 2013). Although 
it’s stability is compromised at higher temperatures, the biodegradation rate of P(3HB) 
increases when the polymer is processed at higher temperatures, which is explained by 
decreasing of the polymer crystallinity, which facilitates the capability of the extra-cellular 
enzymes responsible for P(3HB) degradation to attack its chains (Pachekoski et al., 2013). 
There is evidence to show that the degradation products of P(3HB) are not only 
biocompatible, but also growth promoting (Cheng et al., 2006).  
1.6.2. P(3HB) Biosynthesis 
P(3HB), as mentioned earlier is a storage molecule in response to physiological stress in 
various microorganisms. It is a linear polymer produced by both Gram positive and 
Gramnegative microorganisms such as Cupriavidus necator, several species of 
Pseudomonas, Bacillus, Azotobacter and also recombinant Escherichia coli, expressing the 
P(3HB) biosynthetic genes from C. necator and A. vinelandii. Gram positive bacteria such as 
Bacillus spp., are specifically useful for medical applications due to the absence of 
lipopolysaccharides, a group of immunogens that coprecipitate with polymer extraction. 
P(3HB) is produced by fermentation either in batch, fed batch, continuous cultures, or 
multistage fermentation systems (Rai et al., 2011). P(3HB) can be synthesised using 
inexpensive carbon sources such as beet and cane molasses, corn starch, alcohols, and 
vegetable oils. There are 3 main enzymes involved in the biosynthesis of P(3HB), 
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corresponding to 3 distinctive steps. The first step is the condensation of two molecules of 
acetyl-CoA to form acetoacetyl-CoA catalysed by the enzyme ketothiolase, encoded by the 
phbA gene. This is followed by the enzymatic action of an NADPH dependent acetoacetyl-
CoA reductase (encoded by phbB) which catalyses the conversion of acetoacetyl-CoA to 3-
hydroxybutyryl-CoA using NADPH. The enzyme PHA synthase (encoded by phbC) then 
polymerizes the 3-hydroxybutyryl-CoA monomers to P(3HB), liberating CoA (Rehm, 2003). 
Under non- liming conditions acetyl CoA enters the TCA cycle, and the enzyme-ketothiolase 
is negatively regulated by CoASH (Figure 1.11) (Shrivastav et al., 2013) 
 
Figure 1.11: Biosynthetic pathway of P(3HB) in C. necator (adapted from Shrivastav et 
al., 2013) 
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1.6.3. Thermal and physical properties of P(3HB) 
P(3HB), an isotactic homopolymer of 3-hydroxybutyrate is the most commonly known PHA. 
The molecular mass of P(3HB) (between 200-20,000 KDa) is pivotal in all its biomedical 
applications and the manipulation of this feature is key in improving and altering the 
properties relevant to biomedical applications (Peña et al., 2014). The thermoplastic and 
crystalline properties of P(3HB) vary with increasing molecular mass. P(3HB) is known to 
exhibit a melting temperature (Tm) of 160 oC to 177 oC and a glass transition temperature 
(Tg) of -4 to 15oC. The Young’s modulus exhibited by P(3HB) is 400 MPa and compressive 
elastic modulus of 317 MPa. The properties of P(3HB) are comparable with petroleum-
derived plastics with 60-80 % crystallinity (Valappil et al., 2007).  P(3HB) is semi crystalline 
and often undergoes polymorphic crystallisation where the polymer crystallises into 
lamellar crystals and into zigzag crystals. 
1.6.4. Biodegradability of P(3HB) 
The significance of using biodegradable polymers in medical applications is to ensure that 
there are no post-operative procedures required for the removal of these polymers or their 
degradation products from the body (Verlinden et al., 2007). The degradation rate depends 
on the nature of the polymer, composition, molecular weight, crystallinity, structure, 
thickness, surface properties and environmental conditions. As a critical element in 
biomedical applications of polymers is the development of a temporary physical and 
mechanical support for the regeneration of newly formed tissues over time, it is imperative 
to understand the degradation rates of the polymer in question (Manavitehrani et al., 
2016).  
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Polyesters are primarily degraded through bulk and surface degradation brought about by 
hydrolysis and enzymatic activities. Hydrolytic degradation proceeds by autocatalysis that 
involves the hydrolysis of the ester linkages, and the enzymatic degradation explicitly 
depends on the specific enzyme that is responsible for the degradation of the ester linkage. 
3-Hydroxybutyric acid, the degradation product of P(3HB) naturally occurs in mammals and 
it has been observed that P(3HB) undergoes 35% reduction in molecular weight after six 
months within the body (Manavitehrani et al., 2016; Kunze et al., 2006). An earlier study 
however reported only 1.4% reduction over a period of six months for P(3HB) implanted in 
mice (Verlinden et al., 2007). This variation is concurrent with the argument that rates of 
enzymatic degradation of P(3HB) by PHA depolymerase is largely dependent on the 
crystallinity of the polymer as well as the availability of the enzyme. The absorption 
isotherms of PHA depolymerases obey Langmuir adsorption model where the enzyme 
irreversibly binds to the surface of the substrate until a saturation point is reached (Numata 
et al., 2009). As the degradation of amorphous regions of the polymer is much faster, the 
degradation rate of P(3HB) is primarily controlled by its crystallinity including the size of 
crystals, and lamellar thickness (Numata et al., 2009). 
1.6.5. Biocompatibility of P(3HB) 
To be suitable for use in biomedical applications, materials must not induce any 
immunological reactions when in contact with soft tissue or blood of the host, during 
implantation/ administration or degradation. Widespread occurrence of low molecular 
weight P(3HB) as an oligomer in animals and humans lead to high biocompatibility of 
P(3HB). R-3-hydroxybutanoic acid, the degradation product and monomeric component of 
P(3HB), is an innate cell metabolic product during de novo fatty acid synthesis in the liver 
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mitochondria. Various structures fabricated using P(3HB) have been shown to be 
compatible in animal models. These include sutures, nerve conduits, drug delivery systems, 
implantable rods and 3D scaffolds. The earliest studies on in vivo studies on P(3HB) were 
carried out by WR Grace and Co., in the 1960s. Subcutaneously and intramuscularly 
implanted P(3HB) filmstrips on removal after 8 weeks revealed no signs of immunogenic 
reactions or damage to the underlying area (Valappil et al., 2006). One of the longest in 
vivo investigations involving PHAs was conducted using P(3HB-co-3HV) films with 7, 14 and 
22% of valerate content, implanted in sheep for up to 90 days (Williams and Martin 2005). 
Although after one week of implantation, numerous macrophages, neutrophils and 
fibroblasts concurrent with inflammatory responses were observed at the site, which 
decreased with time. These immune cells were found to be present in fibrous capsules 
around the site of implantation and consisted largely of lymphocytes towards the later 
stages of implantation. Similar observations of fibrous capsule formation were made in 
mice subcutaneously implanted with P(3HB) and P(3HB-co-3HV) samples. The fibrous 
capsules formed were of 100-200 m in diameter and reduced to 100 m in six months. It 
was revealed that the size of capsules increased with valerate content. Sterilization of 
P(3HB) does not interfere with mechanical properties or molecular weight of the polymer. 
There are many reported instances of P(3HB) supporting excellent cell proliferation 
(Brigham and Sinskey 2012). P(3HB-co-3HV-co-3HHx) was researched as a supporting 
matrix for mesenchymal stem cells and it was noted that the material’s surface roughness 
and increased water contact angle contributed to enhanced adherence and cell 
proliferation (Guang-Zhen 2009). Most of the observed tissue responses elicited during 
implantation of P(3HB) based structures were found to be due to the implantation 
procedure, rather than its material properties. Even this was comparable with implants 
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made from silk or catgut materials currently used in surgical procedures. A study comparing 
immune responses elicited by PLA, P(3HB) and P(3HB-co-3HV) showed that P(3HB-co-3HV) 
elicited the least extent of immune response, followed by P(3HB) and then PLA, a 
biopolymer extensively used in commercial medical applications (Brigham and Sinskey 
2012). This makes a strong case for the need for switching to PHA based biomedical 
implants with suitable surface modifications. Hemocompatibility of P(3HB) films were also 
found to be favourable for its use in biomedical applications as the polymer did not affect 
platelet response or activate the complement system, when in contact with mammalian 
blood. The associated responses if any, were found to be due to the bacterial cell wall, 
necessitating a requirement for better purification methods as polymer from Gram 
negative bacteria may contain lipopolysaccharides. The alternative is to use P(3HB) 
produced from Gram positive bacteria. 
1.6.6. Biomedical applications of P(3HB) 
Due to the favourable biodegradation and biocompatibility of P(3HB) in in vitro and in vivo 
studies, the use of P(3HB) as homopolymer, co-polymer and blends of other organic 
materials such as hydroxyapatite (HA) and polyglycolic acid (PGA) has gained momentum. 
An early research established that materials based on P(3HB) to be structurally robust with 
no extensive break down during implantation. Bone tissue adaptation response had no 
evidence of an undesirable chronic inflammatory response after implantation periods up 
to 12 months. Bone regeneration occurred in close proximity to the implant interface with 
subsequent structural organisation, with up to 80% of the implant surface lying in direct 
contact with the new bone (Doyle, Tanner and Bonfield, 1991). In a similar research, 10-
50% compositions of HA with P(3HB) were analysed for its correlation to crystallinity and it 
Chapter 1: Introduction 
  41 
 
was observed that crystallinity increased from 77- 89% within this window. Ectopic bone 
formation assay performed in vitro and in vivo proved that the hybrid PHB/HA composites 
can function as scaffolds and that bone tissue develops on their surface and in pores 
(Shishatskaya, 2016). The other medical applications of P(3HB) are in the form of sutures, 
pericardial patches, stents, separating films, conduits, damaged tissue and dura mater 
substitutes, hard and soft tissue regenerative scaffolds and most extensively, drug delivery 
systems.  
1.7. P(3HB) in drug delivery 
Although there are many polymers with comparable thermal and physical properties to 
P(3HB), its surface eroding mode of degradation and non-toxic degradation products make 
it highly relevant and useful in the area of controlled drug delivery. P(3HB) microspheres, 
vesicles of polymer with entrapped or encapsulated Active Pharmaceutical ingredient (API), 
are conventionally fabricated using solvent evaporation of water-in-oil-in-water emulsions. 
Briefly, the polymer is dissolved in organic solvents such as chloroform, dichloromethane 
and methyl chloride, and then emulsified in water containing chosen surfactants. The 
emulsion is allowed to stir, during which the organic solvent evaporates, leaving behind 
spherical matrices of the polymer. This method, although easy to achieve on a bench scale, 
have few shortcomings in the form of polydisperse particle size distributions and low 
encapsulation efficiency, especially in the case of hydrophilic drugs (Chew, Hinojosa and 
Arriaga, 2017).  
Anaesthetics, antibiotics, anti-inflammatory agents, anticancer agents, hormones, steroids, 
and vaccines are some examples of the classes of APIs investigated in association with 
P(3HB) microspheres (Shrivastav et al., 2013). Gangrade and Price had reported one of the 
Chapter 1: Introduction 
  42 
 
earliest applications of P(3HB) microspheres for the incorporation of progesterone as a 
model drug. P(3HB) microspheres and P(3HB-co-3HV) microspheres were compared with 
respect to release kinetics, and P(3HB-co-3HV) spheres being less porous than P(3HB), 
exhibited slower release of the drug. This group also compared the effect of chloroform 
and methyl chloride as organic phases in the emulsion and it was found that the spheres 
formed using methyl chloride had smoother surfaces compared to the ones with 
chloroform (Gangrade and Price, 1992).  
Over the years, a lot of research has been carried out in antibiotic pharmacokinetics using 
P(3HB) microspheres. Francis et al., reported encapsulation of gentamycin, a hydrophilic 
aminoglycoside used against Gram positive and Gram-negative inflammatory bacteria, 
especially in the treatment of osteomyelitis. Systemic delivery of gentamycin extending up 
to 4-6 weeks is required for efficient control of infection and oral and parenteral delivery 
has been known to cause patient discomfort. This was proposed to be ameliorated by the 
use of P(3HB) microspheres, intended to be incorporated into 3D scaffolds for localised 
delivery. Uniform sized microspheres ranging from 1-2 m in diameter were obtained with 
an encapsulation efficiency of 48%. X- ray diffraction studies indicated the presence of 
surface adsorption of gentamycin that led to a burst release of about 60% and the 
remaining drug content was released in an almost zero order fashion within 24 hours 
(Francis et al., 2011). The same group followed up on these results with the incorporation 
of gentamycin encapsulated P(3HB) microspheres in 45S5 Bioglass®-based composite 
scaffolds, to be used in bone tissue engineering (Francis et al., 2010). The release kinetics 
of gentamycin from free microspheres compared with microspheres coated on the bioglass 
clearly showed a reduction in burst release, from 60% to 24% and was extended for 30 days 
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as opposed to the 24 -hour long deliveries from free microspheres (Francis et al., 2010). In 
a more recent study, titanium implants coupled with antibiotic loaded P(3HB) and PEG 
microspheres have also been reported with the same intent of post-operative infection 
prevention, which successfully rendered the titanium implants with antibacterial 
properties (Rodríguez-Contreras et al., 2016).   
One of the earlier reported studies involving P(3HB) in anticancer drug delivery has been 
the encapsulation of 5‐fluorouracil in microspheres fabricated using the copolymer P(3HB-
co-3HV), with a molar ratio of 85:15. Encapsulation efficiency of the microspheres prepared 
using water‐in‐oil‐in‐water (W/O/W), oil‐in‐water (O/W) and oil‐in‐oil (O/O) solvent 
evaporation method differed dramatically with 1% in the case of (W/O/W), 7% in the case 
of O/W and 80% in the case of O/O (Khang et al., 2001). The effect of acylglycerols on the 
release rate of the anticancer drug Lastet from P(3HB) microspheres (Abe, 1992), rifampicin 
loaded microspheres as chemoembolization agents (Kassab, 1997), the effect of fatty acids 
and alkyl esters on the release rate of anthracycline anticancer drug and aclarubicin from 
microspheres (Kazuhiko, Masahiro and Miko, 1986) are some of the noteworthy research 
in this context.  
Nanoparticles intended for drug delivery are submicron particles in which API is dissolved, 
adsorbed, dispersed, or encapsulated. The advantages of using nanoparticles include high 
stability, high carrier capacity, feasibility of incorporating both hydrophilic and hydrophobic 
drugs, and the feasibility of subcutaneous, and oral administration and inhalation 
(Gelperina et al., 2005). Polymeric nanoparticles have attracted huge interest due to the 
ease of surface modification, a strategy for target specific drug delivery. The specific 
advantage of nanospheres due to their smaller size range is that they can reach tissue 
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spaces that larger carrier systems cannot penetrate. In vitro and in vivo transdermal 
permeation of P(3HB-co-3HV) micro and nanospheres were compared by Eke et al., with 
the use of fluorescent Nile red to observe permeability. It was observed that while particles 
larger than 1.9 m were not suitable for intracellular uptake, nanoparticles were taken up 
by macrophages using phagocytosis (Eke et al., 2014). Along the same lines, a comparative 
study on P(3HB), P(3HBHHx) and PLA nanospheres of size 160, 250 and 150 nm were 
conducted to analyse cellular uptake, in this case using rhodamine B isothiocyanate (RBITC) 
as a fluorescent label. The study that demonstrated intracellular uptake of PHA 
nanospheres for the first time, established that PHA nanospheres had higher sustained 
release of 20 days as opposed to 15 days of release using PLA, and 7 days using free drug 
administrations. PHA nanospheres also exhibited 75% encapsulation efficiency of the 
hydrophilic dye (Xiong et al., 2010). P(3HB) and its copolymers are also employed in 
targeted drug delivery. Addition of PHA binding proteins, folate mediated targeting and 
PEGylation are some examples for strategies applied in targeted drug delivery using these. 
1.7.1. Addition of PHA binding proteins 
This strategy involves biochemical engineering of the PHA biosynthetic enzymes to 
incorporate favourable ligands or molecules that can help direct PHA granules to the 
designated delivery site. Two enzymes, namely PHA granule-associated proteins (PhaP) and 
PHA synthase (PhaC) were involved in this process. The former is a small molecular weight 
amphiphilic protein, which helps in stabilising the hydrophobic PHA granules in the 
aqueous environment of the bacterial cytoplasm and the latter covalently binds to cysteine 
residues of the PHA granules during polymerisation. Both these proteins are viable targets 
for modification of the granules, in creating fusion proteins (Nigmatullin et al., 2015). 
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Hepatocellular carcinoma is distinguished by overexpression of the epidermal growth 
factor receptor (EGFR). Yao et al., engineered PhaPs linked with recombinant human 
epidermal growth factor (rhEGF) and these were adsorbed on P(3HB-co-HHx) nanoparticles 
encapsulated with RBITC. In vivo studies in mice models demonstrated selective 
accumulation of the nanoparticles in tumour tissues, confirming the targeting ability of 
these constructs (Yao et al., 2008). In a similar study, P(3HB) nanoparticles surface 
functionalized with RGD4C coupled with PhaC were used to analyse the permeability of 
these nanoparticles in the breast cancer cell line MDA-MB 231. These Nile Red 
encapsulated particles exhibited effective internalization, emphasizing the feasibility of 
P(3HB) nanoparticles in surface modification to aid targeting (Lee et al., 2011). Following 
this, Kwon et al., incorporated A33scFv, specific to the A33 antigen overexpressed in 
colorectal cancers. The accumulation of particles was observed using fluorescence 
microscope and specificity was confirmed as cancerous cells accumulated increased 
amount of the nanoparticles (Kwon et al., 2014).  
1.7.2. Folate mediated targeting 
Cancer, by definition, is uncontrolled cell division. Folate, a molecule used in the 
biosynthesis of DNA bases, is abundantly used by continuously dividing cancer cells, and 
hence, certain cancer cells overexpress folate receptors. The density of these receptors on 
the cell surfaces is found to be linear with disease progression. Therefore, folate target is 
one of the most popular approaches in targeted delivery of anticancer agents (Nigmatullin 
et al., 2015).  Zhang et al. compared inhibitory concentrations (IC50) of free doxorubicin, 
P(3HB-co-3HO) nanoparticles encapsulating doxorubicin, and folate-conjugated P(3HB-co-
3HO) nanoparticles encapsulating doxorubicin (DOX/FA-P(3HB-co-3HO)) and the IC50 were 
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found to be 2.8 μmol L−1, 27.3 μmol L−1 and 0.87 μmol L−1 respectively.  The drastic change 
in IC50 with folate incorporation affirms its role in cellular uptake of particles (Zhang et al., 
2010). In a similar study Hazer et al., compared etoposide encapsulated P(3HB-co-3HHx) 
nanoparticles conjugated with folate and free etoposide and found that the former elicited 
32% cytotoxicity and the latter only 12%. The comparatively low cytotoxicity may have 
been due to the reduced folate receptor expression on L929 cells used in this study (Hazer 
et al., 2011). Folate conjugation of DDS is far more efficient than folate conjugation of free 
drug as receptor saturation is sooner to occur with small molecules and therefore 
comparatively less amount of drug would be endocytosed, whereas when the entire DDS 
is endocytosed, it would have larger amount of the drug encapsulated in it. 
Folate mediated targeting has certain limitations. First of all, not all cancer types over 
express folate receptors (example: prostate cancer). Due to high affinity of folate to its 
receptors, the folate conjugated DDS particle might not be able to release the drug cargo 
at a rate that would achieve the desired therapeutic window (Garcia-Bennett, Nees and 
Fadeel, 2011). Folate can also be competitively inhibited by serum folate binding (Xing et 
al., 2018). 
1.7.3. Other surface functionalization strategies 
With growing understanding of the metabolics and genomics of cancer, it has been easier 
to strategize the development of various theranostic nanoparticles. PEGylation is such a 
common strategy, which enhances retention time by increasing serum circulation, 
solubility and to some extent, targeting (Mishra et al., 2016). However, PEG is a non- 
biodegradable polymer and therefore it is put to best use when in combination with 
biodegradable polymers, in small quantities. Marine bacterial enzyme glutaminase, which 
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inhibits cancer proliferation by inducing glutamine deprivation was immobilized on 
PEGylated P(3HB) nanoparticles. These were tested on HeLa cells for the effect of the 
immobilized enzyme on cancer proliferation. Concomitantly, the cells were also subjected 
to growth in glutamine free medium. The results obtained were comparable with similar 
dented anatomy of cells and shrunken nucleus (Pandian et al., 2015).Other targeting 
strategies include the use of markers specific for receptors such as HER-2 (breast), CD 44+ 
(breast, head and neck, ovarian, pancreas), CD 133+ (colon, pancreas), CD34+, CD 38- 
(Acute Lymphoblastic Leukemia) and CD 34+ (Multiple Myeloma) (Schatton, Frand and 
Frank, 2010). 
1.8. Aims and objectives 
The aim of this project was to produce LPS free P(3HB) from B. cereus SPV and B. subtilis 
OK2, and to optimise the production of microspheres and nanospheres from them, for 
various drug delivery applications. The specific objectives of this research are as follows: 
1) Large scale production of P(3HB) from B. cereus SPV and B. subtilis OK2, and 
characterisation: The polymer will be produced from these two microorganisms to 
obtain LPS free P(3HB). The polymer thus obtained will be characterised for their 
structural properties using FTIR, chemical properties using NMR and thermal 
properties using DSC. The molecular weight of the polymer produced will be 
analysed using GPC 
2) Optimisation of the synthesis of P(3HB) microspheres and nanospheres: The 
polymer produced will be used to synthesise microspheres and nanospheres of 
varying size ranges. Process parameters such as polymer concentration, PVA 
concentration and stirrer speed will be manipulated to obtain optimum conditions, 
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using Box-Behnken Response surface methodology. The spheres produced will be 
characterised for particle diameter, porosity, surface hydrophobicity and 
degradation. 
3) Encapsulation of cardiovascular drugs: Antiproliferative drugs namely rapamycin 
and tacrolimus will be encapsulated in P(3HB) spheres. P(3HB) microspheres 
encapsulated with rapamycin will be compared against PLLA microspheres with 
respect to fabrication process and physical characteristics. The drug release profile 
of these will be compared using widely published mathematical and kinetic models. 
Release of tacrolimus from P(3HB) microspheres and nanospheres will be analysed 
the same way as mentioned above. Finally, VEGF release from P(3HB) microspheres 
and nanospheres will be compared with their counterparts embedded in collagen. 
4) Encapsulation of porphyrin derivatives and analysis of their effectiveness in 
targeted anticancer therapy: P(3HB) microspheres will be encapsulated with 3 
different porphyrin derivatives and their effectiveness in reducing cell viability will 
be tested. The data generated will be compared against the same formulations 
conjugated with the anticancer marker anti-HER-2. 
5) Optimisation of microsphere synthesis from P(3HB)- HA conjugate: The 
amphiphilic conjugate will be used to produce microspheres using cross-linking 
method in oil-in-water emulsion. Hydrophilic drugs (aspirin and gentamicin) and 
hydrophobic drug (curcumin) will be encapsulated in these and their drug release 
profile will be compared. The formulations with encapsulated curcumin will be 
tested for their antimicrobial activity against MRSA.
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2.1. Materials  
2.1.1. Water 
Deionised water was used for media preparation and High-Performance Liquid 
Chromatography grade water was used in all other experiments.  
2.1.2. Chemicals and Reagents 
All the chemicals for growth and production media were purchased from Sigma-Aldrich or 
Thermo Fisher Scientific UK or VWR (Leicestershire, UK) except for nutrient broth and yeast 
extract, which was obtained from DIFCO (BD UK Ltd., Oxford, UK). Antifoam (FG-10) was 
purchased from DOW corning (Edison, NJ, USA) for use in fermentation studies. For 
analytical experiments, such as GC-MS and HPLC, analytical grade reagents were used. Cell 
culture studies were carried out using cell culture grade media and reagents from Sigma-
Aldrich, UK, and Lonza, UK. Human Vascular Endothelial Growth Factor (VEGF) was 
purchased from Sigma- Aldrich and VEGF ELISA kit was purchased from Thermo Fisher 
Scientific UK. 
2.1.3. Bacterial strains and cultures 
P(3HB) was extracted from the Gram-positive bacteria Bacillus cereus SPV and Bacillus 
subtilis OK2, both of which were obtained from the culture collection of University of 
Westminster, London, U.K.  Methicillin Resistant Staphylococcus aureus (MRSA) was 
obtained from the culture collection of University of Westminster, London, U.K.  All 
chemicals required for the polymer production from the two bacteria and extraction of 
polymer from the bacterial cells were obtained from Sigma-Aldrich Company Ltd. and VWR 
Chemicals (England).  
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2.1.4. Cell lines and maintenance 
Human dermal microvascular endothelial cells (HMEC-1), used for biocompatibility studies 
were obtained from the University of Westminster cell line collection. Cell culture studies 
for assessing photodynamic activity of the porphyrin-encapsulated microspheres by 
quantifying cytotoxicity were carried out on SK-BR-3 cells obtained from the University of 
Westminster cell line collection. 
2.1.5. Plasmids 
The red fluorescent protein containing Anti-HER-2 plasmid was obtained from Dr. Anatoily 
Markiv, University of Westminster. 
2.1.6. Porphyrins 
Protoporphyrin IX (PP) was purchased from Sigma- Aldrich. Hematoporphyrin ether (HP) 
and Tetraphenyl porphyrin (TPP) were synthesised by Dr. Eugen Stulz’s Group at the 
University of Southampton. 
2.1.7. Reagents used for the in vitro drug release and in vitro 
degradation studies 
2.1.7.1. Phosphate buffered saline solution (PBS): 
Phosphate buffered saline solution (PBS) purchased from Sigma-Aldrich, (Dorset UK) was 
used for the in vitro drug release studies, one tablet in 200 mL of water. 
2.1.7.2. Simulated body fluid (SBF): 
SBF was prepared using the components, HPLC grade water 1500 mL, sodium chloride 
15.92g, sodium bicarbonate, 0.72g; potassium chloride, 0.44g; potassium phosphate 
dibasic trihydrate 0.45g; magnesium chloride hexahydrate, 0.61g; calcium chloride, 0.55g; 
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sodium sulphate, 0.142g; TRIZMA® base, 12.11g; and hydrochloric acid to adjust pH to 7.25. 
2.1.8. Buffers and Reagents 
2.1.8.1. Buffers for SDS-PAGE: 
2X sample buffer for sodium dodecyl sulphate-Polyacrylamide gel electrophoresis (SDS-
PAGE) 
The components were 0.125 M Tris-HCl, pH 6.8, 15% glycerol (v/v), 6% SDS, and 0.005% 
bromophenol blue. 50 µL of ß-mercaptoethanol was added to 1 mL of sample loading 
buffer. 
2.1.8.2. Resolving gel buffer 
The components were 1.5 M Tris-HCl, 0.4% SDS 
2.1.8.3. Stacking gel buffer 
The components were 0.5 M Tris-HCl, 0.4% SDS 
2.1.8.4. 5X Reservoir Buffer 
The components are Tris Base 15g, 72g glycine, 5g SDS (g/L) 
2.1.8.5. Coomassie brilliant blue stain (for staining SDS-PAGE gels) 
0.025% Brilliant Blue R stain dissolved in 10 mL acetic acid (100%) and 90 mL water. 
2.1.8.6. Destaining solution (for destaining SDS-PAGE) 
10% acetic acid (100%) in water. 
2.1.8.7. 5X TBE, pH 8.0, (g/L) 
The components are Tris Base 54, Boric acid 27.5, EDTA 4.5 
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2.1.9. Media components 
Kannan and Rehacek media (g/L): Yeast extract 2.5, Potassium chloride 3, Ammonium 
sulphate 5 and Soybean dialysate 100 mL/L 
Soybean dialysate: Dialysis of 10 g of defatted soybean flour in 1L of distilled water for 
24 hr. at 4oC. 
Glucose (20g/L for B. cereus SPV and 30g/L for B. subtilis OK2) 
2.2. Experimental methods: 
2.2.1. Production of P(3HB) 
The P(3HB) polymer production was carried out in Kannan and Rehaceck media using 
glucose as a sole carbon source (Rai, 2010). To this end, a single colony of either B. cereus 
SPV or B. subtilis OK2 was used to inoculate nutrient broth and the culture was grown at 
30 oC and 200 rpm until mid-log phase (O.D. 3 at 600nm) was reached. This culture was 
then used to inoculate the PHA production media. P(3HB) production was carried out in 20 
L fermenter with a 14 L working volume with an inoculum of 1.4 L culture, which was 
prepared using a single bacterial colony obtained from a nutrient agar plate. The 
fermenters containing only the salts of the production medium were sterilized separately 
without the addition of glucose and soybean dialysate to avoid any caramelisation. These 
were added later at the time of inoculation. The media components were maintained at a 
pH of 6.8 using 1 N NaOH or 1 N HCl. The fermentation was run with an initial 100% 
Dissolved Oxygen tension (DOT), airflow rate at 1.0 vvm (volumetric air flow rate), impeller 
speed of 200 rev/min and at a temperature of 30°C. The pH, DOT, glucose concentration 
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and optical cell density were monitored throughout the run by taking samples every 3 
hours. Polymer yield over time was recorded as a fraction of dry cell weight. The temporal 
profile of polymer production from the two bacteria was plotted using SYSTAT Software 
Inc. Sigma-Plot 12.5. 
2.2.2. Optical density 
The optical density of the inoculum was measured at all instances using nutrient broth as 
blank. OD readings were taken at 600 nm (absorbance) in a standard spectrophotometer 
(Novaspec II visible spectrophotometer, UK). The mid log phase was used for the 
inoculation of production media. 
2.2.3. Temperature, pH and dissolved oxygen tension (DOT) 
Temperature and DOT levels were monitored online using the temperature and DOT 
probes (polarographic oxygen-sensing probe (Inglold, Metler-Toledo Ltd., Beaumont Leys, 
Leicester, UK) which were connected to the fermenter vessel. The pH of the production 
medium was measured offline (Jenway pH meter 3305, UK) by collecting samples from the 
fermenter at regular intervals. 1 mL of samples drawn at every 3 hours were used to record 
OD. These samples were then centrifuged at 13,000 rpm for 10 minutes and the 
supernatant was used to record pH and the pellets were lyophilised to quantify periodic 
dry cell weight accumulation. 50 mL samples drawn from 4 different time periods during 
growth were used to quantify polymer yield over time. 
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2.2.4. Polymer extraction techniques 
2.2.4.1. Extraction of PHA by chloroform/ sodium hypochlorite dispersion 
The culture was harvested after 48 hours of growth and then was centrifuged at 4600 rpm 
for 30 min. The cell pellet obtained was then washed with deionised water and lyophilised. 
The lyophilised cell biomass was thoroughly ground and incubated in a dispersion 
containing 80% of sodium hypochlorite and chloroform in 1:4 ratio at 30oC, for two hours 
at 150 rpm. The resulting slurry was then centrifuged at 4600 rpm for 20 min, to obtain 3 
layers, of which the first layer was that of the sodium hypochlorite solution, the middle 
layer was that of the cell debris and the bottom most layer was that of the chloroform 
containing the dissolved polymer (Figure 2.1).  
 
Figure 2.1: Layers containing sodium hypochlorite with cell debris and chloroform 
with polymer 
 
The chloroform layer was separated by manually removing the first two layers using spatula 
and filters. This layer of chloroform containing the dissolved polymer was then 
concentrated to an oily consistency using the rotary vacuum evaporator. The dissolved 
polymer was precipitated using ten volumes of ice-cold methanol under continuous 
stirring, on a magnetic stirrer (Rai et al., 2011). 
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2.2.4.2. Soxhlet extraction method 
The lyophilised biomass was thoroughly ground using mortar and pestle and filled in 
cellulosic thimbles up to half way. This was set up in a soxhlet apparatus with methanol as 
the first solvent, to dissolve the cell membrane to expose the polymer. This was allowed to 
reflux until the condensed methanol flowing down the side arm was colourless. The 
methanol was then replaced with chloroform and was refluxed for a further 24 hours to 
allow the polymer to be dissolved in chloroform. This chloroform was then filtered and 
subjected to differential precipitation using ice cold methanol as explained in the section 
above. 
2.2.5. Characterization of the P(3HB) produced 
2.2.5.1. Fourier Transform Infrared Spectroscopy (FTIR) 
The FTIR spectra of the polymers were recorded using Perkin-Elmer Spectrum Two 
Spectrometer in the range between 4000 to 450 cm-1. The spectral resolution was 4 cm−1. 
2.2.5.2. Nuclear Magnetic Resonance Spectroscopy (NMR) 
NMR spectra were analysed using the MestRec software package, at Eastman Dental 
Institute, University College London, UK. 20mg of polymer samples were prepared by 
dissolving in 1 mL of deuterated chloroform. Chemical shifts are referenced against residual 
solvent signal (7.26 ppm and 77.0 ppm for 1H and 13C respectively). Bruker AV400 (400 
MHz) spectrometer was used for analysis. 
2.2.5.3. Molecular weight analysis 
Molecular weight analysis was done using Agilent 1260 Infinity system equipped with a 
refractive index detector (Agilent Technologies, UK). PLgel 5um MIXED-C (300 x 7.5 mm) 
column was calibrated using polystyrene standards (Easivial PS-H, Agilent Technologies, 
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UK) of narrow molecular weights from 162 Da to 7.0 kDa. Chloroform was used as a mobile 
phase at a flow rate of 1 mL/min. 2 mg/mL polymer solutions in chloroform were used for 
the analysis and injection volume was 50 µL. 
2.2.6. Production of P(3HB) micro/nanospheres 
2.2.6.1. Solid-in-oil-in-water emulsion technique 
Micro/nanospheres were synthesised as follows: 20 mL P(3HB) solutions of specified 
concentrations in chloroform were prepared by dissolving the polymer in air tight bottles 
for 15 hours. The solutions were then homogenised for 5 minutes, with 40 mL of Polyvinyl 
alcohol (PVA), of specified concentration. This was then transferred drop wise to 100 mL of 
polyvinyl alcohol (PVA) solution of specified concentrations and stirred at specified speed 
for 10 minutes, to allow evaporation of the chloroform. Alternatively, according to different 
methods tried, the polymer solution was directly added to PVA solution and homogenised 
for 5 minutes. This was further transferred to 500 mL of PVA solution and stirred for 4 hours 
at the specified speed. The process was carried out in the dark where photosensitizers were 
involved. The microspheres were centrifuged at 4600 rpm for 5 min and then washed with 
10% ethanol once and distilled water three times, and freeze dried (Savant Modulyo D 
Freeze drier, Thermoelectron Corp, UK) (Francis et al., 2011).  
The drug-loaded microspheres were also prepared using the same solid-oil-in water 
emulsion technique. For this the drugs were added to the first water-in-oil emulsion (w/o) 
of aqueous polyvinyl alcohol (PVA) solution, in the case of hydrophilic drugs and then 
transferred to a second water-in-oil-in water emulsion (w/o/w) aqueous PVA solution. In 
the case of hydrophobic drugs, these were added directly to the polymer solution and 
homogenised. Following centrifugation, the microspheres were lyophilised and stored at 
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4°C for further use. The different drugs/proteins loaded during P(3HB) microsphere 
production is shown in Table 2.1. 
Drug Amount 
Rapamycin 1 & 5% 
Tacrolimus 1, 5 and10 % 
Protoporphyrin IX 1, 5 and10 % 
Hematoporphyrin ether 1, 5 and10 % 
Tetraphenyl porphyrin 1, 5 and10 % 
Gentamycin 10 % 
Aspirin 10 % 
Curcumin 10 % 
VEGF 10 g/ 0.13g 
Table 2.1: Drugs encapsulated and their wt.% with respect to polymer 
 
2.2.6.2. Optimisation of microsphere production 
Based on literature research and previous established results by Francis et al., 2011, 3 
factors, namely polymer concentration, surfactant concentration and revolutions per 
minute were considered as the most significant contributing factors and a set of pilot 
experiments were carried out to establish boundary limits. A Box-Behnken Response 
surface methodology design was generated using MiniTab software 6.0 (trial version). 
Particle size was set as the response and the significant effects were analysed to obtain 
optimized results. 
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2.2.7. Preparation of Amphiphilic HA- P(3HB) microspheres 
2.2.7.1. Hydrolytic depolymerisation of P(3HB) and HA conjugation 
Oligomeric derivatives of P(3HB) was obtained via partial depolymerisation as follows. 3 g 
of dry P(3HB) was added to a mixture of 166 mL of glacial acetic acid and 34 mL of distilled 
water. The mixture was refluxed at 100-105°C for up to 30 hours. Resulting polymer was 
precipitated into excess of cold methanol and washed several times with distilled water. 
This was then lyophilised to obtain dry polymer. Dr. Rinat Nigmatullin conducted this part 
of the experiment, with the researcher’s minor contributions. This product was sent to 
ContiPro a.s. in Czech Republic for conjugation to hyaluronic acid (HA). The HA- P(3HB) 
conjugate thus produced was chemically characterised at ContiPro a.s. 
2.2.7.2. Amphiphilic HA- P(3HB) microsphere preparation 
Microsphere production using a water-in-oil (w/o) dispersion method was optimised 
through use of varying polymer concentrations, oil phases, surfactants and crosslinking 
agents shown in the Table. Polymer was first dissolved in a specified volume of 1.7% acetic 
acid and homogenised in paraffin oil containing specified surfactants. Encapsulated drugs, 
that include aspirin, gentamicin, and curcumin were added to polymer solution before 
homogenisation. The homogenised solution was added slowly to a specific volume of 
paraffin oil and surfactant under constant stirring at 1000 rpm. Effect of crosslinking agents 
such as Glutaraldehyde Saturated Toluene (GST) and 1% Glutaraldehyde were analysed by 
adding at specified time intervals (Table 2.2.). The spheres were subsequently centrifuged 
(4600 rpm) and washed four times with the desired oil-removing solvent, the final wash 
using acetone. Three separate solvents were trialled: hexane, isopropanol and petroleum 
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ether, with only the isopropanol effectively removing residual oils. The spheres were then 




Oil- Phase Surfactant Crosslinking 
Agent 
0.01 Ethyl acetate Nil Nil 
0.05 Ethyl acetate Nil Nil 
0.01 Ethyl acetate Nil GST 
0.01 Ethyl acetate Span 80 GST 
0.01 Paraffin oil/ 
Petroleum ether 
Tween 80 GST 
0.01 Paraffin oil/ 
Petroleum ether 
Span 80 (1% v/v) GST 
0.01 Paraffin oil Tween 80 1% Glutaraldehyde 
0.01 Paraffin oil 1% Span 80 1% Glutaraldehyde 
0.01 Paraffin oil Span 80 (0.1% v/v) Heat 
0.01 Paraffin oil Span 80 (0.1% v/v) GST 
Table 2.2: Optimization conditions for Amphiphilic microspheres 
2.2.8. P(3HB) microsphere: physical characterization techniques 
2.2.8.1. Microstructural studies using Scanning Electron Microscopy (SEM) 
The surface morphology and size distribution of the microspheres were observed and 
imaged using FEI XL30 FEG Scanning Electron Microscope at Eastman Dental Institute, UCL, 
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UK. The samples placed on 8 mm diameter aluminium stubs were coated with gold using a 
sputtering device (Polaron E5000 Sputter Coater). 
2.2.8.2. Particle size analysis 
Image J software was used to quantify particle distribution using images captured using 
SEM. The images were appropriated to suitable thresholds and the analysis was calibrated 
using pixel to scale bar. Distribution curves were plotted using MS Excel, using data 
generated from particle size analysis on Image J. 
2.2.8.3. Porosity 
The porosity (ε) of the microspheres was measured using liquid displacement method. 5 
mL of ethanol was added to a pre-weighed measuring cylinder and weighed. A certain 
weight of microspheres was added to this ethanol and sonicated to assist penetration of 
methanol into the pore spaces. Excess ethanol above the 5 mL mark was removed, and the 
cylinder was weighed again. Following this, the microspheres were removed from ethanol 
by decanting and the weight of the ethanol and cylinder were recorded. Porosity was 
calculated using the formula, 
ε= (W2-W3-Ws)/ (W1-W3) 
W1 is the weight of the cylinder filled with ethanol before the immersion of the 
microsphere sample, W2 is the weight of the cylinder, the ethanol and the sample after 
removing the excess ethanol above the 5 mL mark, W3 is the weight of the cylinder and 
ethanol after removing the microsphere sample saturated with ethanol, and Ws is the 
weight of the microsphere sample used in the measurement (Francis et al., 2011). 
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2.2.8.4. Determination of Residual PVA content 
Iodine can form a coloured complex between the adjacent hydroxyl groups of PVA and this 
property is exploited in quantifying residual PVA (Yang et al., 2008). 2mg of microsphere 
samples were treated with 2 mL of 0.5 M sodium hydroxide (NaOH) for 15 minutes at 60 
oC followed by neutralization with 900µL of 1 N hydrochloric acid (HCl). The volume was 
adjusted to 5 mL with distilled water. To each of the samples, 3 mL of 0.65 M solution of 
boric acid, 0.5 mL of iodine solution (I2)/Potassium iodide (KI) (0.05 M/0.15 M) and 1.5 mL 
of distilled water were then added. The absorbance of this complex was measured at 690 
nm (Novaspec II Visible spectrophotometer, UK) after 15 mins of incubation. A standard 
plot of PVA was also prepared under identical conditions (Francis et al., 2011). 
2.2.8.5. Determination of surface hydrophobicity 
1 mg microsphere samples were incubated with different concentrations of Rose Bengal 
dye (0-50 g/mL) for 3h at room temperature. Dye solutions of all the concentrations, 
without any microspheres were used as controls. The samples were then centrifuged at 
13,000 rpm for 30 minutes in a microcentrifuge (Sorvall legend RT, UK). The supernatant 
was analysed at 542.7nm (Novaspec II Visible spectrophotometer, UK) to determine the 
unbound dye. Dye bound on microspheres were calculated with reference to each of the 
control. 
2.2.8.6. Protein adsorption studies 
20 mg of samples prepared under different conditions were immersed in a BSA solution of 
0.2mg/mL concentration. These were incubated for 24 hours at 37 oC. The samples were 
centrifuged at 12,000 rpm and the supernatant was subjected to Bradford assay to 
determine the amount of unbound BSA. The basic principle is that amino acid residues such 
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as arginine, lysine and histidine bind with Coomassie blue of the Bradford’s reagent under 
acidic conditions to give a coloured complex. Briefly 1.5 mL of Bradford’s reagent was 
added to 30 μL of diluted samples and standards. This was incubated at room temperature 
for 5 minutes and absorbance was measured at 280nm. Protein adsorbed on the surface of 
the samples was calculated using the following equation 
Q= (Ci - Cf)V/m 
Where Ci is the initial concentration of BSA and Cf is the final BSA concentration in the 
supernatant after centrifugation, V is the total volume of the solution and m is the weight 
of the samples. 
2.2.8.7. In vitro degradation  
In vitro degradation studies were carried out by incubating 10mg of micro/nanosphere 
samples in 1 mL of PBS, at 37 oC, in a shaken incubator. Samples were removed at specified 
time points and analysed for water adsorption (% WA) and weight loss (%WL) and weight 
loss as described below. pH changes of the samples in PBS were also periodically recorded. 
2.2.8.8. Water uptake and weight loss measurement 
The dry weight samples were measured before incubation and recorded (Mo dry, initial dry 
weight). These were then incubated in PBS for time periods ranging up to 12 months and 
samples were periodically removed. The micro/nanosphere samples were centrifuged at 
4600 rpm for 5 minutes and supernatant was removed, and the weights of the samples 
were recorded (Mt wet). The samples were then dried in an incubator overnight at 37 oC 
and the weight was recorded (Mt dry). Water uptake and weight loss were calculated using 
the following equations. 
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%WA= (Mt wet— Mt dry)/ (Mt dry) 
and 
%WL= (Mo dry- Mt dry)/ (Mt dry) 
Where (Mo, dry) is the weight of the samples before immersion (Mt, wet) is the weight of 
the wet samples (Mt, dry) is the weight of the samples after drying. 
2.2.8.9. Swelling studies on HA-P(3HB) microspheres 
HA-P(3HB) microsphere samples were subjected to swelling studies under various physical 
conditions such as different ionic strengths (Five NaCl solutions (pH = 7.4) of ionic strength 
0.0001-1 M), pH (3, 6, 6.8, 7.4 and 10) and temperature (20, 30 and 37 oC). Briefly, Pre-
weighed (Md) samples were immersed in respective solutions and were periodically 
removed and mass of the swollen state (Ms) was measured. Swelling ratio was calculated 
using the formula 
Q = (Ms – Md) x 100 / Md. 
Water content in the amphiphilic microspheres were calculated using the formula 
Water content= Ms x 100 /Md 
Where Md is the dry weight of the microspheres and Ms is the weight of the microspheres 
in swollen state. 
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2.2.8.10. Biocompatibility studies 
I. Cell culture maintenance of HMEC-1 
To establish biocompatibility of the micro/ nanospheres prepared, they were subjected to 
cell viability assays on HMEC-1 cells. All media components and trypsin were filter sterilized 
and pre-warmed to 37 oC prior to use. Cells stored in liquid nitrogen were thawed to 37 oC 
and seeded in 75 cm2 tissue culture grade flask in Dulbecco’s Modified Eagle Medium 
(DMEM), supplemented with 10% foetal calf serum, 2 mM L-glutamine and 1% w/v 
penicillin and 1% w/v streptomycin solution. The cells were incubated at 37 oC, 5% CO2, and 
intermittently changing media every 2 days. The cells were observed for confluency using 
a microscope and were trypsinised to allow for cell detachment. Fresh media was added to 
detached cells and was centrifuged at 500g for 10 minutes. Supernatant was removed, and 
fresh media was added to cells and seeded into new flasks.  
II. Sample sterilization 
Samples were placed using sterilized spatula in 24-well plates and subjected to UV 
sterilization, as alcohol sterilization of samples has been known to compromise sample 
properties. Shortwave 254nm UV sterilization was used in a SI-950 UV Benchtop incubator 
with a height of 18 inches, for 30 minutes.  
III. Cell seeding 
60-70% confluent cells were detached by trypsinisation and added to sterilised samples at 
a cell seeding density of 20,000 cells/cm2. Cell proliferation up to day 21 was quantified 
using the MTT assay. Standard tissue culture plate was used a positive and 4% hydrogen 
peroxide was used as negative control. The plates were incubated under the same 
conditions as mentioned in the above section.  Cell viability was expressed as 
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Cell viability= mean absorbance of cells on samples/ mean absorbance of cells on tissue 
culture plates. 
2.2.9. Drug quantification methods 
2.2.9.1. Determination of the drugs:  encapsulation efficiency 
The percentage encapsulation efficiency of the drugs was calculated using the formula  
%EE= Experimental drug loading/ Actual drug loading. 
The supernatant from washing step in the preparation of microspheres were collected to 
analyse drug loading. Standard plots of each of the drug were prepared using varying 
concentrations, in triplicates. From the linear regression, the amount of drug leached out 
in the supernatant was calculated. This was subtracted from the actual amount of drug 
loaded to get experimental drug loading. 
i. High Performance Liquid Chromatography (HPLC) for Rapamycin 
Isocratic elution at a flow rate of 1.0 mL/min was employed on a C18 60 RP column 
(250x4.6mm, 5µm in particle size) column at 25 oC. The mobile phase consisted of 
acetonitrile: methanol 20:80 (V/V). The UV detection wavelength was 272nm and 20µL 
sample was injected. 
ii. HPLC for Tacrolimus 
HPLC analysis was carried out using a C18 60 RP column (dimensions 250 mm x 4.6 mm,5μm 
in particle size. The UV detection wavelength was 210 nm and 20 μL sample was injected 
(Dionex HPLC). The detector temperature was set at 37 oC. Mobile phase used was 
Acetonitrile (100%) and flow rate was 1 mL/min. 
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iii. Fluorescence spectrometry for Porphyrin quantification 
The amount of porphyrin encapsulated was quantified using a fluorescence 
spectrophotometer (Eppendorf Biophotometer, U.K).  the encapsulated porphyrin 
derivatives were quantified under the following condition: PP: λ excitation: 400 nm; λ 
emission: 632 nm; HP λ excitation: 395 nm; λ emission: 630 nm and TPP was λ excitation: 
420 nm; λ emission: 651 nm; all three with a bandwidth of 0.5 nm and excitation and 
emission slit: 10/10. 
iv. UV-VIS spectrometry for Curcumin quantification 
Curcumin was quantified using UV spectroscopy (Eppendorf Biophotometer, U.K), at 422 
nm. 
v. UV-VIS spectrometry for Gentamycin quantification 
Gentamycin extracted in the water phase was treated with equal volume of ninhydrin and 
subjected to heat treatment in a water bath at 95 oC for 15 minutes and cold treatment in 
ice cold water for 10 minutes. This complex was subjected to UV spectrophotometry 
evaluation with the wavelength of 418 nm (Ismail et al. 2016).  
vi. UV-VIS spectrometry for Aspirin quantification 
Aspirin was quantified using UV spectroscopy (Eppendorf Biophotometer, U.K), at 299 nm. 
vii. VEGF quantification using VEGF human ELISA kit 
VEGF encapsulated was calculated using the VEGF human ELISA kit. The samples and 
controls were added to ELISA plates with immobilized antibody. The VEGF antibody 
complex was washed to remove any unbound samples and then subjected to treatment 
with a second detector antibody with a conjugate enzyme, that binds to a different epitope 
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on the target antibody. The microplates were then washed to remove any unbound 
substances and a substrate specific to the enzyme, was added, resulting in a coloured 
complex. The absorbance of this complex was read at 540 nm. 
2.2.10. Drug release kinetics 
10mg each of drug-encapsulated microspheres were immersed in 2 mL of PBS and 
incubated at 37 oC. 1mL samples were drawn periodically and 1mL fresh PBS was added to 
the samples. Drug release was detected using the methods described as above. 
2.2.11. Application of drug release data on mathematical models 
The cumulative drug release (of each of the DDS prepared) at each time point was 
expressed as a fraction of the actual drug loading. The data generated were fitted in zero- 
order, first- order, Higuchi, Hixson- Crowell and Korsmeyer-Peppas models. All equations 
were fitted to the whole release profile, except for Korsmeyer-Peppas in which only 60% 
was fitted. To linearize the obtained data, the following plots were generated (Table 2.3) 
and the R2  value of each of them was compared. The model with the highest R2 value was 
identified as the best fit for each drug release.  
Model Graph 
Zero- order % Cumulative release vs time 
First- order Log (% cumulative drug remaining) vs time  
Higuchi % Cumulative release vs time1/2 
Hixson- Crowell % cumulative drug remaining1/3 vs time 
Korsmeyer-Peppas Log (% Cumulative release) vs Log (time) 
Table 2.3: Drug release models 
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2.2.12. Protein expression and purification 
To express the RFP-anti HER-2, Rosetta gami B(DE3) E. coli (EMD Chemicals Inc., Gibbstown, 
NJ) cells were transformed with the appropriate plasmid and grow on LB agar 
supplemented with carbenicillin and chloramphenicol (100 μg/ mL and 34 μg/mL final 
concentration respectively), 37°C for 18 hours. A single colony was inoculated into 10 mL 
of LB media (with antibiotics) and grown at 37°C (with shaking at 250 rpm) for 16 hours. 10 
mL of this was then added to 200 mL of pre-warmed LB media, prepared in 1 L conical flasks 
(with antibiotics) and incubated at 37°C and 250 rpm, to O.D. 0.5 at 600 nm. The culture 
was then placed on ice for 30 minutes and isopropyl -D-1- thiogalactopyranoside (IPTG) 
added to a final concentration of 1mM to induce expression. This was then incubated at 
20°C for 20 hours at 250 rpm. 50 mL aliquots of the culture were centrifuged for 20 minutes, 
5,000 rpm at 4°C (using Sorvall SuperT 21 bench top centrifuge, with SL-250T rotor) and the 
pellets were used for cytoplasmic protein extraction. Using immobilised metal ion 
chromatography (IMAC), the proteins were enriched from the cell lysate on 1 mL HisTrap 
HP Ni Sepharose™ column using the ÄKTAprime™ plus purification system. The fractions 
were then analysed with 12% SDS-PAGE Tris- glycine gels stained with Coomassie blue 
(Markiv et al., 2011). Concentration of the protein purified was calculated by the 
spectrometric method using Thermo Scientific™ NanoDrop. 
2.2.13. Surface adsorption of anti-HER2 on porphyrin encapsulated 
microspheres 
Microspheres were dispersed in PBS, pH 5.0, (10 mg/mL) and a 600 μL aliquot was mixed 
with 200 μL of a solution of anti-HER-2 (2 mg/mL) and adjusted to the volume of 500 μL 
with phosphate buffer. Monoclonal antibody (anti-HER-2) was adsorbed onto the 
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microspheres at 4°C for 24 h, and then centrifuged at 10,000 rpm for 15 min 
(microcentrifuge Sorvall legend RT, UK) to separate microspheres from free anti-HER-2. The 
pellet was washed with phosphate buffer saline (PBS), pH 7.4, and re-dispersed in 500 μL 
of PBS, pH 7.4. The control was run the same way as the sample, but PBS was used instead 
of anti-HER-2 solution. The supernatant was subjected to Bradford’s assay to quantify anti-
HER-2 adsorbed on the microspheres (Kocbek et al., 2007). Briefly 1.5 mL of Bradford’s 
reagent was added to 30 μL of diluted supernatants and standards. This was incubated at 
room temperature for 5 minutes and absorbance was measured at 280nm. Protein 
adsorbed on the surface of the samples was calculated using the following equation 
Q= (Ci - Cf)V/m 
Where Ci is the initial concentration of anti-HER-2 and Cf is the final concentration of anti-
HER-2 concentration in the supernatant after centrifugation, V is the total volume of the 
solution and m is the weight of the samples. 
2.2.14. Cell viability studies 
2.2.14.1. Cell culture maintenance of SK-BR-3 
SK-BR-3 cells (Fogh, Wright and Loveless, 1977) were grown in McCoy’s 5A media, 
supplemented with 10% foetal calf serum, and 1% w/v penicillin and 1% w/v streptomycin 
solution, as described by ATCC (Wu et al., 2003). The medium was changed every 2-3 days. 
The cell cultures were maintained at 37 oC, 5% CO2 and passaged, on 60-70% confluence, 
by trypsin treatment for 10 minutes. Following cell detachment, fresh medium was added 
to the cell suspension, which was then centrifuged at 1000 rpm for 10 minutes. The 
resulting cell pellet was suspended in fresh medium and transferred to 75 cm2 tissue 
culture flasks. 
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2.2.14.2. Metabolic activity assay 
Metabolic activity of the SK-BR-3 cells when treated with microspheres encapsulated with 
porphyrin derivatives was quantified using the MTT assay. The cells were incubated at a 
density of 1x104 in the presence of 2mg porphyrin derivative encapsulated microspheres, 
for 48 hours, in dark. The tissue culture plates were covered in aluminium foil to prevent 
light exposure. These were then exposed to white light 30 minutes, to allow for 
photoexcitation. The cytotoxic effect was quantified using cell viability calculations, as 
indicated by the MTT assay. Briefly, the media was aspirated from the wells and 1mg/mL 
MTT in 200 mL serum free media (media without addition of FBS) was added. This is then 
incubated for 3 hours, after which the MTT solution was removed and an equal volume of 
isopropanol was added. The plate was then covered with aluminium foil and absorbance 
was read at 540nm.  
2.2.14.3. Calculation of Inhibitory concentration (IC50) 
Varying concentrations (0.05, 0.1, 0.2, 0.5, 1, 2 and 3mg/mL) of the microspheres were 
incubated in SK-BR-3 and cytotoxicity was quantified using the MTT assay. Linear regression 
of the variables was used to analyse the inhibitory concentration for 50% cytotoxicity.  
2.2.15. Confocal imaging 
 For confocal imaging, Promokine Live/Dead Cell Staining Kit II containing two fluorescent 
dyes, Calcein-AM and Ethidium homodimer III (EthD-III) were used. The virtually non- 
fluorescent Calcein-AM attains green fluorescence by the ubiquitous esterase activity that 
characterizes live cells. EthD-III selectively excludes intact live cells and enters damaged 
cells and binds to nucleic acids, resulting in red fluorescence (Probes, 2005). Stained cells 
were observed and imaged using the confocal microscope Leica TCS SP2 50. 
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2.2.16. Determination of the Minimum Inhibitory Concentration (MIC) 
of HA-P(3HB) with encapsulated curcumin against Methicillin 
Resistant Staphylococcus aureus  
MIC is defined as the minimum concentration of an antimicrobial agent that can cause an 
inhibitory effect. To estimate MIC, a single colony of MRSA was grown in LB medium at 37 
oC and 250 rpm and an optical density at 595nm was recorded to observe its growth profile. 
At mid log phase 1 mL aliquots of the culture was further inoculated into 10 mL of media 
and this was then allowed to grow in 96 well plates, in the presence of different 
concentrations of microspheres (500, 250,125, 62.5, 31.25, 16, 8, 4, 2, 1 μg /mL of curcumin 
respectively). The growth profile was observed, with O.D recorded at 595nm at intervals of 
1 hour, with free inoculum as control. MIC was determined as the lowest concentration at 
which bacterial growth was inhibited (Ortiz & Torres 2014). 
2.2.17. Determination of Minimum Bactericidal Concentration (MBC) 
of curcumin encapsulated HA-P(3HB) against Methicillin Resistant 
Staphylococcus aureus  
MBC is defined as the minimum bactericidal concentration to kill 100% of the bacteria. The 
lowest concentration that exhibited the absence of viable microorganisms was reported as 
MBC. The contents of each well (200 μL) as described in the section above was transferred 
into 2 mL of fresh LB medium and grown for 12 hours. The tubes were observed for 
turbidity and 20μL of the culture from the least turbid looking tubes were inoculated on LB 
Agar plates and incubated at 37°C for 24 hours. The concentration of microspheres 
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corresponding to absolute absence of colonies was recorded as MBC (Ortiz and Torres 
2014).  
2.2.18. Statistical analysis 
All experiments were done in triplicates and data is expressed along with their mean 
standard deviation. The data, where appropriate, were compared using the student’s t-test 
and ANOVA and was used to analyse significant differences amongst factors assessed. The 
differences were considered significant when *p<0.05, very significant when **p<0.01 and 
highly significant ***p<0.001, respectively. Any p-value higher than 0.05 (p>0.05) was 
insignificant. The statistical analysis for comparing drug release models was done using 
ANOVA on excel Analysis ToolPak, within 95% confidence interval. 
Chapter 3 
 







nanospheres as drug 
delivery systems: 











  75 
 
3.1. Introduction 
Micro/Nano encapsulations are one of the most common and developing strategies of drug 
delivery. Geometrically, spherical constructions are superior for efficient drug delivery as 
they have higher specific surface area and hence higher therapeutic coverage (Kim and 
Pack, 2006). The advantages of spheres over other DDS are several; they can be tailored to 
have uniform size and geometry, they can have external or internal interconnected pore 
networks and their porosity can be modulated, degradation rate is linear in the case of 
surface eroding polymers and can be made stand alone or in combination with other 3-D 
structures (Hossain, Patel and Ahmed, 2014). Sphericity is thought to improve cell 
attachment, especially with low density spheres that have interconnected pore networks. 
Spherical geometry also enhances ease of subcutaneous administration via injections.  
Depending on the nature of the drug to be encapsulated, single or double emulsion 
methods can be approached for hydrophobic and hydrophilic drugs, respectively. In single 
emulsion method, the polymer is dissolved in a water immiscible, volatile solvent and 
emulsified with water containing an appropriate surfactant/ emulsifier forming an 
oil/water (O/W) emulsion. The organic solvent is then allowed to evaporate under 
agitation, and this leaves behind solid spherical microspheres with a polymeric inner core 
(Figure 3.1). In the case of hydrophilic drugs, a double emulsion of water/oil/water is 
preferred as in W/O method, there are increased chances of the hydrophilic drug to 
partition into the aqueous phase. In double emulsion method, the hydrophilic drug is 
dissolved in a water phase and then emulsified with the oil phase containing polymer 
solution. This is then transferred to an excess amount of water to form a secondary 
emulsion. During solvent evaporation, the polymer starts decreasing in volume towards 
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the core, also entrapping microdroplets of the emulsion, which coalesce to form a honey, 
comb structure characterised with hydrophilic points (Vilos and Velasquez, 2012).  
 
Figure 3.1: Schematic representation of polymeric particles prepared by a) single 
emulsion method and b) double emulsion method (Adapted from (Vilos and Velasquez, 
2012)). 
 
Subsequently, with a variety of determinants to consider, it is essential for a polymer to be 
used in an application as specific as drug delivery, to have predictive models for process 
parameters. Bearing this in mind, in this study, a select set of pilot experiments were 
carried out to establish boundary conditions of each of the parameters analysed (Polymer 
concentration, PVA concentration and stirrer speed), within the limits of practical 
feasibility. Having set these boundary limits, Box–Behnken experimental design and 
response surface methodology (RSM) were applied to predict process parameters for a set 
goal of particle size range. RSM is a strategy to device or design of experiments that can 
correlate interactions between variables and map a response surface that can provide 
optimal parameter settings. Box- Behnken is the least expensive RSM strategy, that takes 
into account three variables and three representatives of each of the variables at their 
extremities and midpoints (Joseph and Manohar, 2013). There are 15 sets of experiments 
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in three-factor Box-Behnken design, as represented by the points on the Figure below 
(Figure 3.2). 
 
Figure 3.2: Representation of experimental runs on a Box-Behnken design. 
 
RSM follows 4 steps to generate a predictive model where the first step is to design a series 
of experiments to generate reliable measurement of the intended response. This is 
followed by the development of a second order, best-fitted response surface, to find an 
optimal set of parameters for predictive responses and finally, generation of plots to 
correlate the variables and responses. Validation of this method can be done by comparing 
the prediction models with the experimental results (Joseph and Manohar, 2013).  
In this chapter, P(3HB) was produced using B. cereus SPV and was chemically well 
characterised. This was used for the optimization of microsphere production, using PVA as 
the surfactant. The effect of polymer concentration, PVA concentration, stirrer speed, 
nature of the solvent used, and temperature were initially observed to set boundary limits 
for RSM, and of these three most influential variables on determining particles formation 
were identified. A Box- Behnken design was then generated using the software Design 
expert and a set of 15 experiments were run, keeping particle size as the response analysed. 
(The microspheres produced were also characterised for other parameters, but in the 
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interest of its efficient applications, particle size was identified as the most desirable 
response that necessitated optimising). The predicted model was then validated using a set 
of experiments.  
B. cereus SPV is known to produce emetic toxins and enterotoxins, leading to food 
poisoning (Granum and Lund, 1997). Although, the purity of the polymer extracted from 
this organism is ensured by complete removal of cell content during polymer extraction, 
this factor can be a hindrance in the use of these polymers for biomedical applications. 
Therefore, P(3HB) extracted from B. subtilis OK2, which has a higher molecular weight was 
also used in this project to produce micro and nanospheres. P(3HB) from B. subtilis OK2 is 
of higher molecular weight as compared to that produced using B.cereus SPV, production 
of relatively larger microspheres were expected in this case. 
3.2. Results 
Part I: Statistical optimisation of synthesis of P(3HB) microspheres 
3.2.1. Production of P(3HB) from B. cereus SPV 
Figure 3.3 represents the temporal growth profile obtained from the culture of B. cereus 
SPV for P(3HB) production, in a 5 L Bioreactor using Kannan and Rehacek (KR) nitrogen-
limiting media. This was carried out to analyse the temporal pattern of biomass and P(3HB) 
accumulation to establish a production strategy and ensure a reasonable yield. This pattern 
was found to correlate with changes in optical density, pH and estimated glucose 
consumption. The initial lag phase was not visible, possibly suggesting it might have been 
either less than 3 hours or absent.  OD600 increased sharply until the 36th hour, clearly 
indicating log phase of growth.  A decrease in OD600 was observed at the 36th hour due to 
Chapter 3 
 
  79 
 
excess foaming and increased again on addition of antifoam and plateaued around a value 
of 17, until the 72nd hour, indicating a stationary phase of growth. The intermittent dips in 
the OD600 profile were observed to correspond with excessive foaming. As expected, there 
is a direct correlation observed between OD600 and biomass. The pH decreased throughout 
the experiment from 6.8 ± 0.3 and reached a value of 3.7 ± 0.4 at 48 hours. Dissolved 
Oxygen Tension (DOT) was observed to decrease rapidly until the 9th hour when it reached 
a minimum and a steady rise was observed between 48 and 72 hours. The decrease in DOT 
overlapped with the log phase, confirming oxygen consumption during growth. P(3HB) 
accumulation demonstrated a positive correlation with time. After 72 hours, a P(3HB) yield 
of 26.3% dry cell weight was observed. 
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3.2.2. Characterisation of the polymer 
The P(3HB) thus produced was extracted using the soxhlet method with methanol and 
chloroform as solvents and was precipitated using differential precipitation.  
3.2.2.1. FTIR analysis of P(3HB) produced using B. cereus SPV 
 
Figure 3.4: FTIR spectra of P(3HB) produced using B. cereus SPV 
 
Preliminary confirmation of the polymer produced was obtained using the FTIR spectra. 
The FTIR spectrum showed two distinct peaks at wavenumbers 1721.17 cm-1 and 1277.92 
cm-1, corresponding to the ester carbonyl group and the –CH group, respectively, which is 
characteristic of SCL PHAs (Figure 3.4).   
3.2.2.2. Nuclear Magnetic Resonance 
The proton NMR shows peaks corresponding to 3 different hydrogen environments (Figure 
3.5.a). These are manifested as a duplet at 1.26 ppm, a multiplet around 2.5 ppm and a 
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sextet around 5.2 ppm.  13C NMR shows four different peaks corresponding to four separate 
carbon environments. The chemical shifts respectively are at 169 ppm corresponding to C3 
(C=O group), 68 ppm corresponding to C1 (-CH group), 41 ppm corresponding to C2 (-CH2) 
and the 19ppm corresponding to C4, which is the part of the -CH3 group (Figure 3.5.b). 
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3.2.2.3. Molecular weight analysis  
The polymer produced and purified was subjected to molecular weight analysis using gas 
permeation chromatography (GPC). The molecular weight of the polymer was found to be 
158kDa with a polydispersity Index of 1.73.  
3.2.3. Optimisation of microsphere production 
3.2.3.1. Pilot experiments 
A set of pilot experiments were (not statistically optimised) carried out by varying the 
process parameters, namely, type of organic solvent used, concentration of polymer in the 
organic solvent, PVA concentration, fabrication method, mode of drying and stirrer speed, 









Fabrication method Drying 
1 2.5 Dichloro-
methane 











and magnetic stirring 
at 500 rpm 
Freeze drying 
4 35 Chloroform 1 Sonication for 10 s, 
maximum power 
Freeze drying 
5 50 Chloroform 0.5 Sonication for 10 s, 
maximum power 
Air drying 
6 62.5 Chloroform 1 Magnetic stirring at 
1000 rpm 
Air drying 
7 5 Chloroform 0.01 Magnetic stirring at 
500 rpm 
Freeze drying 
8 50 Chloroform 0.5 Magnetic stirring at 
800 rpm 
Freeze drying 
9 35 Chloroform 0.5 Magnetic stirring at 
1000 rpm 
Freeze drying 
Table 3.1: Conditions used for pilot experiments in making P(3HB) microspheres 
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The P(3HB) microspheres were prepared by the solid-in-oil-in-water (s/o/w) technique and 
their surface morphology was analysed using SEM. It was found that microspheres 
produced using DCM as the solvent did not yield spheres with good morphology. The 
spheres formed were polydisperse in size, forming occasional structures that looked like 
agglomerations of smaller spheres. For the most part, the polymer did not yield spherical 
structures, when dissolved in DCM. Sonicated emulsion did not yield any microspheres and 
the polymer was found to precipitate from the emulsion on to the sides of the liquid vessel 
in which the experiments were being carried out. Air drying resulted in microspheres with 
extensive interconnecting water channels that assumed the shape of the surface on which 
they were placed for drying.  These did not yield free flowing powder forms at all and hence 
weren’t imaged. 
SEM images corresponding to experiment numbers 1-10 (Table 3.1) are represented below 
(Figure 3.6 a & b): 
 
Figure 3.6.a: SEM images of microspheres corresponding to experiments 1,3&4 
 
Figure 3.6.b: SEM images of microspheres corresponding to 7-10 
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3.2.3.2. Design of experiments 
A set of pilot experiments were carried out using varying polymer concentrations, PVA 
concentrations and stirrer speeds. Microspheres of appreciable spherical shape and yield 
were produced within the concentration range of 0.3- 0.8 g of polymer in 8 mL of 
chloroform, using 0.5-1% solution of PVA as the aqueous phase, under circular agitation 
using a magnetic stirrer between stirrer speeds of 500 to 1000 rpm (Table 3.2).   
 Polymer concentration (%) PVA concentration (%) Stirrer speed (rpm) 
Level 1 (-1) 0.0375 0.5 500 
Level 2 (0) 0.0625 0.8 800 
Level 3 (+1) 0.1 1 1000 
Table 3.2: Boundary conditions for microsphere optimization 
Therefore, based on the preliminary experimental trials, the tabulated process parameters 
and three levels for each of them were assigned.  Based on these three parameters a Box-
Behnken design with 15 runs for modelling a response surface was generated using the 
software MiniTab Express (Table 3.3). 
 Pattern Polymer concentration (mg/mL) PVA concentration (%) Stirrer speed (rpm) 
1 0+- 0.0625 1 500 
2 +0+ 0.1 0.8 1000 
3 000 0.0625 0.8 800 
4 -0+ 0.1 0.8 1000 
5 +-0 0.1 0.8 800 
6 0-- 0.0625 0.5 500 
7 -+0 0.1 1 800 
8 +0- 0.1 0.8 500 
9 ++0 0.1 1 800 
10 -0- 0.1 0.8 500 
11 0-+ 0.0625 0.5 1000 
12 000 0.0625 0.8 800 
13 --0 0.1 0.5 800 
14 0++ 0.0625 1 1000 
15 000 0.0625 0.8 800 
Table 3.3: Design of experiments generated using MiniTab Express 
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3.2.4. Surface morphology and particle size analysis 
Morphological characterisation of microspheres produced was done by observing SEM 
images under different magnifications (Figure 3.7).  
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Of the 15 runs, all except, experiment number 4 and 14, gave well- formed microspheres 
of defined spherical shape and smooth surface. The microspheres corresponding to 
experiment number 4 was found to be extremely porous with a ruptured wall revealing an 
empty core. Diameter of the microspheres corresponding to each experiment run was 
calculated after analysing the SEM images on ImageJ software. SEM images of varying 
magnifications corresponding to each experiment run were adjusted to the right threshold 
and gain, and the analysis tool was calibrated using the size bar of the SEM images against 
pixels. From the surface area output, diameters of the images were calculated, and an 
average value was recorded (Figure 3.8).  
 
Figure 3.8: Average diameter of microspheres corresponding to experiments 1-15 [code 
(polymer concentration: PVA concentration: Stirrer speed); For polymer concentration, -= 
0.0375, 0= 0.0625 and += 0.1 g/mL; PVA concentration, -= 0.5, 0= 0.8 and += 1 % w/v and 
stirrer speed, -= 500, 0= 800 and += 1000 rpm].  (n=3, error bars= ±SD) 
In all the preparations, microspheres were found to be largely polydisperse in size. 
Microspheres corresponding to experiment number 4, 7 and 13 were found to be the 
smallest (with mean diameter of 25.5, 28.1 and 29.8 μm respectively) and the factor 
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common to these conditions is that they were synthesised using the least concentration of 
P(3HB) used in the design. Images corresponding to experiment number 1, 8 and 9 were 
found to be of the largest (with diameter of 46.02, 43.1 and 41.733 μm respectively) and 
the common factor amongst was the highest polymer concentration. However, experiment 
number 11, although was run with the least polymer concentration, and least stirrer speed, 
was of an average diameter of 35.2 m. The microspheres corresponding to experiment 
number 4, although were small, were found to be visibly highly porous, and lacking a 
spherical shape. 
3.2.5. Modelling of response surface 
Based on the input parameters under the 15 conditions given by the Box- Behnken design, 
microspheres were prepared. The average diameter obtained from each of the trials was 
recorded as output parameter. The table below (Table 3.4) summarizes the values for the 
experimental output (observed value as represented in Figure 3.8) and predicted output 
(fitted value). A total of 15 experiments were run as randomized trials as generated by the 
Box- Behnken design and the relationship between input variables and expressed outcome 
was analysed. On running the 3- level, 3- factor design, the relationship between 
independent variables and dependent variables were statistically analysed using ANOVA. 
The variables and variable interactions with a p value <0.05 was considered highly 
significant. Variables and variable interactions with regression coefficients of a positive 
value were thought to have an agonistic and with regression coefficients of negative value 
were considered to have antagonistic effects on the lowering of particles size. When the 
coefficient of determination (R2), approached 1, the model was considered to be more 
fitting.   
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Table 3.4: The observed and fitted value for particle diameter 
Table 3.5 shows the result of variance of analysis performed for mean particle size. From 
the analysis, based on p value, Polymer concentration was found to have the highest F ratio 
and the least p value, making it the most significant variable. Table 3.6 below represents 
the analysis of variance for the independent variables and the parameters are coded as A: 
Polymer concentration, B: PVA concentration, and C: Stirrer speed. 
Variable Regression Coefficient P value 
Constant 24.203 <0.001 
A  195.73 <0.001 
B 5.734 0.00854 
C -0.008134 0.0214 
A.A 4.102 0.0009 
A.B -4.95 0.0101 
Table 3.5: Analysis of variance for factors and factor interactions influencing particles 
size, performed using the JMP software. A: Polymer concentration, B: PVA 
concentration, and C: Stirrer speed. 
Expt. 
number 
Concentration of P(3HB) 
(g/mL) 






1 0.0625 1 500 43.21 42.84 
2 0.1 0.8 1000 39.83 39.31 
3 0.0625 0.8 800 37.20 37.1990 
4 0.0375 0.8 1000 25.09 28.82 
5 0.1 0.8 800 41.33 39.80 
6 0.0625 0.5 500 36.61 36.69 
7 0.0625 1 800 28.13 25.35 
8 0.0375 0.8 500 46.21 45.69 
9 0.1 1 800 43.37 44.18 
10 0.1 0.8 500 31.02 30.76 
11 0.0375 0.5 1000 35.23 35.25 
12 0.0625 0.8 800 37.19 37.19 
13 0.0375 0.5 800 29.82 28.05 
14 0.0625 1 1000 39.05 37.60 
15 0.0625 0.8 800 37.68 37.19 
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3.2.5.1. Mathematical modelling and effect of independent variables on the particle 
properties  
The results obtained from statistical analysis confirmed that all the tested parameters 
namely polymer concentration, PVA concentration and stirrer speed have significant effect 
in determining the size of particles. Using regression coefficients of factors and factor 
interactions with p values less than 0.05, a model was designed to predict the effects of 
input variables on the output response. The model considered individual independent 
variables and their interactions. The equation generated has linear terms corresponding to 
single factor effects and second order terms corresponding to interactions, used to express 
nonlinearity of the response. The equation generated for the model given below: 
Mean particle size= 24.203 + (195.73*A) + (5.734*B) - (0.008134*C) + (4.102*A*B) -
(4.95*A2) 
Where A= Polymer concentration 
 B= PVA concentration 
 C=Stirrer speed. 
The linear regression plot corresponding to experimental values and predicted values for 
mean particle diameter are given below. As the predicted values come closer to the actual 
values, the points on the scatterplot fall closer to the red line. (Figure 3.9). Because the 
points are all very close to the line, it can be concluded that the model predicts particle size 
based on the defined parameters very well. The R2 value was found to be 0.91, which is 
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Figure 3.9: Linear regression plot correlating the actual value and predicted value for 
mean particle diameter. 
 
3.2.5.2. Graphical representation of significant effect of independent variables 
The significance of the independent variables on particle size was graphically demonstrated 
by using 3-D plots. The plots were generated by keeping one of the parameters constant 
and mapping the response as a function of interaction between the other two parameters. 
These plots are useful in analysing the influence of two independent parameters on the 
response, simultaneously. The 3-D plot representing the effects of P(3HB) concentration 
and PVA concentration, P(3HB) concentration and stirrer speed and PVA concentration and 
stirrer speed are represented below (Figure 3.10 a, b &c). 
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Figure 3.10.a: response surface plots showing the effect of PVA concentration and 
polymer concentration on particle size  
 
Figure 3.10.b: response surface plots showing the effect of PVA concentration and 
stirrer speed on particle size  
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Figure 3.10.c: 3- D response surface plots showing the effect of polymer concentration 
and stirrer speed on particle size.  
3.2.5.3. Validation of method 
The optimisation design was intended to minimise particle size and the optimal conditions 
were found to be 0.0375% of polymer concentration, 0.5% PVA concentration and 1000 
rpm and surface morphology was observed under SEM (Figure 3.11.a&b).  
 
Figure 3.11: a) SEM images of microspheres prepared using 0.0375% of polymer 
concentration, 0.5% PVA concentration and 1000 rpm b) Particle size distribution curve. 
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The predicted results were compared with experimental results and error was calculated. 
The predicted result gave a particle diameter of 26.3 μm, and the experimental result was 
25.2 ± 1.12 μm, hence the error was 4.41% (Figure 3.11 & b). 
3.2.6. P(3HB) microsphere characterization 
Note: In the following sections, experiment number 12 and 15 are omitted as they 
correspond to the same data as experiment number 3 (This is because the design 
considered triplicates of the mid- level parameters and experiments corresponding to 
numbers 3, 12 and 15 are carried out under the same parameters). 
3.2.6.1. Porosity 
Porosity of the microspheres prepared was calculated using the liquid displacement 
method. The microspheres were found to have porosity within the range of 48-60%. 
Porosity was observed to increase with stirrer speed. P(3HB) microspheres, prepared with 
a low concentration of polymer and high stirrer speed were found to be the most porous, 
corresponding to experiment number 4. These were prepared with 0.0375 g/mL polymer 
concentration at 1000 rpm. However, increasing the polymer concentration appeared to 
have a deleterious effect on porosity as in the second experiment prepared with 0.1 
polymer at a stirrer speed of 1000 rpm was found to have a porosity of 49 ± 4.1% compared 
to the porosity corresponding to experiment number 4, which was 62 ± 1.5%. PVA 
concentration was not found to have a significant effect on porosity. Between experiment 
number 2 and 8, both polymer concentration and PVA concentration was kept constant, 
but stirrer speed was decreased from 500 to 100 rpm, which was found to decrease 
porosity of the respective microspheres from 49 to 43%. The effect of polymer 
concentration and stirrer speed were analysed separately, keeping the other 2 variables 
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constant, and it was found that stirrer speed has a positive influence and polymer 
concentration has a negative influence on porosity and the differences were statistically 
significant (Figure 3.12.a, b and c).  
 
Figure 3.12: a) Porosity of microspheres corresponding to experiment number 1-11 
and 13 and 14 b) Comparison of effect of stirrer speed on porosity c) Comparison of 
effect of polymer concentration on porosity [code (polymer concentration: PVA 
concentration: Stirrer speed); For polymer concentration, -= 0.0375, 0= 0.0625 and += 0.1 
g/mL; PVA concentration, -= 0.5, 0= 0.8 and += 1 % w/v and stirrer speed, -= 500, 0= 800 
and += 1000 rpm].  (n=3, error bars= ±SD) 
3.2.6.2. Surface residual PVA 
Surface residual PVA of the microspheres prepared was measured by the method described 
in section 2.2.8.4. Residual PVA was expressed as a percentage of mass of PVA per mass of 
Chapter 3 
 
  95 
 
microspheres. There was a clear correlation between the concentration of PVA used in the 
preparation and the amount of residual PVA on the surface of microspheres (Figure 3.13).  
 
Figure 3.13: Surface residual PVA of microspheres corresponding to experiment 
numbers 1-13 and 14 [code (polymer concentration: PVA concentration: Stirrer speed); For 
polymer concentration, -= 0.0375, 0= 0.0625 and += 0.1 g/mL; PVA concentration, -= 0.5, 
0= 0.8 and += 1 % w/v and stirrer speed, -= 500, 0= 800 and += 1000 rpm]. (n=3, error bars= 
±SD) 
The highest amount of surface associated PVA was 0.091% w/w, corresponding to 
microspheres prepared under process conditions as in experiment number 7. Here, 
0.0375g/mL polymer concentration and 1% PVA concentration was used at a stirrer speed 
of 800 rpm. The second highest amount of residual PVA (0.083 ± 0.002 % w/w) 
corresponded to microspheres prepared with process conditions under experiment 
number 1, with 0.0625 g/mL of polymer, 1% PVA concentration and 500 rpm stirrer speed. 
This was followed by a residual PVA of 0.077 ± 0.0012 % w/w, in the case of microspheres 
prepared as per conditions corresponding to experiment number 14, with 0.0625 g/mL 
polymer concentration, 1% PVA concentration and 800 rpm stirrer speed. It follows that 
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the highest amounts of residual PVA calculated corresponded to microspheres prepared 
with process conditions as per 7, 1, 14, 4 and 9. These are the 4 experiments in the design, 
which were conducted with the maximum PVA concentration. On the other hand, the least 
amount of residual PVA was found associated with microspheres corresponding to 
experiment number 5 (0.017± 0.0027 % w/w), 6 (0.021 ± 0.0007 % w/w), 11 (0.031 ± 0.0029 
% w/w) and (13 0.041 ± 0.0071 % w/w) respectively, all of which were prepared with the 
minimum concentration of PVA.  
3.2.4.1. Hydrophobicity and correlation between residual PVA and 
hydrophobicity 
Surface hydrophobicity was estimated as a function of the amount of Rose Bengal dye 
adsorbed on the surface of microspheres. The amount of Rose Bengal dye bound is directly 
proportional to the hydrophobicity of the microspheres (Figure 3.14). It was found that 
there is an inverse proportionality between the amount of surface residual PVA and 
hydrophobicity of microspheres. The least amount of surface associated PVA corresponded 
to experiment number 5, and 6 and 11 and in the case of hydrophobicity, these had the 
highest amount of surface bound Rose Bengal dye (0.91± 0.001 and 0.72 ± 0.01 μg/mg 
respectively). The least amount of surface bound Rose Bengal dye corresponded to 
experiment number 7 and 1, (0.13 ± 0.21 and 0.20 ± 0.02 μg/mg respectively) both of which 
had belonged to the group of microspheres with highest amount of surface residual PVA. 
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Figure 3.14: Surface hydrophobicity microspheres corresponding to experiment number 
1-3 & 14, represented as a function of amount of surface bound Rose Bengal dye at 
saturation [code (polymer concentration: PVA concentration: Stirrer speed); For polymer 
concentration, -= 0.0375, 0= 0.0625 and += 0.1 g/mL; PVA concentration, -= 0.5, 0= 0.8 and 
+= 1 % w/v and stirrer speed, -= 500, 0= 800 and += 1000 rpm] (n=3, error bars= SD).  
 
3.2.7. Optimisation of production parameters for microspheres and 
nanospheres of varying size ranges.  
The model generated demonstrated that to lower particle size, the main parameter to vary 
was the concentration of P(3HB). The model generated was tested for a range of 
microsphere sizes from 20 m to 100 m and was proven to be fitting. Although the model 
had very good predictability, the model was impractical to implement for lower working 
concentration since the resulting yield of microspheres would be too low. Therefore, a 
series of other process parameters were tested, mainly focusing to reduce the viscosity of 
the emulsion and thereby to reduce the size of the microspheres, even to nanoscale ranges. 
Varying P(3HB) concentrations, PVA concentrations, stirrer speed as well as 
homogenisation techniques were employed (Table 3.6).  
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1 0.0065 0.05 Magnetic stirring 
at 800 rpm 
Freeze drying 
2 0.0065 0.25 Magnetic stirring 
at 1000 rpm 
Freeze drying 
3 0.0065 0.25 Homogenization 
for 5 minutes, 
followed by 
Magnetic stirring 
at 1000 rpm 
Freeze drying with 1 mL of 
0.5% trehalose dihydrate 
4 0.009 0.05 Magnetic stirring 
at 800 rpm 
Freeze drying 
5 0.009 0.25 Magnetic stirring 
at 1000 rpm 
Freeze drying 
6 0.009 0.25 Homogenization 
for 5 minutes, 
followed by 
magnetic stirring 
at 800 rpm 
Freeze drying with 1 mL of 
0.5% trehalose dihydrate 
7 0.015 0.25 Magnetic stirring 
at 1000 rpm 
Freeze drying 
8 0.015 0.5 Magnetic stirring 
at 1000 rpm 
Freeze drying 
9 0.03 0.25 Magnetic stirring 
at 1000 rpm 
Freeze drying 
10 0.035 0.5 Magnetic stirring 
at 800 rpm 
Freeze drying 
 
Table 3.6: Conditions for the optimization of micro and nanospheres of varying size 
ranges 
 
3.2.7.1. Surface morphology of nanospheres and microspheres under SEM 
Nanospheres and microspheres of P(3HB) were successfully produced in 4 different size 
ranges. Surface morphology of these were observed under SEM at different magnifications. 
The spheres produced appeared to be of good spherical shape in general, except for the 
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intermittent disc shaped structures amongst the nanospheres. The process conditions 
corresponding to experiment number 1-3 involved a very low polymer concentration of 
0.001 g/mL and the spheres produced with these were of the size range 400-800 nm. 
Experiment number 1 was set up with a polymer concentration of 0.0065 g/mL, PVA 
concentration of 0.05 %w/v at 1000 rpm. The spheres produced were highly 
interconnected and completely lacked the spherical shape. In the second experiment, the 
same conditions with respect to polymer concentration and stirrer speed were maintained, 
but PVA concentration was increased to 0.25 %w/v. This was found to decrease the 
appearance of interconnecting water channels; however, they were not entirely absent, 
and the spheres lacked sphericity. The SEM images of spheres produced using process 
parameters corresponding to experiment number 1 and 2 are given in Figure 3.15 a & b. In 
the third experiment, the emulsion was first subjected to homogenisation for 5 minutes 
before being subjected to magnetic stirring and the resulting spheres were lyophilised in 
the presence of the cryoprotectant trehalose dihydrate. The resultant spheres were of 
appreciable sphericity with no interconnecting water channels (Figure 3.18.a).  
 
Figure 3.15: SEM images of nanospheres prepared under process conditions 
corresponding to a) experiment number 1, b) experiment number 2 
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Experiment number 4 -6 involved the use of 0.009 g/mL polymer concentration. Spheres 
produced under conditions corresponding to experiment number 4 (PVA concentration 
0.05 %w/v, stirrer speed 800 rpm) produced microspheres within the range of 1-2 m, with 
intermittent spheres of about 5 m in diameter (Figure 3.16.a.). The spheres lacked in 
sphericity and had interconnecting water channels although not as extensive as in the case 
of spheres produced using conditions under experiment number 1. In experiment number 
5, PVA concentration was increased to 0.25% and stirrer speed of 1000 rpm applied. This 
was found to be effective in achieving uniformity of size distribution and improved 
sphericity, although not ideal (Figure 3.16.b). In experiment number 6, the emulsion was 
homogenised for 5 minutes and then was subjected to magnetic stirring at 800 rpm and 
lyophilised with the presence of the cryoprotectant. This experiment produced 
microspheres in the size range of 1-2 m, with good sphericity, even size distribution and 
appreciable separation (Figure 3.8.b).  
 
Figure 3.16: SEM images of microspheres produced using process parameters 
corresponding to a) experiment number 4, b) experiment number 5. 
 
Experiment number 7 and 8 were carried out using 0.015 g/mL concentration of polymer 
solution at 1000 rpm, with 0.25 and 0.5 % PVA solution respectively. The microspheres 
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produced with 0.25% of PVA had a shrunken appearance and lacked in sphericity (Figure 
3.17 a). However, the microspheres produced with 0.5% PVA solution were of excellent 
sphericity and smoothness, in a size range of 4-10 m in diameter (Figure 3.18.c). No 
interconnecting water channels were observed in both the cases.  
 
Figure 3.17.a: SEM image of microspheres prepared under process conditions 
corresponding to experiment number 7.  
 
Finally, experiment number 9 and 10 involved the use of 0.03 and 0.0035 g/mL 
concentration of polymer solution at 1000 rpm with 0.25% and 0.5% PVA solutions 
respectively. The results obtained were similar to the case of experiment number 7 and 8, 
with extremely shrunken and uneven surface morphology of microspheres in the case of 
lower concentration of PVA (Figure 3.17.b).  
 




  102 
 
In experiment number 10, sphericity had improved considerably, but the surface of the 
spheres appeared to be comparatively porous and coarse (Figure 3.18.d).  
Process conditions corresponding to experiment number 3 resulted in the successful 
nanospheres in the size range of 400-800 nm, and process conditions corresponding to 
experiment number 6, 8 and 10 resulted in the successful production of microspheres in 
the size range of 1-2 mm, 4-10 μm and 15-25 μm respectively. The SEM images of these 
microspheres under X2000 magnification are given in Figure 3.18.  
 
Figure.3.18: SEM images of a) Nanospheres prepared under conditions corresponding 
to experiment 3, microspheres prepared under conditions corresponding to 
experiment number b)6, c)8, and d)10 
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Part II: Optimisation of nanospheres production from P(3HB) extracted 
using B. subtilis OK2. 
3.2.8. P(3HB) production using B. subtilis OK2 
Figure 3.19 represents the temporal growth profile obtained from the culture of B. subtilis 
OK2 for P(3HB) production, in a 5 L Bioreactor using Kannan and Rehacek (KR) nitrogen-
limiting media with 30g/L glucose as the carbon source. This was carried out to analyse the 
pattern of biomass and P(3HB) accumulation in order to establish a production strategy 
and ensure a reasonable yield. This pattern was found to correlate with changes in optical 
density, pH and estimated glucose consumption. The initial lag phase was not visible, 
possibly suggesting it might have been either less than 3 hours or missing.  OD600 increased 
sharply until the 32th hour, clearly indicating a prolonged log phase of growth.  Beyond this 
O.D started declining with no clear indication of a stationary phase. 
 
Figure 3.19: Temporal growth profile of B. subtilis OK2 for the production of P(3HB) 
in 5L bioreactors 
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 As expected, there is a direct correlation observed between OD600 and biomass. Biomass 
was found to increase throughout the profile, peaking at 48 hours with a maximum biomass 
accumulation of 3.2 g/L. The pH decreased throughout the experiment and dropped from 
6.6 to 5.1 by the end of 48 hours. Dissolved Oxygen Tension (DOT) was observed to 
decrease rapidly until 9th hour when it reached a minimum and a steady rise was observed 
between 48 and 72 hours. The decrease in DOT overlapped with the log phase, confirming 
oxygen consumption during microbial growth. P(3HB) accumulation demonstrated a 
positive correlation with time. After 48 hours, a P(3HB) yield of 26.3% dry cell weight was 
observed. Slow glucose depletion was experienced as the glucose concentration dropped 
from the initial 30g/L to 16 g/L at the end of 48 hours. Polymer yield over the period of 48 
hours was found to be steady, with a maximum of 30.2 % dcw.  
3.2.9. Characterisation of the polymer 
The P(3HB) thus produced was extracted using the soxhlet method with methanol and 
chloroform and was purified using the differential precipitation.  
3.2.9.1. FTIR analysis of P(3HB) produced using B. subtilis OK2 
Preliminary confirmation of the structure of the polymer produced was obtained using 
FTIR. The FTIR spectrum showed two distinct peaks at wavenumber of 1719.69 cm-1 and  
1276 cm-1, corresponding to the ester carbonyl group and the–CH group, respectively 
which is characteristic of SCL PHA (3.20).   
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Figure 3.20: FTIR analysis spectrum of P(3HB) produced from B. subtilis OK2 
 
3.2.9.2. Nuclear Magnetic Resonance 
The proton NMR showed peaks corresponding to 3 different hydrogen environments 
(Figure 3.21a). These were observed as a duplet at 1.26 ppm, a multiplet around 2.5 ppm 
and a sextet around 5.2 ppm.  13C NMR shows four different peaks corresponding to four 
separate carbon environments (Figure 4b). The chemical shifts respectively are at 169 ppm 
corresponding to C3 (C=O group), 68 ppm corresponding to C1 (-CH group), 41 ppm 
corresponding to C2 (-CH2) and the 19 ppm corresponding to C4, which is the part of the -
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Figure 3.21: a) Proton NMR and b) 13C NMR of P(3HB) produced using B. subtilis OK2 
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3.2.9.3. Molecular weight analysis  
The polymer produced and purified was subjected to molecular weight analysis using gas 
permeation chromatography (GPC). The molecular weight of the polymer was found to be 
868kDa with a polydispersity Index of 3.674. 
3.2.10. Optimisation of nanospheres production using P(3HB) extracted 
from B. subtilis OK2 









Fabrication method Drying 
1 1 0.25 Homogenization for 5 minutes, 
followed by Magnetic stirring at 
1000 rpm 
Freeze drying with mL of 
0.5% Trehalose 
dihydrate 
2 1 0.25 Homogenization for 5 minutes, 
followed by Magnetic stirring at 
1000 rpm 
Freeze drying with mL of 
0.1% Trehalose 
dihydrate 
3 1 0.3 Homogenization for 5 minutes, 
followed by Magnetic stirring at 
1000 rpm 
Freeze drying with mL of 
0.5% Trehalose 
dihydrate 
4 1 0.3 Homogenization for 5 minutes, 
followed by Magnetic stirring at 
1000 rpm 
Freeze drying with 1 mL 
of 1% Trehalose 
dihydrate 
5 0.75 0.3 Homogenization for 10 minutes, 
followed by Magnetic stirring at 
1000 rpm 
Freeze drying with mL of 
1% Trehalose dihydrate 
6 0.75 0.35 Homogenization for 10 minutes, 
followed by magnetic stirring at 
800 rpm 
Freeze drying with mL of 
1% Trehalose dihydrate 
7 0.5 0.35 Homogenization for 10 minutes, 
followed by magnetic stirring at 
800 rpm 
Freeze drying with mL of 
1% Trehalose dihydrate 
Table 3.7: Process conditions for the preparation of nanospheres using P(3HB) 
extracted from B. subtilis OK2. 
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This is because, P(3HB) from B. subtilis OK2 being of higher molecular weight was assumed 
to result in nanospheres of increased size distribution. Hence, the conditions optimised 
from nanospheres production of P(3HB) extracted from B. cereus SPV were employed here 
for the purpose of comparison. However, the resulting nanospheres were of much larger 
size range. 
3.2.10.1. Observation of surface morphology under SEM 
Condition 1 was carried out with a polymer concentration was 1mg/mL, with a PVA 
concentration of 0.25% and a stirrer speed of 1000 rpm, following a five minutes’ 
homogenization. The spheres thus produced were lyophilised using 0.5% of trehalose 
dihydrate as a cryoprotectant. These samples were subjected to TEM to observe the nature 
and sphericity of spheres that might have formed between these water channels and they 
appeared to be roughly of 300nm and of good sphericity (Figure 3.22)  
 
Figure 3.22: TEM images of nanospheres prepared under process conditions 
corresponding to Experiment number 1. The arrows point towards spheres trapped 
between interconnecting water channels (Size bar= 500nm). 
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 The size range of nanospheres produced was observed to have been reduced, however, 
they were not well separated and appeared agglomerated, forming a mesh of 
interconnected channels.  
In condition 2, the polymer concentration was kept at 1mg/mL and increased amount of 
cryopreservants were added. Although the water channels were found to have 
disappeared. However, the sphericity of the nanospheres formed were compromised and 
to circumvent this, PVA concentration was increased as in condition 3, and this however, 
resulted in the formation of water channels once again. In condition 4, the same condition 
was repeated, this time increasing the concentration of cryoprotectant to 1%, which 
resulted in better separation of the spheres (Figure 3.23). 
 
Figure 3.23: SEM images of spheres prepared using process conditions corresponding 
to experiment number a)1, b) 2, c)3 and d)4. 
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Following these results, further attempts were made to reduce particle size, by altering the 
polymer concentration and increasing the time of homogenisation. Experiment number 5 
was prepared with 0.5 mg/mL polymer concentration, 0.3% PVA concentration, 
homogenization of the emulsion for 10 minutes followed by magnetic stirring at 1000 rpm 
and then lyophilisation with 1% cryoprotectant. However, although the spheres were well 
separated, the spheres formed had a shrunken morphology and were of the size range 
~500-800 nm (Figure 3.24.a). In experiment number 6, polymer concentration was reduced 
to 0.75 mg/mL and PVA concentration was increased to 0.3%. The nanospheres formed 
was of a smaller size range and had better sphericity (Figure 3.24.b). Finally, in experiment 
number 7, polymer concentration was further reduced to 0.5 mg/mL and the resulting 
nanospheres had a size range of 100-200 nm with appreciable sphericity (Figure 3.24.c).  
 
Figure 3.24: SEM images of nanospheres prepared under process conditions 
corresponding to experiment number a)5, b)6, and c)7. 
Part III: Comparison of nanospheres and microspheres prepared using 
P(3HB) extracted from B. cereus SPV and B. subtilis OK2  
Note: These experiments were carried at different stages of optimisation, during 
encapsulation of various drug molecules mentioned in following chapters. Therefore, 
they are not fabricated using the same parameters.  
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3.2.11. Characterisation  
The microspheres and nanospheres produced using P(3HB) extracted from B. cereus SPV 
and B. subtilis OK2 were compared with respect to their particle size, porosity, surface 
residual PVA, hydrophobicity, protein adsorption and degradation profile. For ease of 








Fabrication method Drying 
A 0.5, from B. 
subtilis OK2 
0.35 Homogenization for 10 
minutes, followed by 
magnetic stirring at 800 
rpm 
Freeze drying with 1mL 
of 1% trehalose 
dihydrate 
B 6.5, from B. 
cereus SPV 
0.25 Homogenization for 5 
minutes, followed by 
Magnetic stirring at 1000 
rpm 
Freeze drying with 1mL 
of 0.5% trehalose 
dihydrate 
C 9, from  
B. cereus SPV 
0.25 Homogenization for 5 
minutes, followed by 
magnetic stirring at 800 
rpm 
Freeze drying with 1mL 
of 0.5% trehalose 
dihydrate 
D 15, from  
B. cereus SPV 
0.5 Magnetic stirring at 1000 
rpm 
Freeze drying 
E 35, from  
B. cereus SPV 
0.5 Magnetic stirring at 800 
rpm 
Freeze drying 
Table 3.8: Coding for microspheres used in comparative study and their corresponding 
fabrication methods 
 
3.2.11.1. Particle size distribution 
Particle size of both nanospheres and microspheres were found to depend primarily on the 
viscosity of the oil phase, either as an effect of concentration or molecular weight. The 
nanospheres prepared with 2.5 mg/mL of polymer concentration using P(3HB) from  
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B. subtilis OK2 were found to be of the smallest size range, of 50-200 nm. It was observed 
that increasing polymer concentration of P(3HB) extracted from B. cereus SPV 
corresponded to an increase in particle size, from a mean particle size of 728 ± 32. 96 nm 
to 22.83 ± 1.21 μm. Figure 3.25 represents particle size distribution of the nanospheres and 
microspheres A- E and Table 3.9 represents the mean particles size of the same. 
 
 
Figure 3.25: Size distribution charts of nanospheres and microspheres prepared from  
A) B. subtilis OK2 B-E) B. cereus SPV, corresponding to conditions in table 3.8 
 
Sample code Mean particle size 
A 118 ± 12.3 nm 
B 728 ± 32. 96 nm 
C 1.6 ± 0.13 μm 
D 9.8 ± 2.18μm 
E 22.83 ± 1.21 μm 
Table 3.9: Table representing the mean particle size of nanospheres prepared using 
P(3HB) extracted from B. subtilis OK2 and nanospheres and microspheres prepared 
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3.2.11.2. Porosity 
Porosity of the nanospheres and microspheres prepared using P(3HB) of two different 
molecular weights were estimated using the liquid displacement method. Of the 5 samples 
compared, nanospheres corresponding to sample code A was found to be the most porous 
with a porosity of 81.32 ± 1.98%. Porosity was influenced by polymer concentration and 
stirrer speed. Lower polymer concentration and higher stirrer speed contributed to 
increased porosity. Sample B with a polymer concentration of 1 mg/mL prepared at 1000 
rpm had a porosity of 77.908 ± 2.93%, while sample C prepared with 2 mg/L polymer 
concentration at 800 rpm had a porosity of 73.183 ± 1.89 %. Sample D prepared with 5 
mg/L polymer concentration at 1000 rpm was found to have a porosity of 71. 093 ± 4.18% 
and sample E prepared with 35 mg/L polymer concentration at 800 rpm had a porosity of 
68.243 ± 3.93% (Figure 3.26). 
 
Figure 3.26: Porosity of nanospheres prepared using P(3HB) extracted from B. subtilis 
OK2 and nanospheres and microspheres prepared using B. cereus SPV, corresponding 
to conditions in table 3.8 
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3.2.11.3. Surface residual PVA 
Surface residual PVA is expressed as the percentage of the mass of PVA on unit mass of 
microspheres. Surface residual PVA was found to vary, primarily as a function of the 
concentration of PVA used during the fabrication process. The highest amount of surface 
associated PVA was found on sample D and E, prepared with 0.5% PVA. This was followed 
by sample A, prepared with 0.35% PVA. Between sample B and C, both of which were 
prepared with 0.25% of PVA, sample B had a higher amount of surface residual PVA (Figure 
3.27).   
 
Figure 3.27: Representation of percentage residual PVA on nanospheres prepared 
using P(3HB) extracted from B. subtilis OK2 and nanospheres and microspheres 
prepared using B. cereus SPV, corresponding to conditions in table 3.8 
3.2.11.4. Hydrophobicity 
Hydrophobicity of the nanospheres and microspheres prepared from P(3HB) of 2 different 
molecular weights were estimated using Rose Bengal assay and was expressed as a function 
of the amount of Rose Bengal dye bound at saturation. Hydrophobicity was found to have 
an inverse proportionality with the amount of surface residual PVA. Samples D and E, 
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prepared with 0.5% PVA, had the least amount of surface bound Rose Bengal dye and 
amongst these, sample D had a lower amount than sample E. Sample C was found to have 
the highest amount of surface bound Rose Bengal dye (Figure 3.28). 
 
Figure 3.28: Comparison of hydrophobicity of nanospheres prepared using P(3HB) 
extracted from B. subtilis OK2 and nanospheres and microspheres prepared using B. 
cereus SPV, corresponding to conditions in table 3.8 
3.3. Discussion 
The use of P(3HB) is in the development of various biomedical devices is gaining 
momentum and the results obtained across the spectrum look promising. The fact that it 
has great processability, proven by the demonstration of its manipulation using techniques 
such as spray coating, electrospinning and 3-D printing, combined with its natural origin 
makes it a suitable candidate for a great variety of biomedical applications. P(3HB) of 
consistent molecular weight has been achieved to be produced, ensuring reproducibility of 
results, in the fabrication of biomedical structures. In this study, optimisation of the 
preparation of P(3HB) microspheres using polymer produced using B. cereus SPV was 
achieved. A surface response methodology using Box- Behnken design was followed. 
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Polymer concentration was established as the most significant variable in controlling 
particle size and further optimisations based on this parameter to obtain spheres of 
different size ranges were attempted. These were well characterised and the results of 
these were compared with spheres synthesised using P(3HB) using B. subtilis OK2. 
3.3.1. Effect of process parameters on particle size and morphology 
An initial set of pilot experiments were used to set suitable boundary conditions and 
solvent to be used. Based on experiments, a randomized Box-Behnken design was 
generated and according to this, 15 different experiments were carried out. The 
optimisation experiments intended to lower the size diameter of particles formed showed 
that a lower concentration of polymer with intermediate PVA concentration and 
intermediate stirrer speed (with respect to the boundary limits employed in this study) 
gave the best results. The rheology of the emulsion varies considerably based on the 
polymer concentration, interaction between the two phases (chloroform and PVA) of the 
emulsion and stirring speed (O'Donnell and McGinity 1997, Errico et al., 2009). These, along 
with the rate of chloroform evaporation have a significant influence on how well the 
microspheres can be formed.   
Polymer concentration has a linear effect on the viscosity of the emulsion and hence, an 
increased polymer concertation would result in an emulsion that is increasingly viscous and 
therefore more resistant to shear forces (Chen, Zhain and Schreyer 2013). This means, unless 
there is an increased source of energy or force to oppose this resistance, it becomes 
difficult to overcome the viscous forces and larger emulsion droplets would be formed. The 
process optimisation of microspheres production was carried out by a set of experiments 
designed using MiniTab express software as described in section 2.2.6.2. Microspheres 
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corresponding to experiment number 7, 4 and 3 prepared using the lowest concentration 
of polymer (0.0375g/mL) were found to be the smallest (with diameter of 25.5, 28 and 28.6 
μm respectively). Subsequently microspheres corresponding to experiment number 10, 8 
and 5 prepared using the highest concentration of polymer (0.1g/mL) were found to be of 
the largest (with diameter of 46.02, 43.1 and 41.733 μm respectively). However, 
experiment number 10, although was run with the least polymer concentration, and least 
stirrer speed, was of an average diameter of 32 m. This is probably due to the fact that 
the stirrer speed in this case was 500 rpm, and although the viscosity of the emulsion was 
lowered due to low polymer concentration, the stirrer speed might not have been sufficient 
to break down the emulsion droplets to a small enough size.  
There are several studies corroborating this finding as that of Farhangi, Dadashzadeh and 
Bolourchian who in their study on the effect of formulation variables in the synthesis of 
gelatin microspheres observed 1.5-1.8 times increase in diameter of microspheres, when 
polymer concentration was increased from 25 w/v% to 45 w/v% (Farhangi, Dadashzadeh 
and Bolourchian, 2017).  
This effect was also exemplified when spheres were synthesised using P(3HB) produced 
from B. subtilis OK2. Molecular weight of P(3HB) produced using B. subtilis OK2 is around 
~850 kDa, while that of B. cereus SPV is ~150 kDa. P(3HB) from B. subtilis OK2 being of 
higher molecular weight resulted in increased viscosity of the oil phase and hence produced 
nanospheres of increased size distribution. In comparison with nanospheres prepared 
under the same conditions as that of P(3HB) produced using B. cereus SPV, nanospheres 
prepared using P(3HB) from B. subtilis OK2 resulted in nanospheres of much larger size 
range. However, when the concentration was lowered, this resulted in reduction of particle 
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size. These spheres appeared to be clumped, with the presence of an intensive network of 
water channels. The issue of interconnecting water channels was circumvented by the use 
of the cryoprotectant trehalose dihydrate. Spheres, especially of smaller diameters, tend 
to aggregate due to many reasons. These may not separate in suspension, eventually 
resulting in embolization, during intravenous administration. Cryoprotectants coat the 
nanospheres during freeze drying stage and protect them from mechanical stress of ice 
crystals. Trehalose dihydrate is a commonly used cryoprotectant due to the following 
advantages; less hygroscopicity, an absence of internal hydrogen bounds which allows 
more flexible formation of hydrogen bonds with nanoparticles during freeze-drying and 
very low chemical reactivity (Abdelwahed et al., 2006).  
The P(3HB) microspheres as expected were found to be quite porous in nature ranging 
between ~40-80% porosity. Lower polymer concentration, lower PVA concentration and 
increased stirring speed were observed to be contributing factors for porosity. Yang et al., 
2001, are of the opinion that during the synthesis of microspheres, after the solvent has 
evaporated, water droplets collect within the spheres (Yang et al., 2001). Thus, rapid 
evaporation of the solvent would result in rapid entrapment and coalescing of the water 
droplets forming uneven pores. This can be contributed by high temperature, increased 
stirring speed and lower polymer concentration. However, at higher concentration of PVA, 
the surfactant might occupy the interstitial spaces not allowing for water droplets to 
collect, thus decreasing porosity (Yang et al., 2001).  
PVA, the surfactant used for the emulsion is amphiphilic and binds to the polymer by means 
of its hydrophobic end. During microsphere formation, when the organic phase is at its 
highest miscibility with the water phase, the hydrophobic vinyl acetate end of PVA binds 
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irretrievably with the polymer leaving the hydrophilic end of PVA exposed on the surface 
of the spheres (Sahoo et al., 2002, Lee et al., 1999). Hence, there is an inverse correlation 
between percentage surface residual PVA and hydrophobicity of the spheres, which has 
been exemplified in this study. Rose Bengal dye, which is a hydrophobic dye, binds to 
hydrophobic surfaces. The amount of Rose Bengal dye bound on the surface of the 
microspheres were inversely proportional to the % residual PVA on the microspheres. The 
exposed hydrophilic end renders hydrophilicity to the microspheres, if excess of residual 
PVA is present on them. This can have a direct impact on uptake of these particles as 
increased hydrophobicity is desirable for increased uptake. Therefore, it is essential to get 
rid of the excess PVA and this was achieved by washing the microspheres with 10% ethanol. 
The resulting % residual PVA was estimated and correlated with the hydrophobicity, which 
was expressed as a function of the hydrophobic Rose Bengal dye bound on the surface at 
a maximum concentration (50 μg/mL). 
Percentage surface residual PVA exhibited a positive correlation with the PVA 
concentration employed in each experimental condition. Where a higher concentration of 
PVA was used, a higher residual PVA concentration was observed. This was also in 
accordance with the previous argument of increased PVA concentration resulting in 
decreased porosity.  
The significance of surface residual PVA is a key factor in determining one of the very 
important features of a drug delivery system, hydrophobicity. Hydrophobicity is a desired 
feature for cancer drug delivery systems as tumour tissues have increased affinity for 
hydrophobic substances, due to the presence of increased LDL receptors than the normal 
tissues. Hydrophobic drug delivery systems entering the blood stream primarily attach 
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themselves to serum lipoproteins such as LDL and HDL. Due to the abundance of LDL 
receptors on tumour tissues, uptake of hydrophobic delivery systems becomes easier 
(Warren et al., 2009).  Oenbrink, Jurgenlimke, and Gabel, 1988 reported a positive 
correlation between hydrophobicity and tumour uptake of porphyrin derivatives 
(Oenbrink, Jurgenlimke, and Gabel, 1988). 
The residual PVA content reported in these experiments are much lower than the ones 
reported in literature. Zielhuis et al., 2005, reported residual PVA concentration of the 
order of 0.2-0.3% on PLGA microspheres and Francis et al., 2011 reported PVA 
concentration of the order of 0.1-0.6% on P(3HB) microspheres (Zielhuis et al., 2005, 
Francis et al., 2011). The reason for lowered amount of residual PVA in this work could be 
the additional ethanol wash step involved that helped in removing PVA. 
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4.1. Introduction 
Cardiovascular diseases (CVD) are listed as the number one cause of mortality worldwide, 
as listed by Word Health Organization (WHO). CVDs are characterised by occlusion or 
narrowing of blood flow to any part of the body and is primarily caused by atherosclerosis. 
Atherosclerosis is the condition where arterial walls thicken because of plaque 
accumulation comprising of calcium, cholesterol, fat and inflammatory components, along 
the arterial walls, which reduces blood flow (Mitra and Agrawal 2006; Daemen and Serruys 
2007; Charpentier et al., 2015). This can result in Angina, which is a discomfort in the chest 
due to reduced blood supply to the heart, myocardial infarction (MI) where blood supply 
to the heart is blocked, stroke where the blood supply to parts of brain is stopped and 
Peripheral Arterial Diseases where blood supply to leg, calves and hip muscles are blocked. 
Disease management for CVDs commonly involve strategies to increase blood flow to 
vascular beds and vary depending on the severity of the condition (Deveza, Choi and Yang, 
2012). The most progressed stages of CVDs often necessitate the use of vascular stents, 
which are devices inserted in the lumen of the arteries to keep them open.  
 In-stent restenosis is elicited by the endothelial injury that the mechanical placement of 
the stent initiates, followed by thrombus formation and fibrin and platelet accumulation, 
which leads to classic anti-inflammatory agglomerates (Mitra and Agrawal 2006). To 
ameliorate these issues associated with bare metal stents, the second- generation stents 
with antiproliferative drugs such as rapamycin and paclitaxel incorporated on bare metal 
stents were introduced, which again had the problems of late restenosis and thrombosis. 
These drug eluting stents while helped in activation of signal-transduction pathways and 
inhibition of proliferation of vascular smooth muscle cell proliferation, also impaired 
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reendothelization, finally leading to a prothrombogenic environment (Ruiz-Esparza et al., 
2013). This led to the development of third generation bioresorbable drug eluting stents 
made of biodegradable polymers.  The main advantage of using these stents is that they do 
not cause permanent physical irritation with the risk of long-term endothelial dysfunction 
or inflammation, as in the case of bare metal stents (Daemen and Serruys 2007).  
The most commonly used antiproliferative drug in the context of drug eluting stents belong 
to the limus group of drugs, which target the mTOR to initiate apoptosis (Figure 4.1).  
 
Figure 4.1: Mechanism of action of ‘Limus’ group of drugs (taken from Daemen and 
Serruys, 2007) 
 
Since the inception of first commercialized resorbable stent ‘Abbott’s ABSORB’, research 
interest in the development of biodegradable materials suitable for this application has 
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increased. The improved performance of these stents led to the consideration of other 
bioresorbable polymers such as PHAs, which compared to PLLA offers, less acidic 
degradation products, higher toughness/elongation at break and a surface erosion vs the 
bulk erosion of PLLA. A strategy to render the stents drug eluting has been to coat the stent 
surface with drug incorporated synthetic polymers such as PDLLA, as in the case of Abbott 
ABSORB. However, there are disadvantages associated with spray coating stent surfaces as 
these do not lead to controlled delivery of the incorporated drugs. This is because the 
release of drug depends on the degradation of the coated polymer and this can exert design 
constraints on stent development, and the overall modulation of drug release. Particulate 
systems such as micro and nanospheres offer better tunability of drug delivery, and they 
can be modified to be target specific and responsive to external stimuli (Dawson, Puranik 
and Peppas 2013).  
 In the first part of this chapter, a comparison of P(3HB) microspheres versus PLLA 
microspheres with encapsulated rapamycin, a well investigated antiproliferative and 
immunosuppressant drug was carried out. These were then characterized to determine the 
effect of drug loading on their physical properties. In the second part, P(3HB) microspheres 
of two different sizes encapsulated with Tacrolimus- another antiproliferative drug in the 
context of drug eluting stents- are compared with respect to their physical properties and 
drug release kinetics.  
While antiproliferative drugs are administered to prevent the occurrence of MI as a result 
of atherosclerosis, an approach antagonistic to this is adopted in patients post MI. Rupture 
of atherosclerotic plaque leads to blocked blood supply to and hence nutrients and oxygen 
to any part of cardiac tissues and causes ischemia followed by MI. As the heart is a dynamic 
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organ and the function of the heart is vital to the functioning of the entire organism, several 
significant advancements have been made to circumvent the occurrence of tissue necrosis 
resulting in the loss of functionality in the case of MI. VEGF is a soluble, diffusible protein, 
first extracted from the medium conditioned by bovine pituitary folliculo-stellate cells by 
Henzel and Ferrara (Henzel, Ferrara and Winer, 1992). Since its discovery, a tremendous 
amount of research has been invested in the use of VEGF both in the perspective of 
angiogenesis and pro- angiogenesis. Vasculogenesis and succeeding angiogenesis are 
required to maintain a tissue’s oxygen supply and support its functionalities (T Shoji et 
al.,2010). Therefore, VEGF plays a vital role in sustaining functionality of tissues and this is 
particularly relevant in the case of myocardial infarctions. The third part of this chapter 
discusses collagen scaffolds embedded with VEGF encapsulated microspheres of various 
sizes. VEGF encapsulated P(3HB) microspheres and nanospheres were synthesised and 
characterised and these were embedded in collagen scaffolds. The release kinetics of VEGF 
from neat spheres and spheres embedded in collagen scaffold were compared. Two 
different sizes of P(3HB) spheres were considered to analyse the changes in release profile, 
with respect to particle size.  
To summarise, this study considered encapsulation and controlled release of therapeutic 
agents relevant before and after the occurrence of MI. The results of these were compared 
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4.2. Results 
Part I: Comparison of P(3HB) and PLLA microspheres in the encapsulation 
and controlled release of rapamycin 
4.2.1. Hydrolytic depolymerisation of P(3HB) 
P(3HB) was subjected to hydrolytic depolymerisation with acetic acid, for 8 and 12 hours 
of reflux respectively. These were then precipitated in excess of methanol and washed, 
centrifuged and lyophilised. Molecular weight analysis and polydispersity index (PDI) of 
polymers thus produced and non- hydrolysed polymer were determined using Agilent 1260 
Infinity system equipped with a refractive index detector (Agilent Technologies, UK). 
Molecular weights decreased with time, however the PDI of the hydrolysed polymers were 
considerably high (Table 4.1). 
Hydrolysis time (h) Mn, Da Mw, Da PDI 
0 27914 98628 1.674 
8 12724 19820 3.71 
12 6921 9341 4.18 
Table 4.1: Molecular weight analysis of P(3HB) subjected to hydrolytic 
depolymerization. 
 
4.2.2. Optimisation of the process of microsphere production using solid-in-
oil-in-water emulsion technique 
Initial optimisation experiments were carried out using PLLA of three different molecular 
weights such as 30-50 KDa, 80-100 KDa and 300-400 KDa. Three different volumes of the 
dispersion phase (chloroform) were used to vary the polymer concentration. P(3HB) 
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subjected to hydrolytic depolymerization for 8 hours and 12 hours and non-hydrolysed 
P(3HB) were used to carry out the optimisation of microsphere production. Three different 
volumes of the dispersion phase (chloroform) were used to vary the polymer concentration 
(Table 4.2).  
PLLA P(3HB) 
Molecular weight 












30-50 20 mL 98628 20 mL 
40 mL 40 mL 
60 mL 60 mL 
80-100 20 mL 19820 20 mL 
40 mL 40 mL 
60 mL 60 mL 
300-400 20 mL 9341 20 mL 
40 mL 40 mL 
60 mL 60 mL 
Table 4.2: Processing conditions for the optimization of PLLA and P(3HB) 
microspheres. 
 
4.2.3. Characterisation of PLLA and P(3HB) microspheres  
4.2.3.1. Surface morphology under SEM 
Microspheres were successfully synthesized using PLLA of molecular weight 30-50 KDa and 
non- hydrolysed P(3HB) in 60 mL of chloroform. These two combinations were chosen for 
further characterisation. Microspheres prepared using other combinations resulted in 
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either polydisperse or poorly formed microspheres and in some cases, microspheres were 
not formed at all. Hydrolysis of P(3HB) was carried out to compare using P(3HB) of much 
lower molecular weight. However, the microspheres formed of hydrolysed polymer were 
widely polydispersed with lumps of polymer found intermittently with partially-formed 
microspheres (Figure 4.2).  
 
Figure 4.2: SEM images of a) microspheres produced using P(3HB) of Mw 9341 Da, b) 
magnified image of intermittent nanospheres c & d) microspheres produced using 
P(3HB) (98,268 Da) and PLLA (30-50 kDa). 
 
These intermittent spheres were in the nanospheres range and were found to be clumped 
together with interconnecting channels, as discussed in Chapter 3. P(3HB) hydrolysed for 8 
hours did not yield any microspheres at all. P(3HB) hydrolysed for 12 hours resulted in 
microspheres, when the organic phase contained 0.1 g of the polymer in 60 mL of 
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chloroform, but highly polydispersed. This indicated that further optimisation in the 
hydrolysis process was required. However, both PLLA and P(3HB) at a concentration of 
0.1g/ 60 mL of chloroform resulted in excellent P(3HB) microspheres, within the size range 
of 1- 8 m and PLLA within the range of 1-5.5 m.  
4.2.3.2. Rapamycin encapsulation in P(3HB) and PLLA microspheres: Surface 
morphology under SEM 
5wt% and 10wt% respectively of rapamycin was added to the polymer solution and was 
homogenized for 5 minutes and then emulsified with 0.5 % w/v PVA. Microstructural 
studies of chosen PLLA and P(3HB) microspheres were carried out using Scanning Electron 
Microscopy (SEM) as shown in Figure 4.3.a &b.  
 
Figure 4.3: a) P(3HB) microspheres with 5 wt% Rapamycin, b) P(3HB) microspheres 
with 10 wt% Rapamycin, c) PLLA microspheres with 5 wt% Rapamycin, d) PLLA) 
microspheres with 10 wt% Rapamycin  
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SEM studies revealed microspheres that were well formed with smooth surface and good 
spherical shape. The particles were free flowing and well separated from one another 
without the presence of interconnecting water channels. 
4.2.3.3. Particle size analysis 
Microsphere images obtained under various magnifications were adjusted to appropriate 
threshold and analysed using the ImageJ software, calibrated with size bars of each of the 
image captured. The particle size distribution curve of microspheres corresponding to free 
P(3HB) and PLLA microspheres, P(3HB) and PLLA microspheres encapsulated with 5wt% of 
Rapamycin and P(3HB) and PLLA microspheres encapsulated with 10wt% Rapamycin are 
represented below (Figure 4.4). Table 4.3 summarises the percentage distribution of 
microsphere into smaller and larger size range to analyse the influence of drug loading and 
type of polymer used. Figure 4.4 and Table 4.3 shows that the both free and Rapamycin 
encapsulated PLLA microspheres are smaller than P(3HB) microspheres. 20.73% of PLLA 
microspheres fall under the smaller size range of 1-3 m while only 12.5% of P(3HB) 
microspheres are in this range. In the case of PLLA, with Rapamycin encapsulation, although 
particle size range remained within 1-5.5 m, the percentage of microspheres in the larger 
size range of 3-5.5 m increased with drug/polymer ratio. The trend observed was the 
same in the case of P(3HB) microspheres with the cumulative frequency of larger 
microspheres increasing with drug/polymer ratio. It was observed that the frequency of 
P(3HB) microspheres in the 1-3 m range decreased from 18.77% to 8.5 % with 10 wt% 
Rapamycin encapsulations. 11.56% microspheres of 10 wt% Rapamycin encapsulated 
P(3HB) were in the size range of 5.5-7 m. The change in size distribution of PLLA was not 
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as pronounced with Rapamycin encapsulation, with a reduction of only 2.9% in the smaller 
size range, with Rapamycin encapsulation. 
 
Figure 4.4: Size distribution analysis of a) neat P(3HB) microspheres, b) P(3HB) 
microspheres with 5 wt% rapamycin, c) P(3HB) microspheres with 10 wt% rapamycin, d) 
neat PLLA microspheres, e) PLLA microspheres with 5 wt% rapamycin, f) PLLA microspheres 
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 1-3 m 3-5.5 m 
P(3HB) 18.77 80.73 
P(3HB) with 5 wt% Rapamycin 15 84.7 
P(3HB) with 10 wt% Rapamycin 8.5 79.94 
PLLA 23.21 76.54 
PLLA with 5 wt% Rapamycin 21.3 78.1 
PLLA with 10 wt% Rapamycin 20.73 79.26 
Table 4.3: Size distribution analysis of P(3HB) and PLLA microspheres with and without 
encapsulated rapamycin. 
 
4.2.3.4. Porosity  
The optimization studies revealed that PLLA microspheres were 15±1.1 % porous whereas 
P(3HB) microspheres amounted to a significant 37.5± 3.12% porosity (Figure 4.5).  
 
Figure 4.5: Porosity measurements of microspheres prepared using P(3HB) and PLLA with 
and without Rapamycin encapsulation (n=3; error bars= ±SD). The data was compared 
using t- test and the differences were considered very significant (**p<0.01) 
 
However, the rapamycin encapsulated microspheres of both the polymers exhibited much 
higher porosity. Rapamycin encapsulated PLLA microspheres exhibited porosity in the 
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range of ~50- 56% with a direct correlation between porosity and drug loading. Rapamycin 
encapsulated P(3HB) microspheres exhibited a similar trend, however, with a very high 
porosity range of ~69-71% porosity.  
4.2.3.5. Surface residual PVA 
Surface residual PVA associated with free and Rapamycin encapsulated microspheres were 
quantified using the method described in section 2.2.8.4 (Figure 4.6).  
 
Figure 4.6: Surface residual PVA measurements of microspheres prepared using P(3HB) 
and PLLA with and without Rapamycin encapsulation (n=3; error bars= ±SD). The data was 
compared using t- test and the differences were considered significant (*p<0.05) 
 
Free P(3HB) microspheres had 0.029 ± 0.0012 % residual PVA associated on the surface 
when compared to the 0.037 ± 0.0012% residual PVA associated on the PLLA microsphere 
surface. % Surface residual PVA decreased with increasing drug loading and the decrease 
was significant between free P(3HB) microspheres and P(3HB) microspheres encapsulated 
with 10 wt% Rapamycin. Same trend was observed between free PLLA microspheres and 
PLLA microspheres encapsulated with Rapamycin. The decrease in % residual PVA between 
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free PLLA microspheres and PLLA microspheres encapsulated with 5 wt% Rapamycin (0.037 
± 0.0012% and 0.030 ± 0.009% respectively) was found to be statistically significant but the 
differences between PLLA microspheres encapsulated with 5 wt% and 10 wt% Rapamycin 
(0.030 ± 0.009% and 0.029 ± 0.0021 respectively) were statistically insignificant.  
4.2.3.6. Surface hydrophobicity 
The surface hydrophobicity of the microspheres fabricated using P(3HB) and PLLA with and 
without the incorporation of Rapamycin was determined by comparing the amount of Rose 
Bengal dye that was adsorbed per mg of the microspheres. As shown in figure 4.7, P(3HB) 
microspheres are markedly more hydrophobic than PLLA microspheres with 3.3 ± 0.051 μg 
of surface bound Rose Bengal dye as opposed to a 1.43 ± 0.188 μg of PLLA microspheres.  
 
Figure 4.7: Hydrophobicity expressed as a function of surface bound Rose Bengal dye 
for microspheres prepared using P(3HB) and PLLA with and without Rapamycin 
encapsulation (n=3; error bars= ± SD). The data was compared using t- test.  
 
Hydrophobicity expressed as a function of surface bound Rose Bengal dye was found to 
increase with drug loading and the differences were statistically very significant amongst 
P(3HB) microspheres (3.3 ± 0.051 μg/mg on free microspheres, 4.15 ± 0.148 μg/mg on 
P(3HB) microspheres with 5 wt% Rapamycin and 5.23 ± 0.148 μg/mg on P(3HB) 
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microspheres with 10 wt% rapamycin, respectively). The trend was observed to be the 
same between free and Rapamycin encapsulated PLLA microspheres. The amount of Rose 
Bengal dye bound increased to 3.43 ± 0.200 μg/mg with 5 wt% Rapamycin encapsulations 
and the difference was found to be statistically very significant and the amount increased 
to 4.24 ± 0.04 μg/mg with 10 wt% of Rapamycin encapsulations.  
4.2.3.7. Protein adsorption 
Passive protein adsorption on the surface of microspheres was estimated by immersing 
samples in BSA solution for 24 hours and subjecting the supernatant to Bradford assay 
(Figure 4.8).  
 
Figure 4.8: Protein adsorption on the surface of microspheres prepared using P(3HB) and 
PLLA with and without Rapamycin encapsulation (n=3; error bars= ± SD).  
 
In comparison with PLLA microspheres (221.67 ± 10.21 μg/mg), protein adsorption on 
P(3HB) microspheres was found to be higher (297 ± 19.31 μg/mg). Rapamycin 
incorporation was found to have a positive correlation with protein adsorption in the case 
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of both P(3HB) and PLLA microspheres. In the case of PLLA, 255. 67 ± 2.8 μg/mg was 
adsorbed on microspheres with 5 wt% drug loading and 258. 66 ± 3.05 μg/mg was adsorbed 
on microspheres with 10 wt% drug loading. In the case of P(3HB), this was 371. 33 ± 33.21 
μg/mg and 396.38 ± 5.68 μg/mg respectively. 
4.2.3.8. In vitro Degradation of P(3HB) and PLLA microspheres 
I. Water uptake and weight loss analysis 
In vitro degradation of P(3HB) and PLLA microspheres with and without encapsulated 
Rapamycin was analysed using data from water uptake and water loss measurements. In 
the case of unloaded P(3HB), water uptake was gradual from 201% to 405% over a span of 
36 days. This trend was followed even in the case of Rapamycin loaded P(3HB), with a 
maximum water uptake of 402% in the case of both 5 wt% and 10 wt% rapamycin 
encapsulations (Figure 4.9). 
Maximum weight loss in the case of unloaded P(3HB) microspheres was 11.9%, followed 
by a 10.5% in the case of 5 wt% Rapamycin encapsulated microspheres and 10.2% of 10 
wt% Rapamycin encapsulated microspheres. PLLA microspheres were found to show 
increased water uptake in comparison with P(3HB) microspheres, starting with 248% on 
day 3 and ending at a maximum of 583 on day 36 (Figure 4.9). 5 wt% rapamycin 
encapsulated PLLA microspheres showed a maximum water uptake of 560% and 10 wt% 
Rapamycin encapsulated PLLA microspheres showed a maximum water uptake of 555%. 
Weight loss also was found to be more in the case of PLLA, with a maximum of 14.3% in 
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Figure 4.9: Water uptake and weight loss measurements in   measurements in a & b) 
unloaded P(3HB) microspheres P(3HB) microspheres with 5 wt% Rapamycin and 10 wt% 
Rapamycin, and c & d) Water uptake measurements in unloaded PLLA microspheres, PLLA 
microspheres with 5 wt% rapamycin and PLLA microspheres with 10 wt% Rapamycin and 
(n=3; error bars= ±SD) 
 
I. pH changes 
Rapamycin loaded and unloaded P(3HB) and PLLA microspheres were immersed in PBS at 
pH 7.4 and pH changes over time was recorded (Figure 4.10). It was observed that while 
pH changes in P(3HB) microspheres over a span of 36 days remained within the range on 
7.2-6, PLLA microspheres showed drastic pH changes from 7.2 to 3.1. in the case of P(3HB), 
the degradation products of rapamycin encapsulated microspheres were found to be even 
more acidic compared to unloaded microspheres while no such differences were observed 
in the case of PLLA microspheres.  
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Figure 4.10: pH changes observed in the PBS solution containing a) unloaded and 
rapamycin loaded P(3HB) microspheres and b) unloaded and rapamycin loaded PLLA 
microspheres, (n=3; error bars = SD). 
 
4.2.4. Rapamycin encapsulation and release kinetics 
4.2.4.1. Encapsulation efficiency 
The best optimised microspheres were chosen to incorporate 5 wt% and 10 wt% drug 
loadings of Rapamycin. Briefly, 0.1g of each polymer was dissolved in 20 mL of chloroform 
and 5 wt% and 10 wt% each of Rapamycin was added to this solution, followed by 
homogenization, at 4 oC. Microspheres prepared using this organic phase was lyophilized 
and was observed for release kinetics. Prior to that the experimental loading of 
encapsulation in these microspheres were quantified using HPLC (Figure 4.11).   
The release profile in both the cases were found have a pronounced burst release in the 
first 48 hours, for up to 11% cumulative release. P(3HB) microspheres exhibited a slightly 
faster release when compared to PLLA microspheres, with 5 wt% Rapamycin loaded P(3HB) 
microspheres releasing up to 22.70% and 10 wt% rapamycin loaded P(3HB) microspheres 
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releasing up to 22.97% in 30 days. This was found to be 19.01 and 22.02 respectively, in the 
case of 5 wt% and 10 wt% loaded PLLA microspheres. 
 
 
Figure 4.11: Encapsulation efficiency of P(3HB) and PLLA microspheres at 5 wt% and 10 
wt% rapamycin loading (n=3; error bars = SD). 
 
At 5 wt% loading (5mg of rapamycin), P(3HB) microspheres had a higher encapsulation 
efficiency of 62.37% compared to the 58.58% of PLLA microspheres. However, at 10 wt% 
loading (10mg of rapamycin) PLLA microspheres had a higher encapsulation efficiency of 
67. 26% compared to the 62.37% of P(3HB) microspheres. The amount of Rapamycin 
encapsulated in P(3HB) microspheres with 5 and 10 wt% drug loadings are 3.16mg and 6.68 
mg respectively and the amount of Rapamycin encapsulated in PLLA microspheres with 5 
and 10 wt% drug loadings are 2.92 mg and 6.7 mg respectively. In both the cases, 
encapsulation efficiency was found to increase with increase in drug/polymer ratio.  
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4.2.4.2. In vitro Release kinetics 
In vitro release profiles of rapamycin encapsulated P(3HB) and PLLA microspheres were 
carried out for a period of 30 days, after which the drug was detected using HPLC was found 
to be inaccurate, possibly due to degradation of the drug. Samples were drawn periodically 
from PBS immersed with 5 wt% and 10 wt% rapamycin loaded P(3HB) and PLLA 
microspheres and these were analysed for their drug content using HPLC (Figure 4.12).  
 
Figure 4.12: Rapamycin release profile from a) P(3HB) microspheres, b) PLLA 
microspheres (n=3; error bars = SD). 
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The release data was fitted in models as described in section 2.2.11. R2 value of each of the 
linear regression was compared (Table 4.4).  
 
Table 4.4: Summary of model fitting for Rapamycin release from P(3HB) and PLLA 
microspheres. 
 
In all the 4 preparations, the release data was found to be more fitting to Higuchi model. 
In the case of both PLLA and P(3HB), microspheres with 5% rapamycin loading was 
Model Parameters  5 wt%  10 wt%   5 wt%  10 wt%  
R 2 0.827 0.786 0.790 0.766
Adj- R 2 0.909 0.764 0.769 0.742
Slope 0.028 0.029 0.0241 0.0277
SSR 102.13 143.89 94.48 139.01
R 2 0.853 0.813 0.811 0.793
Adj- R 2 0.838 0.794 0.792 0.773
Slope -0.0001 -0.0001 -0.0001 -0.0001
SSR 0.002 0.003 0.002 0.003
R 2 0.956 0.947 0.952 0.932
Adj- R 2 0.952 0.941 0.947 0.926
Slope 0.796 0.846 0.693 0.789
SSR 25.78 35.79 21.68 40.08
R 2 0.804 0.804 0.804 0.784
Adj- R 2 0.784 0.784 0.784 0.763
Slope -0.0005 -0.0005 -0.0004 -0.0005
SSR 0.026 0.037 0.024 0.036
R 2 0.943 0.933 0.985 0.917
Adj- R 2 0.936 0.925 0.983 0.908
Slope 0.351 0.384 0.353 0.357
SSR 0.052 0.074 0.014 0.080
P(3HB) microspheres with 
Rapamycin loading of 
PLLA microspheres with 
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observed to have a higher correlation in comparison with 10% loading. This indicates 
diffusion mode of drug release. To assess the nature of drug release, the slope (which 
corresponds to ‘n’, the release exponent) for Korsmeyer- Peppas regression was analysed, 
and since all the values were less than 0.43, it was confirmed that in all the 4 cases, diffusion 
follows Fickian mode. 
Part II: Comparison of P(3HB) nano and microspheres with encapsulated 
tacrolimus 
4.2.5. Production of micro/nanospheres with encapsulated tacrolimus using 
solid-in-oil-in-water emulsion technique 
P(3HB) microspheres and nanospheres with encapsulated tacrolimus were prepared using 
solid-in-oil-in-water emulsion technique by the solvent evaporation method. Unloaded 
microspheres and nanospheres are used as controls throughout this chapter. After an initial 
set of pilot experiments for optimization, 1, 5 and 10 wt% of tacrolimus was dissolved in 20 
mL solution of 6.5 mg/ mL solution of P(3HB) to produce nanospheres and in an 8 mL 
solution of 12.5 mg/ mL solution of P(3HB) to produce microspheres. 0.5 w/v% of PVA was 
used as the surfactant in both cases. The processing conditions are as represented in the 
Table 4.5. These were centrifuged, washed, and lyophilized and subjected to thermal and 
















Stirrer speed (rpm) 
P(3HB) (n)  
6.5 
20 - 800 
1 wt% Tac (n) 20 0.0013 800 
5 wt% Tac (n) 20 0.0065 800 
10 wt% Tac (n) 20 0.013 1000 
P(3HB) (m)  
12.5 
8 - 1000 
1 wt% Tac (m) 8 0.01 1000 
5 wt% Tac (m) 8 0.05 1000 
10 wt% Tac (m) 8 0.1 1000 
Table 4.5: Processing conditions for the production of P(3HB) microspheres and 
nanospheres with encapsulated Tacrolimus 
 
4.2.6. Characterization of P(3HB) microspheres and nanospheres with 
encapsulated tacrolimus 
4.2.6.1. Surface morphology analysis using SEM 
The nanospheres and microspheres compared had very distinct differences in surface 
morphology (Figure 4.13).  
 
Figure 4.13: SEM images of a) unloaded P(3HB) nanospheres, b) unloaded P(3HB) 
microspheres (size bar= 10 m) 
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While the microspheres had more pronounced sphericity, tacrolimus encapsulated 
nanospheres in comparison with the unloaded ones had slight occurrence of intermittent 
disc shaped particles. However, their size distribution was observed to be sufficiently 
monodisperse. Both microspheres and nanospheres had smooth surfaces with minimal 
agglomeration. In the case of microspheres, with increasing drug loading, particle size and 
was observed to increase markedly with drug loading and smoothness of the surface was 
observed to decrease.  With increased drug loading, the microspheres seemed to have the 
presence of some thread like features and residual particulates on the surface of spheres 
(Figure 4.14) 
 
Figure 4.14: SEM images of a-c) 1 wt%, 5 wt% and 10 wt% Tacrolimus encapsulated 
nanospheres, d-e) 1 wt%, 5 wt% and 10 wt% Tacrolimus encapsulated microspheres 
 
4.2.6.2. Particle size analysis 
Particle sizes of the micro and nanospheres produced with and without Tacrolimus were 
analysed using the software imageJ, with appropriate threshold adjustments. It was found 
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that in the case of both nanospheres and microspheres, the average size of microspheres 
increased with drug loading and the differences were statistically significant (Figure 4.15). 
 
Figure 4.15: Particle size distribution of a-d) unloaded nanospheres and 1 wt%, 5 wt% 
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In the case of nanospheres, there was no pronounced differences in size between the three 
different drug loadings of Tacrolimus tested. While the unloaded nanospheres had an 
average diameter size of 672.2 ± 12.89 nm, 1, 5 and 10 wt% Tacrolimus loaded nanospheres 
were found to be 763.1 ± 19.87, 765.6 ± 27.9 and 761.4 ± 18.21nm respectively. In the case 
of microspheres, there was a gradual increase in microsphere size after drug loading. While 
the unloaded microspheres had an average diameter size of 6.15 ± 0.32 μm, 1, 5 and 10 
wt% Tacrolimus loaded microspheres were found to have diameter size of 11.75 ± 0.58, 
13.12 ± 0.93 and 14.62 ± 0.82 μm respectively. 
 
4.2.6.3. Porosity 
Porosity was quantified using liquid displacement method as explained in section 2.2.8.3. 
In comparison with unloaded nanospheres, unloaded microspheres were found to be more 
porous with a porosity of 77.09 ± 3.83%, as opposed to 67.90 ± 2.12% for the nanospheres 
(Figure 4.16).  
 
Figure 4.16: Porosity measurements of microspheres and nanospheres prepared with 
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Porosity was found to increase with drug loading, in the case of both microspheres and 
nanospheres. However, comparing between unloaded and Tacrolimus loaded spheres in 
both micro and nano size range, spheres with encapsulated tacrolimus were found to be 
more porous. In the case of nanospheres, porosity was found to have increased from 63% 
to 70% between 1 wt% and 10 wt% tacrolimus loading and in the case of microspheres, 
porosity was found to have increased from 64% to 73%.  
 
4.2.6.4. Residual PVA 
Residual PVA was estimated to be the highest in the case of unloaded nanospheres and 
was found to be 0.499 ± 0.09 %w/w of unit mass of spheres (Figure 4.17).  
 
Figure 4.17: Surface residual PVA of microspheres and nanospheres prepared with and 
without encapsulated tacrolimus (n=3; error bars= ±SD) [n=nanospheres, 
m=microspheres].  
 
A slight decrease of 0.009% was observed with 1 wt% Tacrolimus loading, but the decrease 
was much more pronounced with 10 wt% loading of the drug, to, 0.298 ± 0.01 %. Although 
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the trend was followed in the case of microspheres, the difference in residual PVA with 
drug loading was not as significant. Residual PVA was found to have reduced from 0. 263 ± 
0.004 to 0.245 ± 0.007 between 1 wt% and 10 wt% drug loading in microspheres. To 
summarize, there was a 40% reduction in residual PVA between unloaded nanospheres and 
nanospheres loaded with 10 wt% Tacrolimus, while there was only a reduction of 12% in 
the case of microspheres. 
4.2.6.5. Hydrophobicity 
Surface hydrophobicity of microspheres and nanospheres prepared were expressed as a 
function of the amount of Rose Bengal dye bound on the surface of the spheres at dye 
saturation (Figure 4.18)   
 
Figure 4.18: Hydrophobicity expressed as a function of surface bound Rose Bengal 
dye on micro/nanospheres with and without encapsulated tacrolimus (n=3; error bars= 
±SD) [n=nanospheres, m=microspheres]. 
 
Unloaded nanospheres had a smaller amount of Rose Bengal dye bound on their surface 
(4.98 ± 0.098 μg/mg), indicating that they are relatively less hydrophobic than the 
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microspheres (5.11 ± 0.07 μg/mg). The amount of Rose Bengal dye bound on the surface 
of the spheres were found to increase with drug loading in the case of both microspheres 
and nanospheres, suggesting that hydrophobicity of the particles increased with drug 
loading. In the case of nanospheres, the amount of surface bound Rose Bengal dye 
increased from 5.074 ± 0.11 μg/mg to 5.162 ± 0.123 μg/mg between 1 wt% and 10 wt% 
drug loading. The difference was found to be higher in the case of microspheres, with an 
increase of 5.149 ± 0.198 μg/mg to 5.288 ± 0.170 μg/mg between 1 wt% and 10 wt% drug 
loading. The differences were found to be statistically insignificant. 
4.2.6.6. Protein adsorption 
Protein adsorption on the surface of microspheres and nanospheres was estimated by 
immersing samples in BSA solution for 24 hours and subjecting the supernatant to Bradford 
assay. The nanospheres in general were found to adsorb an increased amount of proteins 
in comparison with the microspheres (Figure 4.19). 
 
Figure 4.19: Protein adsorption on the surface of unloaded and 1 wt%, 5 wt% and 10 wt% 
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Unloaded nanospheres adsorbed 332.12 ± 17.78 μg/mg, compared to a 297 ± 19.313 
μg/mg for the unloaded microspheres. While in the case of microspheres, the amount of 
protein adsorbed was observed to decrease with drug loading, nanospheres did not follow 
this trend. The amount of protein adsorbed on nanospheres with 5 wt% Tacrolimus (325 ± 
2.9 μg/mg) was slightly higher than the amount on nanospheres with 1 wt% (321 ± 3.2 
μg/mg) and less than nanospheres with 10 wt% tacrolimus (308 ± 11.9 μg/mg). The 
differences in the amount of absorbed protein between each preparation were not 
statistically significant. 
4.2.6.7. In vitro degradation  
I. Water uptake and weight loss 
Water uptake and weight loss was estimated with samples immersed in PBS for a duration 
of 36 days (Figure 4.20). Compared to unloaded and Tacrolimus encapsulated 
microspheres, unloaded and tacrolimus encapsulated nanospheres exhibited higher extent 
of water uptake. The estimated water loss estimated was also found to follow the same 
trend. Unloaded nanospheres absorbed a maximum of 459% water and experienced a 
weight loss of 16.6% over 36 days. In the case of unloaded microspheres maximum water 
uptake was 409% and weight loss was 11.9%. In the case of nanospheres, water uptake was 
found to decrease with drug loading, with nanospheres with, 1 wt% tacrolimus absorbing 
a maximum of 402%, 5 wt% tacrolimus absorbing a maximum of 392% and 10 wt% 
tacrolimus absorbing a maximum of 361%. Weight loss followed a similar trend with a 
decrease from 11.3 to 10.9% between 1 wt% tacrolimus loading and 10 wt% tacrolimus 
loading. In the case of microspheres, maximum water uptake was found to be 442%, 420% 
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and 361% for 1 wt% tacrolimus loading, 5 wt% tacrolimus loading and 10 wt% tacrolimus 
loading respectively.  
But in the case of weight loss, although weight loss was found to have decelerated in the 
beginning, towards the end of 36 days, the weight loss experienced by all the three drug 
loaded microspheres were similar. 
 
Figure 4.20: Water uptake measurements and weight loss measurements in a) & b 
unloaded P(3HB) nanospheres and nanospheres with 1 wt%, 5 wt% and 10 wt% tacrolimus, 
weight loss measurements in and c & d unloaded P(3HB) microspheres and microspheres 
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I. pH changes 
P(3HB) nanospheres and microspheres with and without encapsulated tacrolimus were 
immersed in PBS at pH 7.4 and pH changes over time was recorded. A gradual decrease in 
pH was observed in all 8 cases and the decrease was found to be more in the case of 
nanospheres, in general. Unloaded nanospheres reached a final pH of 6.1 while unloaded 
microspheres reached a final pH of 6.2 (Figure 4.21).  
 
Figure 4.21: pH changes observed in the PBS solution containing a) unloaded and 1 wt%, 
5 wt% and 10 wt% tacrolimus encapsulated nanospheres, b) unloaded and 1 wt%, 5 wt% 
and 10 wt% tacrolimus encapsulated microspheres, (n=3; error bars = ±SD). 
[n=nanospheres, m=microspheres]. 
 
4.2.7. Tacrolimus encapsulation and release kinetics 
1 wt%, 5 wt and 10 wt% tacrolimus was encapsulated in P(3HB) nanospheres and 
microspheres and the experimental drug loading was quantified using HPLC method (Figure 
4.22). Experimental drug loading and hence encapsulation efficiency was found to be 
higher in microspheres, in comparison with nanospheres. Encapsulation efficiency 
increased with increasing drug/ polymer ratio, or in other words drug loading. In the case 
of microspheres, encapsulation efficiency increased from 61.2 ± 4.18% to 69.8 ± 1.9% and 
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72.3 ± 2.21% between 1 wt%, 5 wt% and 10 wt% tacrolimus loading respectively. In the 
case of nanospheres, this was 59.8 ± 2.1%, 62.3 ± 2.01% and 65.8 ± 1.54% respectively. 
 
Figure 4.22: Representation of percentage of Tacrolimus encapsulated in P(3HB) 
nanospheres and microspheres at 1 wt%, 5 wt% and 10 wt% drug loading (n=3; error bars 
= SD). [n=nanospheres, m=microspheres]. 
 
4.2.8. Release kinetics 
Release kinetics of tacrolimus from both P(3HB) nanospheres and microspheres was 
identical in all the 6 cases, with a burst release up to 48 hours (Figure 4.23). Release from 
nanospheres were comparatively faster than microspheres, with a cumulative release of 
71.2%, 73.1% and 76.2% from nanospheres encapsulated with 1 wt%, 5 wt% and 10 wt% 
tacrolimus. In the case of microspheres, this was 68.12, 70.37 and 72.3% respectively. 
Beyond 1440 hours, tacrolimus traces were not detectable as distinct peaks using HPLC, in 
all the cases. Maximum release was obtained from P(3HB) nanospheres with 10 wt% 
tacrolimus loading.  
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Figure 4.23: Tacrolimus release from P(3HB) nanospheres and microspheres with 1 
wt%, 5 wt% and 10 wt% drug loading (n=3; error bars = SD). 
 
The release data was fitted in models as described in section 2.2.11. R2 value of each of the 
linear regression was compared (Table 4.6). In all the 4 preparations, the release data was 
found to be more fitting to Higuchi model. All preparations showed 99% correlation in 
Higuchi model, suggesting a diffusion mode of release mechanism.   
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Table 4.6: Summary of model fitting for Rapamycin release from P(3HB) and PLLA 
microspheres. 
 
All preparations were found to fit with Korsmeyer- Peppas model as well, suggesting a non-
linearity between release and time, when approximated to 60%. The release exponents 
determined from the slope of the linear regression are represented in table 4.7. In all three 
cases of nanospheres, the release exponent was found to be less than 0.43, suggesting a 
Fickian case of diffusion. In the case of microspheres, the preparations with 1 wt% and 10 
wt% tacrolimus loading had a release exponent between 0.43 and 0.85 (0.45 and 0.47 
Model Parameters 1 wt%  5 wt% 10 wt%   1 wt%  5 wt% 10 wt%  
R 2 0.914 0.911 0.920 0.894 0.890 0.895
Adj- R 2 0.908 0.905 0.915 0.887 0.883 0.888
Slope 0.0454 0.0456 0.0471 0.0447 0.0448 0.046
SSR 769.43 808.96 767.55 938.45 985.46 995.75
R 2 0.977 0.977 0.983 0.965 0.965 0.970
Adj- R 2 0.976 0.976 0.982 0.962 0.963 0.968
Slope -0.0004 -0.0004 -0.0004 -0.0003 -0.0003 -0.0004
SSR 0.012 0.012 0.010 0.016 0.017 0.016
R 2 0.992 0.990 0.991 0.992 0.990 0.990
Adj- R 2 0.992 0.989 0.990 0.991 0.989 0.990
Slope 1.7391 1.803 1.856 1.7855 1.793 1.843
SSR 69.98 93.60 88.14 72.64 89.22 90.28
R 2 0.962 0.962 0.970 0.945 0.944 0.950
Adj- R 2 0.959 0.959 0.968 0.942 0.941 0.947
Slope -0.001 -0.001 -0.001 -0.001 -0.001 -0.001
SSR 0.166 0.174 0.152 0.222 0.231 0.230
R 2 0.990 0.988 0.984 0.992 0.990 0.993
Adj- R 2 0.989 0.987 0.983 0.991 0.990 0.993
Slope 0.393 0.377 0.365 0.448 0.437 0.417
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respectively). This suggests anomalous, non- Fickian mode of diffusion where 
heterogenous factors are involved. Microspheres with 10 wt% tacrolimus loading was again 
found to release following Fickian mode, with a release exponent value of 0.41. 
Part III P(3HB) microspheres as VEGF delivery systems in Collagen scaffolds 
for Cardiac regeneration 
4.2.9. Process optimisation of spheres of different size ranges with 
encapsulated VEGF  
Process parameters obtained from initial optimisations (refer chapter 3) were used for the 
synthesis of microspheres and nanospheres with encapsulated VEGF. Initially process 
parameters corresponding to 3 different sizes of 500-1000nm, 5-15 μm and 20-30 μm, were 
tested with VEGF incorporation in the aqueous phase. Particle size and surface morphology 
of production was recorded (Table 4.7). The process parameters corresponding to size 
range 20-30 mm gave microspheres with smooth surface morphology and sphericity, 
whereas the process parameters corresponding to the smaller sizes were not found to be 
suitable for VEGF incorporation as they were found to form agglomerates of smaller 
spheres. Therefore, new set of parameters had to be optimised. The parameters employed 
are as represented in table 4.7. 6.5 mg/mL of P(3HB) with a PVA concentration of 0.25 
w/v% at stirrer speed of 800 rpm gave nanospheres with a mean diameter of 0.71 μm. 9 
mg/mL of P(3HB) with a PVA concentration of 0.5 w/v% at stirrer speed of 1000 rpm gave 
nanospheres with a mean diameter of 0.83 μm. Microspheres prepared under the same 
conditions, but with a polymer concentration of 37.5 mg/mL gave microspheres with a 
mean diameter of 28 μm. 
Chapter 4 
 
















(m) ± S. D 
1 5 0.5 800 Irregular - 
2 6.5 0.5 800 Irregular - 
3 5 0.25 1200 Clustered, 
Porous 
- 
4 5 5 1200 Clustered, 
Porous 
- 
5 10 1 800 Clustered - 
6 10 0.5 1200 irregular - 
7 6.5 0.25 800 Smooth 
spheres 
0.71± .018 
8 9 0.5 1000 Smooth 
spheres 
9.83 ±1.1 
9 37.5 0.5 1000 Smooth 
spheres 
28 ±5.3 
Table 4.7: Process parameters employed for the synthesis of VEGF encapsulated 
microspheres and nanospheres.  
 
4.2.10. Surface morphology under SEM  
Surface morphology of VEGF encapsulate microspheres and nanospheres were observed 
using SEM (Figure 4.24). It was found that the process parameters as established in chapter 
3 for the synthesis of nanospheres in the range of 500-900 nm and microspheres in the size 
range of 5-15 mm needed altering, when VEGF was incorporated in using the water in-oil-
in- water emulsion technique. Particles of suitable morphology were achieved by reducing 
the concentration of PVA in the aqueous phase and reducing the concentration of P(3HB) 
and increasing stirrer speed in the second case.  The process parameters corresponding to 
the highlighted images were chosen for incorporation in collagen 3D-scaffolds.  
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Figure 4.24 a-i: SEM images of spheres corresponding to experiment number 1-9 in 
table 4.7. 
 
4.2.11. Characterization of VEGF encapsulated particles chosen for 
incorporation in 3D-collagen scaffolds 
4.2.11.1. Particle size analysis 
VEGF encapsulated microspheres and nanospheres were imaged using SEM and different 
magnifications of images were used to analyse particle size distribution using the ImageJ 
software (Figure 4.27).  
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Figure 4.25: Particle size distribution of VEGF encapsulated a) nanospheres b) 
microspheres in the size range of 5-15 m and c) microspheres in the size range of 20-
30 m 
 
The nanospheres had an average size of 710 ± 10.11 nm, and the microspheres in the 5-15 
m range had an average size of 9.83 ±1.1 μm and microspheres in the size range of 20-30 
m had an average size of 28 ±5.3 μm.  
4.2.11.2. Porosity 
Porosity of the VEGF encapsulated microspheres and nanospheres were calculated using 
the liquid displacement method and was compared with unloaded controls. Porosity of 
both unloaded and VEGF loaded particles were in the range of 60-80%. However, there was 
no correlation between porosity and VEGF encapsulation. While porosity increased very 
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slightly, from 67.9% to 69 % in the case of nanospheres with VEGF encapsulation, it 
decreased from 77% to 75% in the case of microspheres in the size range of 5-10 m. The 
microspheres in the size range of 20-30 m showed an increase of 0.9% in porosity with 
VEGF encapsulation. None of the differences observed were found to be statistically 
significant (Figure 4.26). It can be concluded that in all the preparations, the differences in 
porosity were considerably small and negligible. 
 
Figure 4.26: Porosity measurements of microspheres prepared with and without 
encapsulated VEGF ((n=3; error bars= ±SD). 
 
4.2.11.3. Surface residual PVA 
Surface residual PVA bound on microspheres and nanospheres prepared with and without 
encapsulated VEGF was estimated and expressed as percentage PVA per unite mass of 
nanosphere/ microsphere sample. It was found that in all the samples, the amount of 
surface residual PVA increased with VEGF loading. The amount of surface residual PVA was 
also found to be inversely proportional to the size of the particles. The unloaded 
nanospheres had 0.50 w/w% residual PVA on them which increased to 0.51 w/w% with 
Chapter 4 
 
  161 
 
VEGF encapsulation. In the case of smaller microspheres, surface residual PVA increased 
from 0.30 w/w% to 0.31 w/w% and in the case of larger microspheres, surface residual PVA 
increased from 0.28 w/w% to 0.29 w/w% with VEGF encapsulation (Figure 4.27).  
 
Figure 4.27: Surface residual PVA of unloaded and VEGF encapsulated P(3HB) 
microspheres and nanospheres (n=3; error bars= ±SD). 
 
4.2.11.4. Hydrophobicity 
Hydrophobicity, expressed as a function of the amount of Rose Bengal dye bound on the 
particles at saturation, was found to decrease with VEGF encapsulation, when compared 
to unloaded particles (Figure 4.28). When compared with unloaded preparations, VEGF 
loaded preparations were found to have a reduced amount of Rose Bengal dye bound on 
their surfaces. The differences in each case were statistically significant. Unloaded 
microspheres in the size range of 20-30 m was found to have 5.12 g/mg of Rose Bengal 
dye bound on their surface.  
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Figure 4.28: Hydrophobicity expressed as a function of amount of Rose Bengal dye 
bound at saturation, for unloaded and VEGF encapsulated microspheres and nanospheres 
(n=3, error bars= ±SD).  
 
4.2.11.5. Protein adsorption 
The amount of protein bound on the surface of VEGF encapsulated nanospheres and 
microspheres were found to be lower than the unloaded controls in all the three cases 
(Figure 4.29). 
 In the case of nanospheres, amount of protein adsorbed decreased from 332.12 ± 8.123 
μg/mg to 32.67 ± 2.89 μg/mg. In the case of smaller microspheres, the change was from 
299.31 ± 5.313 μg/mg to 272.00 ± 21.37 μg/mg and in the case of larger microspheres, the 
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Figure 4.29: Protein adsorption on the surface of unloaded and VEGF encapsulated 
nanospheres and microspheres (n=3; error bars= ± SD).  
 
4.2.11.6. In vitro degradation studies  
I. Water uptake and weight loss 
Changes in water uptake and weight loss with VEGF encapsulation was observed to be the 
same in all three cases (Figure 4.30). Water uptake and weight loss over the period of 36 
days was found to have been increased in all the cases. Amongst the unloaded particles, 
the nanospheres were found to experience the highest water uptake and weight loss, of 
459% and 16.6% respectively. These increased to 472% and 17.17% respectively, with VEGF 
incorporation. In the case of smaller microspheres, the water uptake increased from 444% 
to 469% and weight loss increased from and 16.4% to 16.9%. In the case of larger 
microspheres, the water uptake increased from 405% to 457% and weight loss increased 
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Figure 4.30: Water uptake measurements and weight loss measurements over 36 days 
in a & b) nanospheres with and without encapsulated VEGF, c & d) microspheres of 20-30 
m with and without encapsulated VEGF and e & f) microspheres of 5-15 m with and 
without encapsulated VEGF (n=3; error bars= ± SD). 
 
I. pH changes 
pH changes for unloaded and VEGF loaded particles over the period of 36 days compared 
with their unloaded counterparts (Figure 4.31).  
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Figure 4.31: Comparison of pH changes with and without encapsulated VEGF in a) 
nanospheres, b) microspheres of 5-15 m and c) microspheres of 20-30 m (n=3; error 
bars= ± SD). 
 
pH changes for unloaded and VEGF loaded particles over the period of 36 days were 
between 7.4 to 6. Decrease in pH was found to be inversely proportional with particle size. 
Compared to their unloaded controls, VEGF loaded particles were found to result in higher 
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reduction in pH values of the surrounding medium. The pH of the surrounding medium 
containing the unloaded nanospheres reduced from 7.4 to 6.1 over 36 days while the pH 
of medium containing VEGF encapsulated nanospheres reduced to 6. In the case of smaller 
microspheres, the pH of the medium dropped to 6.3 for unloaded microspheres and 6.1 for 
VEGF loaded microspheres. In the cases of larger microspheres, the pH of the medium 
containing unloaded microspheres dropped to 6.4 and that of the VEGF loaded 
microspheres dropped to 6.2. 
4.2.12. Incorporation of VEGF encapsulated microspheres and nanospheres 
in Collagen scaffolds 
4.2.12.1. Characterization 
I. Surface morphology analysis under SEM 
The microspheres and nanospheres thus produced were incorporated into collagen 
scaffolds by Ms. Rabia Nazir at Oxford University. They were loaded into a 28 wt% collagen 
slurry and press moulded into scaffolds of 12mm diameter and 2-3 mm thickness. 
Nanospheres of a size range 500-900 nm were well incorporated in the scaffold with a 
uniform distribution. Microspheres of the size range 5-15 m were also satisfactorily 
incorporated in the scaffolds whereas microspheres of the size range 20- 30 m formed 
clumped structures in the scaffold (Figure 4.32).  Therefore, collagen scaffolds incorporated 
with the 20-30 m sized microspheres were excluded from the study.  
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Figure 4.32: SEM images of collagen scaffolds embedded with a) nanospheres, b) 
microspheres of size range 5-15 m and c) microspheres of size range 20-30 m.  
 
I. Swelling studies 
Swelling studies were conducted by immersing empty and particle embedded collagen 
scaffolds in PBS over a period of 36 days (Figure 4.33).  
 
Figure 4.33: Comparison of swelling ratio of collagen scaffolds with particle 
embedded collagen scaffolds (n=3, error bars=± SD) 
 
The collagen scaffolds were found to uptake as much as 800% of their volume of water over 
this period. Compared to particle embedded scaffolds, empty scaffolds were found to have 
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a higher swelling ratio. In first three days, empty collagen scaffolds absorbed 343 ± 3.12 % 
and this increased to a maximum of 802 ± 7.9% in 36 days. Compared to the empty controls, 
particle embedded scaffold absorbed a lesser amount of water. The nanospheres 
embedded scaffolds absorbed 323 ± 4.12% in first three days and 791 ± 6.8% water by the 
end of 36 days. The microsphere embedded scaffolds absorbed and 311 ± 4.12% water in 
the first 3 days and 777 ± 8.72% water in 36 days. 
4.2.13. Encapsulation efficiency  
Encapsulation efficiency of the microspheres and nanospheres were quantified using VEGF 
ELISA tests. This was done before and after they were incorporated in the collagen scaffold 
as the processing conditions may have influenced the amount of drug remaining in the 
particles after they were embedded in the scaffolds (Figure 4.34).   
 
Figure 4.34: Encapsulation efficiency of VEGF in nanospheres and microspheres 
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The amount of drug encapsulated was found to reduce once the particles were embedded 
in the scaffolds, probably due to processing. The encapsulation efficiency of P(3HB) 
microspheres was found to be 78.32 ± 3.21% and on being embedded in the scaffolds, the 
encapsulation efficiency was found to have reduced by 7%, to 71.32 ± 6.6%. In the case of 
nanospheres, encapsulation efficiency was found to be 76.52 ± 5% and it was found to 
reduce to 70.70 ± 3.5%.  
4.2.14. Release kinetics 
To assess release kinetics, VEGF encapsulated nanospheres, microspheres, and collagen 
scaffolds embedded with VEGF encapsulated nanospheres and microspheres were 
immersed in PBS at 37 oC and amount of VEGF in periodically drawn samples were 
quantified using the VEGF ELISA assay (Figure 4.35). The release from VEGF encapsulated 
nanospheres were found to be faster than the release from VEGF encapsulated 
microspheres. VEGF release from nanospheres lasted up to 40 days and VEGF release from 
microspheres lasted up to 48 days, beyond which traces of VEGF were not detectable using 
the ELISA assay. A cumulative release of 98.23 ± 1.98% was achieved from VEGF 
encapsulated nanospheres whereas a cumulative release of 94.12 ± 1.21% was achieved 
from VEGF encapsulated microspheres. Release from microspheres were found to have a 
burst release in the first 48 hours.  
However, VEGF release from microspheres embedded in collagen scaffolds did not exhibit 
a burst release. VEGF release from the collagen scaffolds embedded with nanospheres 
lasted up to 44 days and VEGF release form microsphere encapsulated collagen scaffolds 
lasted up to 48 days. The maximum cumulative release from VEGF encapsulated 
nanospheres, collagen scaffolds embedded with the same, VEGF encapsulated 
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microspheres, and collagen scaffolds embedded with the same were found to be 96.21, 
98.23, 93.4 and 99.27% respectively.  
 
Figure 4.35: Comparison of VEGF release profile from a) VGEF encapsulated P(3HB) 
nanospheres and collagen scaffold embedded with the same, b) VEGF encapsulated P(3HB) 
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The release from VEGF encapsulated nanospheres were found to be faster than the release 
from VEGF encapsulated microspheres. VEGF release from nanospheres lasted up to 40 
days and VEGF release from microspheres lasted up to 48 days, beyond which traces of 
VEGF were not detectable using the ELISA assay. A cumulative release of 98.23 ± 1.98% was 
achieved from VEGF encapsulated nanospheres whereas a cumulative release of 94.12 ± 
1.21% was achieved from VEGF encapsulated microspheres. Release from microspheres 
were found to have a burst release in the first 48 hours.  
However, VEGF release from microspheres embedded in collagen scaffolds did not exhibit 
a burst release. VEGF release from the collagen scaffolds embedded with nanospheres 
lasted up to 44 days and VEGF release form microsphere encapsulated collagen scaffolds 
lasted up to 48 days. The maximum cumulative release from VEGF encapsulated 
nanospheres, collagen scaffolds embedded with the same, VEGF encapsulated 
microspheres, and collagen scaffolds embedded with the same were found to be 96.21, 
98.23, 93.4 and 99.27% respectively.  
The release data was fitted in models as described in section 2.2.11. R2 value of each of the 
linear regression was compared (Table 4.8). The release data was found to be most fitting 
with first- order release for all the four preparations with 99% correlation, except free 
microspheres with encapsulated VEGF (R2= 0.956 for first- order). This means, the drug 
release was dependent on the concentration of drug. The data for free microspheres was 
found to fit better with the Hixson- Crowell model, with 98.3 % correlation. However, 
considering Hixson- Crowell model assumes dissolution and reduction in surface area of 
the particles, whether this model can be considered in this scenario is questionable (VEGF 
release was carried out for a maximum of 48 days and this period is too short for P(3HB) to 
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have undergone any substantial erosion). The release data was found to fit with Higuchi 
and First-order as well, (98.3% and 95.6% correlation).  
 
Table 4.8: Summary of model fitting for VEGF release from free P(3HB) nanospheres 






R 2 0.935 0.907 0.973 0.902
Adj- R 2 0.929 0.900 0.971 0.895
Slope 0.1113 0.0874 0.0775 0.0904
SSR 1103.79 1983.39 424.02 2239.31
R 2 0.991 0.990 0.956 0.994
Adj- R 2 0.990 0.989 0.953 0.993
Slope -0.0015 -0.0014 -0.0009 -0.0015
SSR 0.026 0.055 0.092 0.026
R 2 0.986 0.984 0.983 0.981
Adj- R 2 0.985 0.983 0.981 0.980
Slope 3.4645 3.131 2.679 3.241
SSR 231.56 332.78 270.30 429.45
R 2 0.991 0.987 0.985 0.989
Adj- R 2 0.990 0.986 0.984 0.988
Slope -0.0034 -0.003 -0.0022 -0.0032
SSR 0.138 0.289 0.184 0.293
R 2 0.871 0.897 0.841 0.895
Adj- R 2 0.858 0.889 0.827 0.886
Slope 39.45 39.87 33.18 41.53
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4.3. Discussion 
4.3.1. Comparison of rapamycin encapsulated P(3HB) and PLLA 
microspheres 
4.3.1.1. The effect of process parameters on characteristics of microspheres 
PLLA and P(3HB) are two widely researched polymers in drug delivery. Although P(3HB) is 
a recent successor to PLLA in active drug delivery research, the manipulability of it due to 
the availability of a multitude of monomer units make it an interesting biopolymer. This 
study investigated into the process parameters influencing microsphere formation using 
P(3HB) and PLLA. The microspheres fabricated were characterised for their morphology, 
size distribution, porosity, hydrophobicity and protein adsorption. P(3HB) microspheres of 
the size range 1-8 m and PLLA microspheres of the size range 1-5.5 m were obtained. In 
the case of PLLA, the polymer with the least molecular weight was found to produce the 
smallest spheres, corroborating the argument regarding molecular weight and viscosity on 
the size distribution of particles (Honary et al., 2009; Ansary et al., 2014).  
Microspheres of a smaller size ensure high surface area-to-volume ratio (Freiberg and Zhu, 
2004). Microspheres were successfully synthesized using PLLA of molecular weight 30-50 
KDa and non- hydrolysed P(3HB) (~280 kDa). Molecular weight although cannot be stated 
as the single contributing parameter in microsphere fabrication, has a significant effect on 
the formation of spheres (O’Donnell and McGinity, 1997; Freitas, Merkle and Gander, 2005; 
Li, Rouaud and Poncelet, 2008). Hydrolysis of P(3HB) was carried out to obtain P(3HB) of 
lower molecular weight. However, the microspheres formed of hydrolysed polymer were 
widely polydispersed with lumps of polymer intermittently adorned with well-formed 
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microspheres. P(3HB) hydrolysed to 8 and 12 hours had high polydispersity index (3.71 and 
4.18 respectively). This could have been the reason for obtaining highly polydispersed 
microspheres in this case. This indicated that further optimisation of the hydrolysis process 
was imperative.  
However, both PLLA and P(3HB) at a concentration of 5mg/mL of chloroform presented 
excellently formed spheres, the latter being slightly larger than the former. This can be 
interpreted as a correlation between molecular weight and particle size, since all the other 
processing conditions were same for both P(3HB) and PLLA. The molecular weight range of 
PLLA is 30-50 kDa which is smaller than P(3HB) (~280 kDa). Hence, the independent variable 
here is the molecular weight of the polymers which effectively contributes to the viscosity 
and rheology of the emulsion, and subsequently, size of emulsion droplets.  
In the case of polymers that undergo bulk erosion as opposed to surface erosion, molecular 
weight is a key determinant of drug release. This is because, the diffusivity of the drug in 
this case depends on the formation of water channels, which result from the ‘loosening’ of 
oligomers and monomers from the particles, as a result of bulk degradation (Kim and Pack, 
2006). An increase in molecular weight therefore will suggest a decrease in diffusivity. 
However, in the case of surface eroding polymers, their inherent hydrophobicity makes the 
inner layers resistant to water penetration, while only the particle/ water interphase 
undergoes degradation. This mode of delivery is more controlled and independent of 
molecular weight, which is a great advantage when processing natural polymers (Freitas, 
Merkle and Gander, 2005; Kim and Pack, 2006; Hossain, Patel and Ahmed, 2014). PLLA, is 
a bulk eroding polymer, while P(3HB) is a surface eroding polymer.  
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Porosity of the microspheres can impact the release kinetics of the encapsulated drug. 
Controlled drug release can be achieved by optimising these contributing factors during the 
processing stage. Porosity of controlled drug delivery system is a key determinant of 
sustained delivery. P(3HB) based drug delivery system enable drug release by surface 
erosion under the influence of physiological changes in the immediate biological milieu, 
controlled by pH. However, release via means of only surface or bulk erosion may not 
suffice for the required dosage. Under these circumstances, porosity of the microspheres 
become important in allowing the drug molecules to seep through and be released out. 
The optimization studies revealed that PLLA microspheres were about 15% porous whereas 
P(3HB) microspheres amounted to a significant 35% porosity. However, the rapamycin 
encapsulated microspheres of both the polymers exhibited much higher porosity. 
Rapamycin encapsulated PLLA microspheres exhibited porosity in the range of ~50- 56% 
with a direct correlation between porosity and drug loading. Rapamycin encapsulated 
P(3HB) microspheres exhibited similar trend, however with a very high porosity range of 
~64-71% porosity. The microspheres without rapamycin had uniformly arranged polymer 
matrices, thus resulting in a closely packed structure which may have reduced porosity. But 
the presence of rapamycin may have presented oddities in the matrix, thus resulting in 
comparatively less packed matrices leading to increased porosity. This well explains the 
increase in porosity with drug loading. Porous systems increase the diffusivity of drug 
molecules from microspheres matrices, as with porosity, ‘diffusion pathway length’ for the 
drug decrease. This effect of exemplified in a study by Klose et al., 2006, who compared 
the drug release kinetics of Lidocaine from PLGA microspheres of varying porosity. This 
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study concluded that, the presence of pores increases mobility and diffusivity of the drug 
(Klose et al., 2006). 
4.3.1.2. Encapsulation efficiency and drug release 
Encapsulation efficiency of rapamycin in both P(3HB) and PLLA microspheres was found to 
increase with drug loading. In the case of 5 wt% drug loading, P(3HB) had an increased 
encapsulation efficiency (62.37%), in comparison with PLLA (58.58%). Without statistical 
optimisation of all the contributing parameters, it is impossible to establish the effect of 
molecular weight and concentration of the oil phase on encapsulation efficiency. In 
general, increasing the viscosity of the oil phase will produce viscous emulsion droplets, 
which resists the partition of drug molecules into the aqueous phase (Sharma et al., 2016). 
This explains the liner relationship of drug loading with encapsulation efficiency.  Along the 
same lines, an increase in molecular weight results in an emulsion with increased viscosity, 
which explains the higher encapsulation efficiency of P(3HB) microspheres in comparison 
with PLLA microspheres. Another reason for this phenomenon is the availability of more 
polymer for the drug molecules to bind with, per unit volume, when concentration is 
increased. Sharma et al., in their study on process parameters in formulating PLGA: PLA 
nanospheres observed a similar trend, wherein, on increasing the polymer concentration 
from 10 to 20 w/v%, the encapsulation efficiency of paclitaxel in these nanospheres were 
increased from 77.5 to 94.3% (Sharma et al., 2015). 
Drug release kinetics in the case of both P(3HB) and PLLA was found to be have a burst 
release of about 11%, by 48 hours. This can be considered a reasonable amount of burst 
release, especially in the case of PLLA, as bulk eroding polymers are expected to have a 
burst release up to 50% (Kim and Pack, 2006).  After first 48 hours, both P(3HB) and PLLA 
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microspheres exhibited a steady release of Rapamycin. P(3HB) microspheres exhibited a 
slightly faster release when compared to PLLA microspheres, with 5 wt% Rapamycin loaded 
PLLA microspheres releasing up to 22.70% and 10 wt% rapamycin loaded PLLA 
microspheres releasing up to 22.97% in 30 days. This was found to be 19.01% and 22.02% 
respectively, in the case of 5 wt% and 10 wt% loaded PLLA microspheres. P(3HB) 
microspheres produced were found to have increased porosity in comparison with PLLA 
microspheres, which would have resulted in the faster release of rapamycin. However, 
PLLA microspheres were smaller than P(3HB) microspheres, which would mean their 
diffusion pathway length for rapamycin to elute out was smaller. This might have resulted 
in the release rate in both the cases not being significantly different.  
The drug release data was fitted to 5 different models frequently published in literature 
namely, zero- order, first- order, Higuchi, Hixson-Crowell and Korsmeyer- Peppas. The 
release data was found to fit best with Higuchi model, as is expected of polymeric matrix 
systems with poorly soluble drug such as rapamycin (Costa and Sousa Lobo, 2001). This is 
explained well considering both PLLA and P(3HB) microspheres were of considerable 
porosity, which is a contributing parameter in Higuchi diffusion model. Higuchi model 
implies diffusion as the release mechanism and fitting 60% of release data to Korsmeyer- 
Peppas gave insights into the type of diffusion. In all the 4 cases, the release exponent was 
found to be less than 0.43, which suggests the diffusion to follow Fickian mode. The release 
data also gave good correlation with Korsmeyer- Peppas for all the formulations tested, 
and this indicates a non- linearity of release with time (Parhizkar et al., 2016). However, 
this model assumes the reduction of surface area of the DDS with time and considering the 
drug release profiles analysed here were only up to a maximum of 36 days, whether the 
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effects of change in surface area here can be considered is questionable. However, the in 
vitro degradation studies indicate up to 14.3% weight loss in the case of PLLA and 13.8% 
weight loss in the case of P(3HB) within 36 days. Therefore, surface erosion as a 
contributing release mechanism cannot be neglected.  
4.3.2. Comparison of tacrolimus encapsulated P(3HB) microspheres and 
nanospheres 
P(3HB) nanospheres and microspheres were successfully synthesised with 1, 5 and 10 wt% 
drug loading of tacrolimus. The particle size increased with drug loading.  
An interesting observation made with respect to tacrolimus encapsulated P(3HB) spheres 
of two different sizes were their differences in in vitro degradation. As indicated by weight 
loss, and pH changes in the surrounding media. Nanospheres were found to undergo 
slower degradation than microspheres. This is similar to the degradation behaviour of PLGA 
microspheres of different sizes, as studied by Kok et al., in determining the effect of particle 
size on drug loading and Release Kinetics of Gefitinib-Loaded PLGA Microspheres (Kok et 
al., 2016). PLGA is a bulk eroding polymer and once the degradation is initiated, it 
undergoes autocatalysis, from within the microsphere core (Kocbek et al., 2007; Ahmed et 
al., 2016). Larger microspheres with reduced crystallinity are more prone to initiation of 
degradation and hence their faster rate of degradation is expected in bulk eroding 
polymers. In the case of P(3HB), this effect is thought to have resulted from the decreased 
crystallinity, as well as increased porosity of the microspheres, which would have enhanced 
hydrolytic degradation.  
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Experimental drug loading and hence encapsulation efficiency was found to be higher in 
microspheres, in comparison with nanospheres. This could be due to the reduced diffusivity 
of drug to the aqueous phase from emulsion droplets, with increasing viscosity. 
Encapsulation efficiency increased with increasing drug/ polymer ratio, or in other words 
drug loading. Increasing drug polymer ratio would indicate an increased content of drug 
molecules per unit of polymer in given volume. In the case of microspheres, encapsulation 
efficiency increased from 61.2 ± 4.18% to 69.8 ± 1.9% and 72.3 ± 2.21% between 1 wt%, 5 
wt% and 10 wt% tacrolimus loading respectively. In the case of nanospheres, this was 59.8 
± 2.1%, 62.3 ± 2.01% and 65.8 ± 1.54% respectively. 
Release kinetics of tacrolimus from both P(3HB) nanospheres and microspheres was 
identical in all the 6 cases, with a burst release up to 48 hours.  Release from nanospheres 
were comparatively faster than microspheres, with a cumulative release of 71.2%, 73.1% 
and 76.2% from nanospheres encapsulated with 1 wt%, 5 wt% and 10 wt% tacrolimus. In 
the case of microspheres, this was 68.12, 70.37 and 72.3% respectively. Beyond 1440 
hours, tacrolimus traces were not detectable as distinct peaks using HPLC, in all the cases. 
Maximum release was obtained from P(3HB) nanospheres with 10 wt% tacrolimus loading. 
Solubilised form of tacrolimus is only capable of extending release up to 5-14 days and 
therefore, the sustained release extending up to a month (Tajdaran et al., 2015), from 
P(3HB) spheres is quite promising.   
With regards to drug release kinetics, two antagonistic effects can be observed. Since the 
surface to volume ratio of particles is higher in the case of nanospheres, this would mean 
that, for a given mass, there is more efflux of drug into the surrounding media from 
nanospheres than microspheres. This is especially relevant in the case of surface eroding 
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polymers such as P(3HB), where drug release is primarily dependant on a degradation 
behaviour that is analogous to ‘peeling’ off surface layers. The second phenomenon is 
degradation, which is influenced by crystallinity of the spheres. Since larger spheres have 
lower thermal properties, they can be expected to degrade faster, resulting in faster 
release of drug molecules. Drug release rate is a combinatorial effect of these two factors.  
The release data when fitted to zero- order, first- order, Higuchi, Hixson-Crowell and 
Korsmeyer- Peppas models, was found to have the best fit with Higuchi model, as in the 
case of rapamycin release. All the 6 formulations tested had 99% correlation in Higuchi 
model, suggesting diffusion as the mechanism of mass transfer. This is typical of porous 
polymeric matrices containing poorly soluble drug such as tacrolimus. The release 
exponent calculated from Korsmeyer- Peppas model indicated two different modes of 
diffusion in the case of nanospheres and microspheres. All the three formulations of 
nanospheres (1 wt%, 5 wt% and 10 wt% tacrolimus loading) had release exponents less 
than 0.43, suggesting a Fickian mode of diffusion. However, although microspheres with 10 
wt% tacrolimus was found to follow Fickian mode of diffusion, microspheres with 1 and 5 
wt% tacrolimus exhibited anomalous case, indicating the influence of multiple factors for 
mass transfer such as diffusion and degradation. The reason for anomalous diffusion in the 
case of 1 wt% and 5 wt% is not well understood, but perhaps can be assumed as result for 
non- uniform distribution of the drug through the bulk of the matrix, or the increased 
polydispersity of the microspheres.  
The results of this particular study can confirm that P(3HB) has the potential in developing 
DDSs for antiproliferative drugs, ensuring minimal burst release and sustained release up 
to a month. 10 wt% drug loading of tacrolimus in P(3HB) nanospheres eluted out about 
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76.2% of encapsulated drug. It is clearly illustrated that by fine tuning particle size and drug 
polymer ratio, distinctive drug release profiles can be obtained. This is favourable, 
especially when research in controlled drug delivery is moving closer to achieving 
personalised solutions.  
4.3.3. P(3HB) microspheres as VEGF delivery systems in Collagen scaffolds 
for Cardiac regeneration 
The most popular strategy for cardiac regeneration post myocardial infarction is 
reperfusion either by pharmacological means or mechanical means, where the 
percutaneously administered agents or coronary grafts initiate the expression of 
chemotactic factors. These chemotactic factors enable remodelling of the infarcted tissue 
by inducing fibrosis and repair. Various biopolymers have been exploited for the purpose 
of generating mechanically viable grafts with incorporated growth factors, especially 
vascular endothelial growth factor (VEGF) (Ruiz-Esparza et al., 2013). 
Chronic myocardial ischemia after myocardial infarction and associated remodelling can be 
effectively treated by growth factor treatment.   However, the initial stages of research 
concerning direct delivery of the growth factor demonstrated insufficient clinical success, 
mainly due to their short half- life span (Hao, 2007).  Many of the disappointing initial 
results were found to be less effective than placebos, as when injected as intravenous 
infusion or intercoronary delivery in the form of a bolus, VEGF was rendered inactive by 
the time it reached the site of action.  
Although there have been alternate approaches using gene delivery and combine factor 
delivery, these methods rendered the systems overly complicated and resulted in poor 
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success. The latest approach towards this objective is the use of biopolymers as drug 
delivery systems for growth factors, with controllable release rate. Various modes of drug 
delivery systems such as protein delivery, polymeric scaffolds, polymeric 
micro/nanoparticles have been explored.  In this study, VEGF was encapsulated P(3HB) 
nanospheres and microspheres were embedded in collagen scaffolds for their use as 
cardiac regeneration patches. Release kinetics of VEGF from neat spheres and spheres 
embedded in collagen scaffolds were compared.   A reduction in burst release was observed 
when the spheres were embedded in collagen scaffolds. This is similar to the results 
obtained by Tajdaran et al., by immobilizing PLGA microspheres in fibrin network, for the 
release of tacrolimus (Tajdaran et al., 2015). With this system, sustained release was 
observed up to 30 days, in comparison with PLGA particulate system that released only up 
to 15 days. There are several strategies of such immobilizations reported in literature, 
where particulate systems are immobilized on fibrin network (Baumann et al., 2009; 
Garbayo et al., 20010). However, the analysis of collagen in this context, as studied in this 
chapter is the first one of its kind. 
 Swelling studies conducted by immersing empty and particle embedded collagen scaffolds 
in PBS over a period of 36 days revealed collagen to uptake as much as 800% of their 
volume of water over this period. Compared to particle embedded scaffolds, empty 
scaffolds were found to have a higher swelling ratio. This can be hypothesised due to the 
presence of highly hydrophobic P(3HB) microspheres in the patch by 28 w/w%. In first three 
days, empty collagen scaffolds absorbed 343 ± 3.12 % and this increased to a maximum of 
802 ± 7.9% in 36 days. Compared to the empty controls, particle embedded scaffold 
absorbed a lesser amount of water. The nanospheres embedded scaffolds absorbed 323 ± 
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4.12% in first three days and 791 ± 6.8% water by the end of 36 days. The microsphere 
embedded scaffolds absorbed and 311 ± 4.12% water in the first 3 days and 777 ± 8.72% 
water in 36 days. 
This water uptake, however, did not result in an increase in burst release. Immobilization 
of the microspheres on collagen scaffolds was found to increase the duration of release for 
48 hours more, in comparison with the neat spheres. More than 90% of VEGF was released 
in a span of 30 days, in all the 4 cases. This is far more superior to several VEGF 
encapsulation methods describe in literature (Gu, Amsden and Neufeld, 2004; De et al., 
2009; Jay and Saltzman, 2009). 
Contrary to release profiles observed in the case of rapamycin and tacrolimus, VEGF release 
was found to follow first- order release kinetics, except in the case of free microspheres. 
suggesting concentration of the drug to be the most contributing factor of release. First- 
order release kinetics is observed in DDS that are formulated as porous matrices containing 
water soluble drugs (Dash et al., 2010). Since VEGF is a fairly water- soluble drug, its release 
profile to fit well with first- order model is expected. In the case of free microspheres with 
encapsulated VEGF, the release data was found to fit better with Hixson- Crowell and 
Higuchi model (98.5 and 98.3% correlation respectively). From the release data it can also 
be seen that the release from free microspheres follow a slower rate when compared to 
the other three formulations. However, considering the good fit of all the release data to 
Higuchi model as well, it can be concluded that diffusion is a major contributing factor of 
mass transport. Embedding the microspheres and nanospheres did not change the release 
profiles effectively, as VEGF was contained only in the bulk of spheres and not in the 
collagen matrix.  
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Apart from the benefits of controlled delivery of VEGF, immobilization of the spheres on 
collagen scaffold is hypothesized to support cell viability. This is because cells have been 
reported to have increased affinity for surfaces with ‘artefacts’ that provide a better surface 
topography, and the presence of crystalline microspheres in collagen matrix can render 
this. Therefore, these scaffolds, currently in small animal trials can be considered to have 
immense potential in cardiac regeneration. 
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5.1. Introduction 
Controlled drug delivery is the sustained release of therapeutic agents, as a response to 
time or stimuli, allowing for the maintenance of drug concentrations in the biological milieu 
within the therapeutic window (Yun, Lee and Park, 2014). This is achieved by the 
incorporation of therapeutic agents into specialised drug delivery systems, a majority of 
which are made of synthetic and natural polymers. These polymers are primarily 
designated to protect the therapeutic agents from biomolecules of the blood stream and 
ensure delivery at the site of action by virtue of their suitable functionalities (Liechty et al., 
2010). Cancer therapy is a field that can benefit greatly from controlled drug delivery as 
many existing therapeutic agents are found to be of poor water solubility, lack of targeting 
capability, nonspecific distribution, systemic toxicity, and low therapeutic index (Sun et al., 
2014). According to World Health Organisation estimates, cancer is the most prominent 
reason of mortality, having overtaken coronary diseases and strokes (Ferlay et al., 2015). 
In the next 10 years, about 20 million new cancer cases are predicted to be reported. 
Female breast cancer continues to be the most prevalent and most frequently diagnosed 
neoplasm with over 5.2 million breast cancer cases worldwide, and the need for a long-
term and effective care for breast cancer is indisputable (Ferlay et al., 2015).  
Conventional chemotherapy has serious impediments in the form of many side effects such 
as gastro-intestinal damage, peripheral neuropathy, neurological or psychiatric disorders 
and infections (Nordlinger et al., 2008). Hence, novel anticancer therapeutic avenues are 
being explored, an emerging one is the highly promising photodynamic therapy (PDT). 
Photodynamic therapy involves the topical or systemic application of photosensitizers, 
followed by illumination with light of a suitable wavelength and dosage. This elicits a 
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photodynamic reaction (PDR), which in turn results in the release of cytotoxic species, 
specifically reactive oxygen species (ROS), ultimately leading to programmed cell death.   
The exact mechanism of PDR has yet to be revealed, but the ROS have a radius of 
destruction in the nanometre range and elicit a cascade of immunological and necrotic 
events leading to effective tumour control (Dolmans, Fukumara and Jain., 2003). 
Porphyrins are an effective class of photosensitizers with a chemical structure including the 
porphyrin ring formed from tetrapyrrole molecules connected using methine bridges, and 
they are known to produce ROS efficiently through illumination. A few derivatives of 
porphyrins have been synthesised by modifying lateral substituents of the ring, which have 
been explored within the scope of PDT. Here we compare three different porphyrin 
derivatives, namely protoporphyrin IX (PP), hematoporphyrin ether (HP) and 






Figure 5.1: Porphyrin derivatives: a) Protoporphyrin IX, b) Hematoporphyrin ether c) 
Tetraphenylporphyrin (Kadish, 1999, Wintrobe and Greer, 2009) 
 
Both PP and HP are naturally occurring porphyrins, being the precursor to biologically 
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by the acid hydrolysis of haemoglobin, respectively. A derivative of HP is also in clinical use 
as a PDT agent under the trade name Photophrin (HPD, an oligomer of HP), and HP itself is 
an effective PDT agent and is a first-generation PDT agent. Thus, the use of naturally 
occurring agents would have clear advantages. TPP was chosen as a readily available 
synthetic alternative to PP and HP to compare their efficiencies; water soluble TPP 
derivatives have been studied for PDT, but TPP as such has not been used due to its low 
solubility in aqueous solutions, which is a general obstacle in using porphyrins for PDT 
(Ding, 2004). 
After cellular uptake of porphyrins, they are irradiated with light of a suitable wavelength 
(600-800nm), yielding a high energy excited state. This energy is transferred to molecular 
oxygen to produce highly reactive singlet oxygen, leading to cell membrane damage 
(Dolmans, Fukumara and Jain., 2003, Agostinis et al., 2011). The photosensitizers can also 
be oxidised, producing superoxide radicals, leading to more cell damage (Dolmans, 
Fukumara and Jain., 2003). The useful range of wavelength typically applied for PDT is 600-
800nm, which rules out endogenous chromophores of the body, yet provides energy 
suitable for PDT. High-intensity light of this order results in rapid tumour necrosis that 
releases intracellular chemicals and cytokines, contributing to the bystander effect 
(SharmanAllen and Lier, 1999). Here, intercellular necrotic substances are released by 
microcolonies of cells directly exposed to photosensitizers, to alert neighbouring cells to 
undergo apoptosis (Oleinick, Morris, and Belichenko, 2002).  PDT mediated tumour lysis 
also causes the release of tumour specific neo-antigens that are phagocytosed by dendritic 
cells thus resulting in a long-lasting immune response.  
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In addition to choosing efficient PDT agents, controlled delivery of these photosensitizers 
is one of the key aspects, which needs to be improved, as most of the photosensitizers are 
insoluble in an aqueous environment. The drug delivery system should ideally be 
biodegradable, biocompatible, and non-immunogenic and should protect the drug from 
the biological milieu. However, a carrier system can considerably reduce the photodynamic 
effect because of the tendency of photosensitizers to aggregate within the hydrophilic 
carrier. Also, the use of drug delivery systems can result in considerable light quenching 
(Debele, Peng and Tsai, 2015). In addition, the drug delivery vehicle needs to be sufficiently 
porous to result in continuous but controlled release of the drug.  
This chapter describes the optimisation of the production of P(3HB) microspheres based 
on process parameters such as polymer concentration, surfactant concentration and 
stirring speed of the emulsion, for targeted delivery of the porphyrins. The microspheres 
thus produced were characterised for size distribution, porosity, and hydrophobicity. The 
best-optimised conditions were repeated to encapsulate porphyrin derivatives that 
presented possible drug−polymer interactions, leading to a further step of optimisation 
with a different set of boundary conditions. Targeted drug delivery effectively reduces bio 
distribution of the drug delivery system in tissue spaces that aren’t affected, hence 
increasing efficiency of therapy. Targeting was achieved by the introduction of specific 
neoplastic antigens on the surface of breast cancer cells, specifically anti-HER-2 antibodies. 
The cell line used was a SK-BR-3 breast carcinoma cell, which overexpress HER-2 markers. 
Markiv et al., 2011 designed a recombinant antibody-fluorophore conjugate of Red 
Fluorescent Protein (RFP) in-between the variable regions of anti-p185HER2-ECD antibody 
4D5-8, resulting in optimal VH/VL interface interaction to create soluble coloured 
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antibodies (Markiv et al., 2011). Since the anti-HER-2 antibody was coupled with RFP, it was 
used as an imaging strategy to observe the homing effect of the antibody to cancer cells. 
An in-depth analysis of the targeted and non-targeted anticancer photodynamic therapy 
using the three different porphyrins PP, HP and TPP, encapsulated within P(3HB) 
microspheres, was carried out confirming the high potential of this system to be used in 
cancer therapy. 
5.2. Results  
5.2.1. Encapsulation of Porphyrin derivatives 
 Based on the optimisation experiments from Chapter 3, experimental conditions 1 and 9 
(Chapter 3, section 3.2.3.2 were chosen for encapsulation of the porphyrins, which 
however led to microspheres with extremely uneven and collapsed surfaces (Figure 5.2).  
 
Figure 5.2: SEM images of Porphyrin encapsulated microspheres corresponding to 
experiment number a) 1 (0.0625 g/mL Polymer concentration, 1 % w/v PVA concentration 
and 500 rpm stirrer speed) and b) 9 (0.1 g/mL Polymer concentration, 1 % w/v PVA 
concentration and 800 rpm stirrer speed). 
 
All the microspheres formed were exceedingly porous and non-uniform and therefore, did 
not promise successful encapsulation or controlled delivery. Following this, a different set 
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of experimental design was generated using the same software, Design Expert, with lower 
boundary conditions for all parameters- concentration of polymer solution, PVA 
concentration and stirrer speed in rpm (Table 5.1).  
Table 5.1: Experimental design for optimization of porphyrin encapsulated 
microspheres production. 
 
Polymer concentration was lowered to compensate for the increased hydrophobicity 
resulting from the addition of porphyrins. PVA concentration was lowered to attain an 
optimum interphase mechanics of the oil-water emulsion. As the porphyrin encapsulated 






1 0.0125 0.3 300 
2 0.0625 0.3 800 
3 0.0125 0.8 300 
4 0.0625 0.8 800 
5 0.0125 0.3 800 
6 0.0125 0.8 800 
7 0.0625 0.8 300 
8 0.0625 0.3 300 
9 0.0375 0.5 500 
10 0.0125 0.5 500 
11 0.0375 0.3 500 
12 0.0375 0.5 300 
13 0.0625 0.5 500 
14 0.0375 0.8 500 
15 0.0375 0.5 800 
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microspheres corresponding to the initial set of experiments were highly porous, the 
boundary conditions for the stirring speed of the emulsion was lowered, because faster 
stirring can cause quicker evaporation of chloroform resulting in uneven and extensive pore 
formation. 
The resulting microspheres were further optimised, and the best conditions were chosen 
to encapsulate 2.5 wt%, 5 wt% and 10 wt% drug loading of the porphyrin derivatives. The 
microspheres prepared under the conditions of 0.0375g/mL polymer concentration, 0.5 % 
PVA concentration and 800 rpm were chosen for encapsulation of porphyrin derivatives. 
Only this condition, corresponding to experiment number 15 (Table 5.1) yielded well-
formed microspheres when encapsulated with all three porphyrin derivatives.  
5.2.2. Characterization of porphyrin encapsulated microspheres 
5.2.2.1. Surface morphology and particle size analysis of Porphyrin 
encapsulated microspheres  
The surface morphology of microspheres produced with encapsulated porphyrins was 
observed under SEM (Figure 5.3).   
Figure 5.3: Microspheres encapsulated with 10 wt% drug loading of a) PP b) HP c) TPP 
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The microspheres appeared to be more porous than the ones without porphyrins. These 
were also visibly slightly more polydispersed than the empty control microspheres (as 
described in Chapter 3). The microspheres were found to be well separated from one 
another and had appreciable spherical appearance.  
The size distributions of microspheres encapsulated with porphyrins were estimated from 
the SEM images, using the ImageJ software (Figure 5.4). The PP encapsulated microspheres 
were found to be slightly smaller in size compared to HP encapsulated and TPP 
encapsulated ones. In each case, particle size was found to increase with drug loading, as 
represented in Table 5.2.  
Drug loading Average particle diameter (m) 
2.5 wt% PP 12.51 ± 2.21 
5 wt% PP 12.66 ± 1.29 
10 wt% PP 12.78 ± 1.09 
2.5 wt% HP 13.08 ± 0.8 
5 wt% HP 13.44 ± 1.53 
10 wt% HP 13.68 ± 2.09 
2.5 wt% TPP 13.82 ± 1.98 
5 wt% TPP 14.18 ± 1.29 
10 wt% TPP 14.67 ± 1.37 
Table 5.2: Average particle diameter of porphyrin encapsulated microspheres (n=3, 
error= ± s.d). 
 
The average diameter of PP encapsulated microspheres was found to be 12.5 ± 2.21m, in 
the case of 2.5 wt% drug loading and 12.7 ± 1.29 m and 12.7 ± 1.09 m respectively in the 
case of 5 wt% and 10 wt% drug loading. The average diameter of HP encapsulated 
microspheres was found to be higher than PP encapsulated microspheres. With 2.5 wt% 
drug loading, the average diameter was found to be 13.08 ± 0.8 m and this was found to 
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increase to 13.44 ± 1.53 m with 5 wt% and 13.68 ± 2.09 m with 10 wt% drug loading. TPP 
encapsulated microspheres were found to be the largest, with an average diameter of 13.82 
± 1.98 m, 14.18 ± 1.29 m, and 14.67 ± 1.37 m, with 2.5, 5 and 10 wt% drug loading, 
respectively. 
 
Figure 5.4: Particle size distribution of microspheres with a) 2.5 wt% PP, b) 5 wt% PP, c) 
10 wt% PP, d) 2.5 wt% HP, e) 5 wt% HP, f) 10 wt% HP, g) 2.5 wt% TPP, h) 5 wt% TPP and i) 
10 wt% TPP. 
 
5.2.2.2. Porosity 
Porosity of microspheres encapsulated with porphyrins was calculated using the liquid 
displacement method. Porosity was found to be higher than control microspheres 
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prepared under similar conditions, without drug encapsulation (51.82 ± 2.17%). Porosity 
was found to increase with drug loading in each case, and in general TPP encapsulated 
microspheres were found to be more porous than the rest (Figure 5.5). Porosity of 10 wt% 
TPP loaded microspheres (73.21 ± 4.3%) were found to be significantly higher than 10 wt% 
HP loaded (65.29 ± 1.2%) and 10 wt% PP loaded (63.92 ± 1.92%).  
 
Figure 5.5: Porosity of porphyrin encapsulated microspheres (n=3, error= ± s.d). 
 
Porosity of PP encapsulated microspheres was found to be the least of the 3 derivatives, 
however, a trend of increased porosity was observed with increased drug loading, with  
62. 8 ± 2.12%, 63.12 ± 2.0% and 63.92 ± 1.92% for 2.5 wt%, 5 wt% and 10 wt% drug loading 
respectively. This trend was maintained in the case of HP, with 64.29 ± 3.12%, 65.18 ± 
3.07%, and 65.29 ± 1.2, and in the case of TPP, with 65.6 ± 4.12, 71.29 ± 2.61 and 73.21 ± 
4.3 for 2.5 wt%, 5 wt% and 10 wt% drug loading respectively. 
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5.2.2.3. Residual PVA and hydrophobicity 
Surface residual PVA of the microspheres prepared were measured by the method 
described in Chapter 2.  These were represented as percentage mass if PVA residual per 
unit mass of microspheres. There appeared to be an inverse correlation between surface 
residual PVA and hydrophobicity. Surface residual PVA of porphyrin encapsulated 
microspheres ranged from 0.17 ± .002% (for microspheres loaded with 10 wt% TPP) to 0.83 
± 0.014% (for microspheres loaded with 2.5 wt% PP). Amount of PVA residue on the surface 
was found to decrease with drug loading (Figure 5.6.a). In the case of PP encapsulated 
microspheres, surface residual PVA varied from 0.83 ± .014%, 0.77 ± 0.018% and 0.72 ± 
0.011% for 2.5 wt%, 5 wt% and 10 wt% drug loading respectively. In the case of HP, this 
was found to be 0.62 ± 0.03, 0.47 ± 0.027 and 0.36 ± 0.027 for 2.5 wt%, 5 wt% and 10 wt% 
drug loading and in the case of TPP, this was found to be 0.37 ± 0.001, 0.21 ± 0.01 and 0.17 
± 0.001 for 2.5 wt%, 5 wt% and 10 wt% drug loading, respectively. 
 
Figure 5.6.a): Surface residual PVA of porphyrin encapsulated microspheres (n=3, 
error= ± s.d). (* p< 0.05) 
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Porphyrin encapsulated microspheres were found to be extremely hydrophobic in 
comparison with microspheres encapsulated with various other molecules as described in 
previous chapters. Hydrophobicity was found to increase with increased drug loading and 
was found to be significantly higher in the case of 10 wt% TPP encapsulated microspheres 
(9.1 ± 0.28 g/mg), when compared to 10 wt% HP (5.3 ± 0.31 g/mg) and PP encapsulated 
microspheres (3.1 ± 0.47 g/mg) (Figure 5.6.b.).  
 
Figure 5.6.b): Hydrophobicity represented as a function of the amount of Rose Bengal 
dye adsorbed at 50 g/mL on porphyrin encapsulated microspheres (n=3, error= ± s.d). (* 
p< 0.05) 
 
5.2.2.4.  Protein adsorption 
Protein adsorption on the surface of microspheres was estimated by immersing samples in 
BSA solution for 24 hours and subjecting the supernatant to Bradford assay. Protein 
adsorbed on the surface of microspheres were found to have a positive correlation with 
the hydrophobicity, with 10 wt% TPP encapsulated microspheres having the maximum 
amount of surface adsorbed protein (929.9 ± 62.8 g/mg). An exception to this case was 
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microspheres encapsulated with 2.5 wt% of HP (with 443.3 ± 1.9 g/mg surface adsorbed 
BSA), which although were more hydrophobic than 10 wt% PP encapsulated microspheres 
(with 514.7 ± 9.8 g/mg surface adsorbed BSA), had a lower amount of proteins adsorbed 
on their surface (Figure 5.7). In general, protein adsorption was found to increase with drug 
loading, and hydrophobicity.  
 
Figure 5.7: Amount of protein adsorbed on the surface of porphyrin encapsulated 
microspheres (n=3, error= ± s.d) (* p< 0.05). 
 
5.2.3. Encapsulation efficiency 
Encapsulation efficiency as quantified by florescence spectrometry, was found to increase 
with increased drug loading, in each case. TPP, which exhibited the highest solubility in 
chloroform, had the highest amount (87.8%, with 10 wt% drug loading) of encapsulation, 
while PP exhibited the least amount of encapsulation. A few preparations of PP exhibited 
large particles of surface adsorbed drug, indicating low solubility of PP in chloroform as 
compared to the other two derivatives. 
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The graph below (Figure 5.8) compares encapsulation efficiencies of increasing drug 
loadings of PP, TPP and HP.  
 
Figure 5.8: Encapsulation efficiencies of microspheres with increasing loadings of 
porphyrin derivatives (n=3, error= ±sd) (* p< 0.05). 
 
Encapsulation efficiency increased from 59.7 ± 1.8% of 2.5 wt% drug loading of PP, to 63.4 
± 2.6% with 5 wt% drug loading of PP and 71.7 ± 5% with 10 wt% drug loading of PP. This 
was found to be 66 ± 5.3%, 70.2 ± 2.1% and 79.1 ± 4.9%, in the case of 2.5 wt%, 5 wt% and 
10 wt% HP loading. In the case of TPP, encapsulation efficiency was found to be 72.8 ± 
6.2%, 82.1 ± 8.9% and 87.8 ± 8.3% for 2.5 wt%, 5 wt% and 10 wt% drug loading respectively. 
5.2.4. Expression and purification of RFP linked Anti -HER2 antibody 
To achieve target specific drug delivery, the photosensitizer encapsulated microspheres 
with the highest encapsulation efficiency of each porphyrin derivative were used to adsorb 
Anti-HER2 antibody on the surface of the microspheres so as to allow selective binding to 
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the overexpressed cancer marker HER-2 on SK-BR-3 cells. 4D5-8 is an anti-HER-2 antibody 
conventionally used as a therapeutic antibody, also known as Trastuzumab. Markiv et al., 
2011 designed a recombinant antibody-fluorophore conjugate of Red Fluorescent Protein 
(RFP) in-between the variable regions of the anti-HER-2 antibody 4D5-8, to create soluble 
coloured antibodies. This resulting coloured antibody, called 4D5-8RFP12, has an isoelectric 
point of 6.0-6.5, as opposed to the conventional 4D5-8 single chain antibody that 
precipitated at physiological pH (Markiv et al., 2011).  
This recombinant antibody can be used as a homing agent for target specific drug delivery 
of breast cancer as they overexpress HER2. This 52kDa antibody was expressed and purified 
as described in section 2.2.12 and analysed using SDS-PAGE (Figure 5.9). 
 
Figure 5.9: SDS-PAGE and Coomassie stained gel of anti-HER-2 antibody 4D5-8 with 
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SDS-PAGE confirmed the presence of the intact protein in the upper molecular weight 
range (52 kDa). The purified protein had a concentration of 3.63± 0.18 mg/mL as opposed 
to the uninduced sample filtrate that had a concentration of 0.081± 0.08 mg/mL.  
5.2.5. Antibody adsorption on the microspheres 
Antibody purified as described above was adsorbed on porphyrin encapsulated 
microspheres (10% drug loading of PP, HP and TPP) using the method described in section 
2.2.13. Unbound antibodies in the supernatant after centrifugation were quantified using 
Bradford’s assay and were subtracted from the amount initially used. The amounts of 
antibody bound on microspheres were found to be 430 ± 26 g/mg, 490 ± 18 g/mg and 
580 ± 46 g/mg for PP, HP and TPP, respectively, as represented in figure 5.10. 
 
Figure 5.10:  Amount of Anti- HER-2 adsorbed on P(3HB) microspheres encapsulated 
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5.2.6. Cell viability studies 
Cell viability studies were conducted on SK-BR-3 treated with microspheres alone, 
microspheres encapsulated with 2.5 wt%, 5 wt% and 10 wt% drug loading of each 
porphyrin derivative, and anti-HER-2 adsorbed microspheres of 10 wt% drug loading of 
each porphyrin derivative (Figure 5.11).  
Cells were cultured at a density of 1x104 in 96 well plates for 24 hours. These were 
incubated with each of the microsphere constructs for 48 hours, followed by exposure to 
white light for 30 minutes. Metabolic activity was quantified using the MTT assay. Cell 
toxicity was calculated as the reduction in cell viability, in comparison with the positive 
control. Of the three types of porphyrin, TPP was shown to have the best ability to induce 
photodynamic reaction (PDR), followed by HP, whereas PP was the least efficient of the 
three.  
Percentage cell viability decreased with increasing drug loading of all the photosensitizers. 
Anti-HER-2 adsorption seemed to cause a decrease in cell viability in the case of all 
porphyrin derivatives, although not very pronounced in the case of PP. In the case of PP, 
cell cytotoxicity increased from 52.20 ± 1.14% to 58.01 ± 0.53 % with 5 wt% drug loading 
and to a further 59.9 ± 0.8% with 10 wt% drug loading. There was only an increase of 0.8 ± 
0.08% cell cytotoxicity with antibody incorporation.  
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Figure 5.11: Percentage cell viability of SK-BR-3 cells after treatment with microspheres 
encapsulated with varying drug loadings of a) PP, b) HP and c) TPP. Tissue culture plate 
(TCP) was used as the positive control whereas the 4% hydrogen peroxide was used as the 
negative control(*p<0.05) (n=3, error=± s.d). 
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HP encapsulated microspheres exhibited a higher cytotoxicity in comparison with PP, and 
this was found to increase with drug loading. The cytotoxicity of 10 wt% HP encapsulated 
microspheres in conjugation with anti-HER-2 was found to be significantly higher (77.8 ± 
3.3%) than the ones without the antibodies (66.2 ± 0.62%). A similar trend, although not 
statistically significant, was observed in the case of TPP encapsulated microspheres, with 
10 wt% drug loaded microspheres without antibody conjugation exhibiting a cytotoxicity 
of 78.4 ± 2.6% and with antibody, 80.7 ± 1.4%. 
5.2.7. Confocal imaging 
Confocal imaging of the SK-BR-3 cells treated with microspheres alone, microspheres 
encapsulated with 5 wt% and 10 wt% drug loading of each porphyrin derivative, and anti-
HER-2 adsorbed microspheres of 10 wt% drug loading of each of the porphyrin derivatives 
was carried out. Live/Dead analysis was done using Calcein-AM and Ethidium homodimer 
III (EthD-III). The live cells stained green and the dead cells stained red as described in 
section 2.2.15  
Confocal imaging thus confirmed the high tumour cell toxicity of the porphyrin loaded 
P(3HB) microspheres with a further increase of the cytotoxicity in the case of the targeted 
anti-HER-2 adsorbed microspheres. Almost all the cells were found to be dead by the end 
of imaging (2 hours after photoexcitation), in the case of cells cultured with anti-HER-2 
adsorbed microspheres, thus confirming the effectiveness of these modified microspheres 
(Figure 5.12).  
The cells treated with anti-HER-2 adsorbed P(3HB) microspheres containing porphyrin 
were enlarged (~60μm) as opposed to those treated with P(3HB) microspheres containing 
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porphyrins but without the antibodies. There was a clear difference in morphology and size 
of the resulting dead cells. However, whether this is due to any cellular phenomena or as a 
result of the presence of RFP and porphyrins, both of which fluoresce in the same 
wavelength range as (EthD-III) is yet to be understood. 
 
Figure 5.12: Confocal images of live/dead assay conducted on SK-BR-3 grown a) on 
tissue culture plastic, b) with empty microspheres c) with 10wt% drug loading of TPP, but 
non-photo activated, d-f)5wt% drug loadings of PP, HP and TPP, photo activated, g-i) 10wt% 
drug loadings of PP, HP and TPP, photo activated, j-l) anti-HER-2 adsorbed 10wt% drug 
loadings of PP, HP and TPP  
 
Although EthD-III nucleic acid stain, in the case of cells treated with anti-HER-2 adsorbed 
P(3HB) microspheres containing porphyrin, the periphery as well as the nuclei of the cells 
appeared to fluoresce. The exact reason of this phenomenon is yet to be understood, but 
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it can be hypothesised that, since the antibody is conjugated with a red fluorescent protein, 
this is indicative of the presence of the antibody around the cell membrane. 
 
5.2.8. Calculation of IC50 for 10 wt% TPP encapsulated P(3HB) 
microspheres with and without anti-HER-2 conjugation. 
Based on the cell viability, TPP encapsulated microspheres were established to be the most 
potent of the 3 porphyrin derivatives. Therefore, these were chosen to be further 
characterised for establishing IC50 values. Dose response of SK-BR-3 cells treated with 
microspheres encapsulated with 10 wt% drug loading of TPP, with and without antibody 
conjugation was calculated. A plot depicting natural logarithms of microsphere 
concentrations in g/mL against cell viability of microspheres, with and without antibody 
conjugation was generated and from the regression equation, concentration 
corresponding to 50% viability inhibition was calculated (Figure 5.13).  
 




  207 
 
The values 50% growth inhibitory values of antibody conjugated microspheres were found 
to be slightly lower (9 M) than the non-conjugated microspheres (14 M), establishing 
the increased cytotoxicity of the former. The differences were not found to be statistically 
significant. Given the complexity of the formulations, it can be concluded that more trails 
are required to establish a correlation. 
5.3. Discussion 
P(3HB) production was successfully carried out using B. cereus SPV.  Well-formed P(3HB) 
microspheres were produced using optimisation experiments based on process 
parameters such as polymer concentration, surfactant concentration and stirring speed of 
the emulsion, as described in chapter 3. Based on the optimisation experiments, 
experimental conditions 1 and 9 were chosen for encapsulation of the porphyrins, which 
however led to microspheres with extremely uneven and collapsed surfaces. This can be 
attributed to the highly hydrophobic nature of the porphyrins. This increased 
hydrophobicity of the organic phase could have resulted in a drastic change in the 
interphase mechanics of the oil-water emulsion, resulting in unevenly formed 
microspheres. Increase in the amount of drug encapsulated increases viscosity of the 
dispersed phase, leading to larger particles (Allison et al., 2004, Allison et al., 2005). Lee et 
al., 1999, describe viscosity of the organic phase, volume fraction of the organic phase to 
the aqueous phase, quantity of drug in the organic phase and concentration of surfactant 
as critical parameters in microencapsulation (Lee et al., 1999). Witschi et al., 1998 reported 
that addition of drug in the organic phase resulted in more porous and irregular shaped 
microspheres (Witschi et al., 1998).   
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Following this, lower boundary conditions so as to enable a reduced viscosity of the 
dispersed phase were applied. Polymer concentration was lowered to compensate for the 
increased hydrophobicity resulting from the addition of porphyrins. PVA concentration was 
lowered to attain an optimum interphase mechanics of the oil- water emulsion. As the 
porphyrin encapsulated microspheres corresponding to the initial set of experiments were 
highly porous, the boundary conditions for the stirring speed of the emulsion was lowered, 
because faster stirring can cause quicker evaporation of chloroform resulting in uneven and 
extensive pore formation. The microspheres generated were porous enough to expose 
encapsulated porphyrin derivatives to light. The optimised process followed by 
photosensitizer encapsulation showed that polymer-drug interaction is one of the main 
parameters to be considered in drug encapsulation.  
2.5 wt%, 5 wt% and 10 wt% drug loadings of PP, HP and TPP were successfully encapsulated 
in microspheres, with an average diameter in the range of size 12.5 to 14.7μm. Particle size 
was found to increase with drug loading in each case. This is due to the increased viscosity 
of the dispersed phase, in the presence of increased amount of drug. These results are 
consistent with various microsphere formulations reported in literature, such as in the case 
of Paclitaxel loaded PLGA microspheres as described by Sharma, Madan and Lin 2015, that 
exhibited an increase in diameter from 440 nm to 600 nm when the drug loading was 
increased from 2mg to 4mg (Sharma, Madan and Lin, 2015).  
It is generally known that hydrophobic drug molecules entrap better in hydrophobic 
polymer matrices.  Encapsulation efficiency increased with increased drug loading in each 
case and was found to be the highest for 10 wt% drug loading. TPP encapsulated 
microspheres had the highest encapsulation efficiency (87.8%), followed by HP (79.1%) and 
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PP (71.7%).  This was reflected in their ability to induce photodynamic damage, quantified 
by reduction in cell viability. 10 wt% drug loading of each porphyrin derivative was chosen 
to be complexed with anti-HER-2 antibody, to aid in target specific delivery. An increase in 
the cytotoxic effect was observed in microspheres with adsorbed antibodies in the case of 
HP, the differences being statistically significant (p<0.05). In the case of cells treated with 
antibody adsorbed porphyrin encapsulated microspheres, a phenomenon resembling 
autophagy associated with non-apoptotic breast cancer cells was observed, wherein the 
cells were massively enlarged and were multinucleate (Belaid et al., 2013).  Autophagy is 
described as a mechanism, wherein a cell generates an autophagosome to engulf and lyse 
cellular proteins and organelles. Autophagy is also suggested as the cell death mechanism 
in anti-apoptotic cancer cells, a category to which SK-BR-3 belongs (Yang et al., 2011). 
Autophagy results in an increased surface to volume-ratio of cells, providing a plausible 
explanation for the increased size of dead cells (Belaid et al., 2013). These cells also appear 
to be multinucleated which is a common phenomenon in autophagy. However, whether 
this is indeed a change in morphology of the cells or a misrepresentation due to the 
complexity of the factors involved, needs further elucidation. Both porphyrins and RFP 
fluoresce in the same wavelength as EthD-III and therefore, the use of a different stain can 
perhaps make the analysis better and conclusive.  
Successful localisation of the photosensitizer in the target tissue is a key factor in 
determining the extent of PDT. A PDT carrier system has dual selectivity for tumour cells 
attributed by the affinity of lipophilic tumour lesions to both the polymer and 
photosensitizer that are hydrophobic in nature. It is also to be noted that, unlike 
chemotherapeutic moieties that must be released from carrier particles, release is not a 
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prerequisite of PDT (Solban et al., 2006). The life span of singlet oxygen species generated 
is only ~3.5 μs and apoptotic factors generated by these have a diffusion range of only 0.01-
0.02μm (Stuchinskaya et al., 2011). Therefore, absolute localisation of the photosensitizers 
is necessary, which was achievable by the combined hydrophobicity of P(3HB) and 
porphyrin derivatives.  As described in section 5.2.2.3, the porphyrin derivative 
encapsulated microspheres were found to be extremely hydrophobic, an attractive feature 
in this case. A further addition of a target specific monoclonal antibody (mAb) such as anti- 
HER2 recognizing the antigens presented by neoplastic transformation was designed to 
result in a more efficient Photoimmunotargeting (PIT), as we have demonstrated above.   
In summary, both porphyrin encapsulated microspheres with and without antibody 
adsorption were found to cause effective cell death. The phenomenon resembling 
autophagy was only observed in the case of cells treated with porphyrin encapsulated 
microspheres with anti-HER-2 adsorbed on the surface.    
All these findings promise the development of a novel immunotargeting drug delivery 
system based on the biodegradable polymer P(3HB). Investigations using the breast cancer 
cell line SK-BR-3 have shown the effectiveness of the system.  Hence, this work confirms 
that targeted PDT can be used successfully to treat breast cancer, decreasing, or eliminating 
the related cytotoxicity to chemotherapy, a great step forward. 
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6.1. Introduction 
PHAs, although extremely useful in various biomedical applications intended for long-term 
implantation, often fall short in applications that specifically require a shorter period of 
degradation. In addition, PHAs are quite hydrophobic and in applications requiring 
hydrophilicity, this can prove to be a disadvantage. Further, development of amphiphilic 
PHAs that can solubilize in water, while maintaining the presence of hydrophobic domains 
would be useful for drug delivery applications since such amphiphilic structures are known 
to self-assemble in to micelle like structures with the suitable active factors entrapped 
within. Several strategies have been reported, most prominent of which are 
functionalization and grafting. Functionalization involves processes such as 
transesterification, carboxylation, and sulphonation (Hazer, 2010). Melts or solutions of 
PHAs when treated with alcohols exchange ester groups to result in diols. Catalysed 
transesterifications can produce telechelic P(3HB) with insignificant amphiphilic properties 
such as the diol moieties are too short in comparison with the long hydrophobic chains. 
However, these can be used in the synthesis of polyurethanes via diisocyanate chain 
extension reaction, with any chosen aliphatic polyesters as soft segments (Hazer, 2010). 
Unsaturated PHAs such as Poly(3-hydroxy octanoate-co-10-undecenoate), PHOU, have 
been reported to be oxidized to diols and carboxylic acids due to the presence of 
unsaturated pendant groups. The resulting diols were found to be soluble in polar solvents 
(Hazer, 2010).  Saturated PHAs such as P(3HB) were also reported to have been made water 
wettable by subjecting to carboxyl ion incorporation. Graft polymerisation with hydrophilic 
molecules such as chitosan, cellulose and PEG are gaining momentum, but the prospects 
of these are limited by their exogeneity to the human body, particularly within the context 
of biomedical applications.  
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Hyaluronic acid is a ubiquitous polysaccharide, naturally occurring in various species. It is a 
polymer of D-glucuronic acid and N-acetyl-D-glucosamine disaccharide with molecular 
mass as high as 10 MDa, which helps in the polymer’s various functions such as maintaining 
the viscoelasticity of liquid connective tissue, control of tissue hydration, water transport, 
proteoglycan organization in the extracellular matrix (ECM), tissue repair and various 
receptor-mediated functions in cell detachment, tumour development and inflammation 
(Mero and Campisi 2014). These reasons render hyaluronic acids excellent building blocks 
for a variety of biodegradable and biocompatible structures such as hydrogels, self-
assembly micelles, in- situ injections, in biomedical applications, especially drug delivery. 
HAylation is a common strategy adopted in many delivery systems such as protein delivery, 
anticancer drug delivery and anti-inflammatory drug delivery. Hyaluron binding protein vis-
à-vis, CD-44, RHAMM, LYVE-1, IVd4 and LEC receptors have been investigated within the 
context of HA mediated anticancer drug delivery. HA’s biodegradability, biocompatibility, 
increased drug loading capacity, water solubility and receptor mediated endocytosis makes 
it an ideal candidate as carriers. Synthesis of amphiphilic HA have been previously 
attempted and reported in several investigations, however, the process is not 
straightforward from a synthetic point of view. This is mainly due to the lack of availability 
of common working solvents. Most of the research focused on the synthesis of amphiphilic 
HA conjugates have exploited the carboxylic group of HA, which unfortunately is the CD44 
receptor binding site. This has serious implications in hampering the ability of the 
molecule’s inherent binding with tumour cells, which otherwise can exploit the increased 
permeability and retention property presented by cancer tissues. Furthermore, the 
strategy of grafting at the hydroxyl moiety, which has been reported with the use of 
aliphatic polyesters such as PCL, PLGA and PEG, although provided slower clearance from 
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biological systems, still did not manage to achieve desired biocompatibility due to their 
exogenous origin (Mero and Campisi 2014).  
In this study, hydrophilic HA and hydrophobic P(3HB), both of which are of natural origin, 
were used to produce an amphiphilic graft polymer. Hydrolysed P(3HB) was used to 
conjugate with HA, in a DMSO solution. A variety of lengths of the hydrolysed polymer were 
used to obtain the best optimised conjugate and these were well characterised at Contipro 
a.s. and University of Westminster. The polymer thus produced was used to optimise the 
production of amphiphilic microspheres with encapsulated drugs (hydrophilic drugs Aspirin 
and gentamicin and hydrophobic drug curcumin). The degradation profile, and release 
kinetics of the drugs were studied.  
Curcumin is a natural derivative from turmeric and has been implied to have several 
anticancer, anti- inflammatory and antibacterial properties. To date, a wide range of 
researches advertising antibacterial properties of curcumin against various spectra of 
bacteria such as Staphylococcus aureus, Trichophyton gypseum, Salmonella paratyphi, and 
Mycobacterium tuberculosis have been published (Teow et al., 2016). However, native 
curcumin has low solubility and requires much higher doses of administration. This section 
describes the study of P(3HB)-HA conjugate microspheres with encapsulated curcumin and 
their antibacterial activity against (MRSA). 
6.2. Results 
P(3HB) was subjected to hydrolytic depolymerisation to varying lengths of time in 
concentrated acetic acid to produce hydrolysed polymers of low molecular weight (carried 
out by Dr. Rinat Nigmatullin). The conjugate was synthesised using a 93:7% molar ratio of 
HA to OligoHB (Carried out by Contipo a.s.).  
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6.2.1. Optimisation of microsphere production 
The amphiphilic polymer this produced was used for the production of microspheres. 
Microsphere production using an inverse emulsion crosslinking method in water-in-oil 
(w/o) dispersion was optimised as described in section 2.2.7.2. The conditions employed in 










1 0.01 Ethyl acetate Nil Nil Did not yield spheres 
2 0.05 Ethyl acetate Nil Nil Did not yield spheres 
3 0.01 Ethyl acetate Nil GST Did not yield spheres 
4 0.01 Ethyl acetate Span 80 GST Did not yield spheres 
5 0.01 Paraffin oil / 
Petroleum 
ether 
Tween 80 GST Spheres visibility 
dispersed, but on drying 
became too clumped to 
a jelly consistency 
6 0.01 Paraffin oil/ 
Petroleum 
ether 
Span 80 (1% 
v/v) 
GST Spheres visibly 
dispersed, but on drying 
attained a jelly 
consistency 




dispersed, but on drying 
attained a jelly 
consistency 
8 0.01 Paraffin oil 1% Span 80 1% 
Glutaraldehyd
e 
Could not separate oil 
from microspheres 
9 0.01 Paraffin oil Span 80 
(0.1% v/v) 
Heat Formed spheres 
10 0.01 Paraffin oil Span 80 
(0.1% v/v) 
GST Formed spheres 
 
   Table 6.1: Optimization of microspheres using P(3HB)- HA conjugate 
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6.2.2. Analysis of surface morphology and particle size distribution 
The surface morphology of the microspheres was observed under scanning electron 
microscopy. It was found that, an increased concentration of the surfactant (1% v/v) as per 
experiment number 8, yielded in microspheres of smaller size range (1-5 m). However, 
these were too clumped together and were not responsive to washing, to remove excessive 
oil, with any of the three solvents (Figure 6.1). 
 
Figure 6.1: P(3HB)-HA microspheres prepared under conditions corresponding to 
experiment number 8, washed with a) water only, b) hexane, c) petroleum ether and d) 
isopropanol (size bar= 10 m)  
 
Experiment number 9 and 10 resulted in larger microspheres of the range 15- 30 m. 
However, the heat crosslinked microspheres were found to be unstable at room 
temperature, after 6 hours. The GST crosslinked microspheres had smooth surface 
sphericity and was found to be present with surface residual paraffin oil (Figure 6.2).  
 
Figure 6.2: SEM images of P(3HB)-HA microspheres prepared under conditions 
corresponding to experiment number 10 
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These were washed with hexane, petroleum ether and isopropanol respectively. It was 
observed that, without washing the microspheres formed were lumpy and lacked 
sphericity (Figure 4). Washing with hexane and petroleum ether did not result in 
appreciable results and continuous washing resulted in the disintegration of microspheres. 
The microspheres washed with isopropanol, which was found to be effectively devoid of 
the oil, without compromising the structure of the microspheres. 4 washes with 
isopropanol, was found to completely remove the appearance of oil on the surface of 
microspheres (Figure 6.3). The spheres were smooth and porous.  
 
Figure 6.3: P(3HB)-HA microspheres a) not washed with isopropanol b) washed twice 
with isopropanol and c) washed 4 times with isopropanol (size bar= 100 m). 
 
The microspheres produced were within the size range of 15-30 m and exhibited 
increased polydispersity compared to P(3HB) microspheres (Figure 6.4).  
 
Figure 6.4: Particle size distribution of P(3HB)-HA microspheres 
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The average size of microspheres was found to be 22.9 ± 3.2 m. 
6.2.3. Characterisation of P(3HB)- HA microspheres 
6.2.3.1. FTIR 
FTIR spectra of P(3HB)-HA microspheres showed peaks characteristic to HA published in 
literature (Figure 6.5).  
 
Figure 6.5: FTIR spectra of P(3HB)- HA microspheres 
 
The spectra showed several sharp peaks (cm-1) such as at 600.37and at 1041.3 that could 
be due to the C-O-C stretching, at 1407.86 that corresponds to the presence of C-O group 
with C=O combination, at 1606.06 that indicates the presence of amide II group, at 2885.26 
due to the C-H stretching and at 3306.6 that confirms the presence of OH stretching (Reddy 
and Karunakaran 2013). 
6.2.3.2. Swelling studies at different pH 
Swelling studies were conducted by immersing P(3HB)-HA microspheres in phosphate 
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buffer saline of pH 6, 6.8, 7.4 and 10 for a period of 9 days. The degree of swelling was 
found to increase corresponding to increase in pH (Figure 6.6). It was found that with an 
increase in pH from 6 to 10, the maximum swelling ratio increased from 198 to 216%. In all 
the cases, there was an exponential increase in swelling up to day 3, and the swelling was 
found to plateau from that point onwards. The PBS solution containing the microspheres 
had seemed to appear cloudy by this point, with the appearance of structural disintegration 
in the microspheres.  
 
Figure 6.6: Swelling studies of P(3HB)-HA microspheres at different pH values 
 
6.2.4. Hydrophilic drug encapsulation 
2 hydrophilic agents namely aspirin and gentamycin were encapsulated in P(3HB)-HA 
microspheres. These were dispersed in the water phase and homogenised, before being 
emulsified in paraffin oil. The microspheres thus produced were characterised for surface 
morphology, particle size distribution, and microsphere yield and encapsulation efficiency. 
The microspheres produced were of good sphericity, smooth surfaced and porous (Figure 
6.7).  
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Figure 6.7: P(3HB)-HA microspheres encapsulated with a) Aspirin, b) Gentamycin (Size 
bar=100 m) 
 
The FTIR spectra of all the drug encapsulated microspheres resembled that of the controls 
and did not exhibit any significant peaks indicative of the presence of the drug. A 







Aspirin 70.36 19.01 71.34 
Gentamycin 79.38 20.61 82.4 
Table 6.2: Comparison of P(3HB)-HA microspheres encapsulated with Aspirin and 
Gentamycin. 
 
Gentamycin encapsulated microspheres had the highest yield (79.38%), in comparison with 
the other two. The particle size was not found to vary significantly amongst the three 
samples, however, gentamycin encapsulated microspheres were found to be the largest. 
Encapsulation efficiency of Gentamycin in the microspheres were found to be significantly 
higher, in comparison with Aspirin (71.34%). 
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6.2.5. Drug release kinetics 
P(3HB)- HA microspheres encapsulated with the two drugs were immersed in PBS solution 
and incubated at 37oC. Samples were drawn periodically, and cumulative release was 
analysed according to methods described in Chapter 2.  
 
Figure 6.8: Drug release profile of a) Aspirin and b) Gentamycin encapsulated in 
P(3HB)- HA microspheres  
 
Both the microsphere samples exhibited an initial burst release (Figure 6.8). Aspirin and 
gentamycin encapsulated microspheres exhibited a burst release up to 48 hours and 
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followed by a slower rate up to day 11. 46.36% Aspirin and 48.37% gentamycin were 
released by 48 hours. The microspheres underwent complete disintegration by day 11 in 
both the cases.  
6.2.6. Hydrophobic drug encapsulation 
Curcumin was added to the oil phase- paraffin oil containing span 80, and the P(3HB)- HA 
solution was added to this. The microspheres thus produced were characterised for surface 
morphology, particle size distribution, yield and encapsulation efficiency. The microspheres 
produced were of good sphericity, smooth surfaced and porous (Figure 6.9).  
 
Figure 6.9: P(3HB)- HA microspheres encapsulated with curcumin 
 
The FTIR spectra of all the drug encapsulated microspheres resembled as that of the 
controls and did not exhibit any significant peaks indicative of drug conjugation. Curcumin 
encapsulated microspheres were of the size range 17.91 m, and thus were found to be 
smaller than the microspheres encapsulated with hydrophilic drugs. Microsphere yield was 
74.38%. In comparison with hydrophilic drugs, curcumin was encapsulated to a lesser 
amount within P(3HB)- HA microspheres (67.37%).  
6.2.7. Drug release kinetics 
P(3HB)- HA microspheres encapsulated with the curcumin were immersed in PBS solution 
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and incubated at 37oC. Samples were drawn periodically, and cumulative release was 
analysed according to methods described in Chapter 2. Curcumin had a sharp burst release 
within 12 hours, amounting to 44.27%. Curcumin release proceeded up to 13 days, after an 
initial period of rapid release after which the rate fell and thereafter continued to slowly 
decay. (Figure 6.10).  
 
Figure 6.10: Release profile of curcumin from P(3HB)-HA microspheres 
 
6.2.8. Comparison of drug release profiles 
The release data was fitted in models as described in section 2.2.11. R2 value of each of the 
linear regression was compared. A clear difference in release profile was observed between 
the hydrophilic drugs (aspirin and gentamicin). The release profile of aspirin and gentamicin 
was found to fit well with Higuchi model with 98.6 and 99.5% correlation. Curcumin release 
on the other hand was found to follow first- order kinetics, indicating the release was 
dependent on the initial concentration. The release exponent of both aspirin and 
gentamicin was found to correspond to anomalous non- Fickian diffusion, indicating matrix 
degradation and diffusion as contributing parameters. The microspheres underwent 
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complete degradation in 11 days and this corroborates the fit of the release data to 
Korsmeyer- Peppas.  
 
Table 6.3: Summary of model fitting for drug release from free P(3HB)- HA 
microspheres. 
 
6.2.9. Antibacterial activity of Curcumin 
6.2.9.1. Growth inhibition 
Growth inhibition of MRSA was compared using 1mg/mL, 0.5 mg/ml and 0.25 mg/mL of 
free curcumin and encapsulated curcumin for 18 and 36 hours (Figure 6.11). Encapsulation 
was found to increase the antibacterial effect of curcumin in all the cases. While at 18 
Model Parameters Aspirin Gentamicin Curcumin
R2 0.941 0.938 0.767
Adj- R2 0.937 0.934 0.751
Slope 0.943 0.938 0.767
SSR 1130.76 1106.63 2789.34
R2 0.880 0.927 0.960
Adj- R2 0.872 0.922 0.958
Slope -0.0051 -0.0046 -0.0032
SSR 0.514 0.244 0.064
R2 0.986 0.995 0.925
Adj- R2 0.985 0.995 0.920
Slope 6.20 5.99 4.74
SSR 268.79 84.65 898.77
R2 0.982 0.989 0.911
Adj- R2 0.981 0.988 0.904
Slope -0.0109 -0.0103 -0.0077
SSR 0.319 0.174 0.867
R2 0.982 0.993 0.946
Adj- R2 0.980 0.992 0.942
Slope 0.689 0.624 0.300
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hours, 0.25 and 0.5 mg/mL of free curcumin inhibited 33.2% and 42.39% of bacterial 
growth, 1 mg/mL inhibited 56.71%. at 18 hours, 0.25mg/mL, 0.5mg/mL and 1mg/mL 
curcumin encapsulated in P(3HB)-HA microspheres inhibited 42.39%, 42.39% and 57.28% 
respectively in comparison with bacteria grown in culture media. A similar trend was 
observed at 36 hours, with 1 mg/mL of encapsulated curcumin inhibiting 96.21% of 
bacterial growth while the same concentration of free curcumin inhibiting 91.2% bacterial 
growth.  
 
Figure 6.11: MRSA inhibition of free and encapsulated curcumin (**p<0.05) (n=3, 
error=± s.d). 
 
6.2.9.2. Quantification of Minimum inhibitory concentration (MIC) 
An overnight culture of MRSA of equal dilution was used to carry out MIC analysis. Empty 
P(3HB)-HA microspheres were used as controls. From the encapsulation efficiency of 
curcumin in P(3HB)-HA microspheres, 100 μL of various dilutions of the microspheres (500, 
250,125, 62.5, 31.25, 16, 8, 4, 2, 1 μg /mL of curcumin respectively) were prepared. These 
were incubated with 100 ml of overnight culture of MRSA. The tubes were incubated at 37 
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oC for 24 hours. After the incubation period, the OD of each of the wells were recorded and 
compared with controls. MIC of curcumin encapsulated microspheres were found to be 
93.75 μg/mL.  
6.3. Discussion  
HA is a naturally occurring glycosaminoglycan with high biocompatibility, as it is inherently 
present in ECM, cartilage matter and synovial fluid of most animals (Yun et al., 2004). A 
water in oil emulsion was used for the preparation of P(3HB)-HA microspheres, with 
glutaraldehyde as the cross-linking agent. The surface morphology of the microspheres 
prepared using this optimised technique was found to be smooth surfaced, spherical with 
low polydispersity. These appeared to be morphologically superior than some formulations 
that were prepared using spray drying (Fatnassi et al., 2014). The process optimisation of 
P(3HB)-HA microsphere production was successfully achieved with Paraffin as the oil phase 
and in the presence of Span 80 surfactant. It was found that a surfactant concentration of 
(1% v/v) resulted in microspheres of smaller size (less than 5 m), where as a surfactant 
concentration of 0.1% v/v resulted in microspheres of average size (22.9 m). This is similar 
to the observation made in the case of P(3HB) microspheres. An increased concentration 
of surfactant resulted in an increased proximity of water and oil interphase, which results 
in smaller micelles (Maia et al., 2004). However, the viscosity of the emulsion was found to 
be too high in the case of an emulsion with higher concentration of surfactants and resulted 
in microspheres that had an excessive deposition of paraffin oil on the surface. Due to this 
reason, a lower surfactant concentration was used in the preparation of microspheres in 
this work. Span 80 is reported to be the most commonly used surfactant in DDS 
formulations involving HA (Qiu et al., 2016; Ma et al., 2015).  
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Three different solvents namely hexane, petroleum ether and isopropanol were used to 
wash the excessive amount of paraffin oil present on the surface. Of these, isopropanol 
was found to be the most effective in washing off the paraffin oil and span 80 from the 
surface of microspheres, while not compromising the structural integrity of the 
microspheres. Isopropanol is commonly used as surgical spirit and is a good solvent for 
paraffin oil. 
HA microspheres synthesised with 1 v/v% of Span 80 were found to be in the size range of 
6-20 m in a study intended for sustained gene delivery and targeting (Yun et al., 2004). 
Here, the preparation strategy involved the use of adipic dihydrazide as a cross linking 
agent, for 24 hours during the last stage of preparation. Comparing these with the 
preparation strategy employed in the case of P(3HB)-HA microspheres in this work, it can 
be concluded that the latter produced microspheres of a smaller size distribution. Yun et 
al., reported that these microspheres were washed three times with isopropanol and were 
found to appear well separated from one another with no occurrence of residual paraffin 
oil on the surface, corroborating the results obtained in this work (Yun et al., 2004). Ma et 
al., in a similar study describe the synthesis of HA- chitosan microspheres in the context of 
controlled-release of cytokine response modifier A for osteoarthritis (Ma et al., 2015). 
Sodium tripolyphosphate, a commonly used crosslinker was used here, as the mass ratio of 
chitosan dominated in the preparation (2g chitosan and 0.1g HA). With the addition of 10 
w/v% of the cross- linking agent, microspheres of 8-15 m diameter were obtained. 
However, these were washed with acetone to remove residual oil and this method was not 
found to be entirely successful as the SEM images revealed the presence of surface 
deposition of oil residues (Ma et al., 2015). 
Chemical characterisation of the microspheres carried out by FTIR revealed spectra 
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resembling that of standard HA, with no significant peak corresponding to P(3HB). This may 
have been due to the comparatively lower molar proportion (93:7) of P(3HB) in the 
conjugate. The case remained the same in all encapsulated microspheres, indicating that 
the drug encapsulation did not bring about any chemical changes in the structure of the 
conjugate. The FTIR spectra analysed in this study is comparable to standard HA spectra 
published in literature (Reddy and Karunakaran 2013). 
With drug encapsulation, it was found that hydrophilic drug containing microspheres were 
larger (~20 m) than those containing a hydrophobic drug (~17 m). This is probably due 
to the fact that, hydrophilic drug moieties have better affinity for HA, and the a more 
concentrated and viscous emulsion interphase was formed in this case. This increased 
affinity was found to influence drug encapsulation efficiency as well, since the hydrophilic 
drugs were found to have higher encapsulation interphase (aspirin: 71.34%, and 
gentamycin 82.4%) as opposed to the hydrophobic drug (curcumin 67.37%).  
Encapsulation efficiency of the hydrophilic drugs appeared to be influenced by their 
solubility in water, as gentamycin with a higher solubility (50 mg/mL) had significantly 
higher encapsulation efficiency in comparison with aspirin with a lower solubility (3 
mg/mL). An aspect to be improved in the case of P(3HB)- HA microspheres examined here 
would be the extent of burst release. Although comparable with published literature on 
controlled release from HA microspheres (Yun et al., 2004; Mero and Campisi, 2014; Qiu et 
al., 2016), a strategy to minimise burst release would be desirable here. In the case of 
hydrophilic drugs, all the three microsphere samples exhibited a burst release. 
Microspheres with encapsulated aspirin and gentamycin exhibited a burst release of up to 
48 hours and followed a steady release up to day 11. 46.36% aspirin and 48.37% 
gentamycin were released within 48 hours. The microspheres underwent complete 
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disintegration by day 11 in both the cases. In spite of the burst release, there appeared to 
be a linear and controlled release of these drugs after the burst release. This is possibly due 
to the swelling behaviour of these microspheres, as they to absorbed about 200% more 
water than their weight, in 3 days. This influx of water may have resulted in the dissolution 
of a large amount of drug, resulting in burst release. This study has demonstrated the 
controllability of swelling behaviour at different pH. The varied behaviour exhibits a 
potential to further fine tune the swelling behaviour with different stimuli and thereby 
control release. In all the cases, the drug release profile from the point of burst release was 
found to be of zero order, with an R2 value close to 1. This suggests the plausibility of fine 
tuning these microspheres for better control, with interventions to avoid burst release. 
Aspirin and gentamycin being antimicrobial, P(3HB)- HA microspheres containing these 
agents have potential application in wound healing and post -operative care.  
Finally, encapsulation of curcumin in P(3HB)-HA microspheres was examined. In 
comparison with the hydrophilic drugs, curcumin exhibited a lower encapsulation 
efficiency in P(3HB)-HA microspheres (67.37%). An interesting observation made with 
reference to the release kinetics was the reduced window of burst release period. Here, 
burst release was limited to 12 hours, suggesting that the release of curcumin is dependent 
on the disintegration of the microspheres and increased solubility of curcumin rendered by 
the presence of HA. Just water influx does not have a direct correlation to curcumin release 
since curcumin is hydrophobic in nature and would interact relatively strongly with the 
P(3HB), a hydrophobic polymer.  Hence, the burst release was not extended to 48 hours or 
more.  There are very few reported studies on encapsulation of hydrophobic moieties in 
HA, due to the inherent hydrophilic nature of HA. However, there are instances of coating 
hydrophobic pulmonary drugs with HA for enhanced mucosal adhesion (Byron and Patton, 
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2007). The encapsulation efficiency of curcumin achieved here is reasonable and this is due 
to the presence of hydrophobic P(3HB) pockets in the conjugate, with increased affinity to 
hydrophobic curcumin, a great advantage. Hence, this is the first ever report of 
encapsulation of a hydrophobic drug in a HA based drug delivery system. Curcumin is an 
interesting molecule in various therapeutic contexts such as anti- inflammatory, 
anticancerous, and antimicrobial (Teow et al. 2016; Bansal et al., 2011). Here, the 
antimicrobial effects of curcumin against MRSA were examined. MRSA is a widespread 
infective agent, and post-operative MRSA infections are increasing at an alarming rate. As 
new resistant strains of potent pathogens arise under antibiotic selection pressure, 
curcumin, that has been reported to be obliterating methicillin resistance in S. aureus has 
tremendous potential (Mun et al., 2013). In this study, the curcumin encapsulated P(3HB)- 
HA microspheres were found to be more efficient in killing MRSA in comparison with free 
curcumin and this increase was statistically significant. All these results indicate the huge 
potential of P(3HB)-HA microspheres in drug delivery, especially in the context of 
antimicrobials.  
The drug release of aspirin, gentamicin, and curcumin from P(3HB)- HA microspheres were 
compared and fitted to the five models as mentioned before. The release of hydrophilic 
drugs was found to fit better with Higuchi model, where as that of the hydrophobic drug 
was found to fit better with first- order kinetics. The release exponents in the case of 
hydrophilic drugs were found to indicate anomalous non- Fickian mode of mass transfer 
where both diffusion and degradation of the polymer matrix influence mass transfer.  This 
can be true considering the entire sample disintegrated within 11 days.    However, in the 
case of curcumin, the slower release must have been a result of the poor solubility of the 
drug.  Good fit of all the three-release data gives insight into the swellable nature of the 
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polymer, as indicated in section 6.2.3.2. 
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7.1. Conclusions 
P(3HB) particulate drug delivery systems established and characterised in this research 
have the potential in the controlled and sustained delivery of various therapeutic agents. 
There is a growing need for reproducible and controllable drug delivery systems, 
considering the lengthy and costly process of drug development.  P(3HB) is a short chain 
length variety of PHA which has specifically been recognised for its potential to form DDS. 
In the first part of this study the solid-in-oil-in-water technique was used to optimise 
production of P(3HB) microspheres a response surface methodology based on the Box 
Behnken design.  Through statistical optimisation, it has been possible to develop a 
mathematical model for the synthesis of P(3HB) microspheres. The model was validated 
within 95% confidential interval. Along with other contributing parameters such as PVA 
concentration and stirrer speed, polymer concentration was found to be the most 
important variable in determining particles size. Microspheres in a size range of 25-45 m 
were produced with experiments run under a set of 15 randomized trials.  The results of 
these optimisation experiments were used to tailor micro and nanospheres of different size 
ranges and these were characterised for their size distribution, porosity, amount of surface 
residual surfactant and hydrophobicity. Spheres of 5 distinct average diameters (118 ± 12.3 
nm, 728 ± 32. 96 nm, 1.6 ± 0.13 μm, 9.8 ± 2.18μm and 22.83 ± 1.21 μm) were produced 
under varying process parameters. P(3HB) produced from different producer organisms (B. 
cereus SPV and B. subtilis OK2) were found to be of different molecular weight (~150 and 
850 kDa respectively) and therefore, when processed under the same conditions resulted 
in nanospheres of varying morphology and diameter.  
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P(3HB) micro and nanospheres with encapsulated therapeutic agents relevant in 
cardiovascular diseases were developed, for potential incorporation in drug eluting 
biodegradable stents. P(3HB) and PLLA microspheres with encapsulated rapamycin was 
compared with respect to their characteristics such as size distribution, porosity, 
hydrophobicity, encapsulation efficiency and drug release kinetics. PLLA microspheres 
formed were smaller than (average diameter 2.98 m) P(3HB) microspheres (average 
diameter 4.82 m). In both the cases, encapsulation efficiency was found to increase with 
drug loading.  P(3HB) microspheres were more suitable for applications as their 
degradation products were found to be less acidic than that of PLLA microspheres. Drug 
release rate from P(3HB) microspheres were found to be slightly faster than PLLA 
microspheres. In both the cases, an initial burst release for 48 hours was observed. In all 
the 4 preparations, the release data was found to be more fitting to Higuchi model, 
indicating diffusion as the mode of mass transfer. The release exponent indicated that the 
release followed Fickian mode of diffusion. 
 Tacrolimus encapsulated micro and nanospheres of P(3HB) were compared, to analyse 
drug encapsulation and release kinetics with respect to size of the spheres. P(3HB) 
microspheres were found to have increased encapsulation efficiency in comparison with 
P(3HB) nanospheres. In the case of microspheres, encapsulation efficiency increased from 
61.2 ± 4.18% to 69.8 ± 1.9% and 72.3 ± 2.21% between 1 wt%, 5 wt% and 10 wt% tacrolimus 
loading respectively. In the case of nanospheres, this was 59.8 ± 2.1%, 62.3 ± 2.01% and 
65.8 ± 1.54% respectively. Nanospheres were found to exhibit a faster release rate, in 
comparison with microspheres. Both P(3HB) nanospheres and microspheres maintained a 
sustained release of tacrolimus for 30 days, with a cumulative release of 71.2%, 73.1% and 
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76.2% from nanospheres encapsulated with 1 wt%, 5 wt% and 10 wt% tacrolimus. In the 
case of microspheres, this was 68.12, 70.37 and 72.3% respectively. Here again, drug 
release was found to fit well with Higuchi model, suggesting diffusion as the reason for 
mass transfer.  
Vascular Endothelial Growth Factor (VEGF), commonly used in the context of 
cardiovascular regeneration, was encapsulated within P(3HB) micro and nanospheres and 
were embedded in collagen scaffolds. P(3HB) spheres of 3 different size ranges were 
considered for immobilization on collagen scaffolds. Nanospheres of a size range 500-900 
nm were well incorporated in the scaffold with a uniform distribution. Microspheres of the 
size range 5-15 m were also satisfactorily incorporated in the scaffolds whereas 
microspheres of the size range 20- 30 m formed clumped structures in the scaffold, and 
therefore were not considered for further studies. A cumulative release of 98.23 ± 1.98% 
was achieved from VEGF encapsulated microspheres whereas a cumulative release of 
94.12 ± 1.21% was achieved from VEGF encapsulated nanospheres. The differences in 
release of VEGF from spheres embedded and not embedded in the collagen scaffold were 
quantified and it was established that embedding in the scaffolds reduced burst release. In 
all these cases mentioned above an initial burst release up to 48 hours was observed. All 
the four formulations were able to sustain release of VEGF for more than 30 days, implying 
the potential of these in controlled delivery, with relevance in cardiac regeneration. The 
release data was found to be most fitting with first- order release for all the four 
preparations with 99% correlation, except free microspheres with encapsulated VEGF (R2= 
0.956 for first- order). This means, the drug release was dependent on the concentration 
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of drug. The data for free microspheres was found to fit better with the Hixson- Crowell 
model, with 98.3 % correlation. 
P(3HB) microspheres were developed as novel anti- cancer target specific photodynamic 
drug delivery systems. 3 different derivatives of porphyrin, a well- studied photosensitizer 
molecule in the context of photodynamic therapy, was encapsulated in P(3HB) 
microspheres. The optimization process followed by photosensitizer encapsulation showed 
that polymer-drug interaction is one of the main parameters to be taken into account in 
drug encapsulation. 2.5 wt%, 5wt% and 10wt% drug loadings of PP, HP and TPP were 
successfully encapsulated in microspheres of size ~10-20μm. The encapsulation efficiency 
of 10wt% TPP was found to be the highest (87.8%). The encapsulation efficiencies were 
found to be desirably high, within a range of ~60-90%. It is generally agreed that 
hydrophobic drug molecules better entrap in hydrophobic polymer matrices.  
Encapsulation efficiency increased with increased drug loading in each case and was found 
to be the highest for 10wt% drug loading, in each case. TPP encapsulated microspheres had 
the highest encapsulation efficiency, followed by HP and PP. This pattern was reflected in 
their ability to induce photodynamic damage, quantified by cytotoxicity estimations. 10 
wt% drug loading of each porphyrin derivative was chosen to be incorporated with anti-
HER-2 antibody, to aid in target specific delivery. An increase in cytotoxic effects was 
observed in antibody linked microspheres in the case of TPP. P(3HB) microspheres with 10 
wt% loading of TPP, in conjugation with anti-HER-2 was found to be the most potent in 
inducing cytotoxicity. IC50 of this formulation was quantified 9M. The results obtained 
from this study affirms the ability of P(3HB) microspheres encapsulated with porphyrin 
derivatives in conjugation with target specific antibody to evoke cellular stress. All these 
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findings promise the development of a novel Photoimmunotargeting drug delivery system 
based on the biodegradable polymer P(3HB).  
P(3HB) is a crystalline, hydrophobic polymer and degrades through surface erosion. There 
are applications that necessitate drug delivery systems that can retain moisture (especially 
in the context of wound healing) and a quicker release of drug moieties. Bearing this 
requirement in mind, a conjugate of P(3HB) with hyaluronic acid (HA) was synthesised by 
Contipro a.s. and the final part of this study examined the optimisation of microsphere 
synthesis using these conjugates. As this conjugate was amphiphilic, a water in oil emulsion, 
coupled with crosslinking was employed for the synthesis process. Microspheres of ~20 m 
diameter were synthesised, and hydrophilic and hydrophobic drugs were encapsulated 
within them. The microspheres were found to be fast degrading, maintaining their 
structure up to a maximum of 11 days. The drug release kinetics from these showed an 
increased burst release compared to P(3HB) microspheres. The hydrophilic drugs (aspirin 
and gentamicin) were release from these conjugate microspheres following Higuchi model, 
whereas the hydrophobic drug (curcumin) followed first-order.
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8.1. Future work  
The results obtained in this study with regards to the potential of P(3HB) in formulating 
DDS have been promising. However, there are areas that need further exploration and 
improvement. 
8.1.1. Statistical optimisation of preparation of nanospheres using 
P(3HB) from different producer organisms 
The metabolic pool of each microorganism varies and hence the polymer produced by each 
of them differ in molecular weight. This particular study successfully optimised preparation 
of P(3HB) microspheres using different molecular weight polymers. In the future, a similar 
study can be extended to the statistical optimisation of the synthesis of nanospheres, 
incorporating molecular weight as an independent variable. 
8.1.2. Characterization of microspheres and nanospheres 
Throughout this study, there are parameters and effects that can be better understood in 
the light of zeta potential analysis of the microspheres and nanospheres. This can elucidate 
behaviours of spheres such as aggregation, protein adsorption and drug interactions. Also, 
drug polymer interactions could be better studied to be able to explain encapsulation 
efficiency and release kinetics.  
8.1.3. Cardiovascular drugs  
To test the efficacy of micro and nanospheres encapsulated with antiproliferative drugs on 
a cardiac cell line such as C2C12 is another direction that could be undertaken in the future.  
P(3HB) spheres encapsulated with VEGF are currently being implanted in small animal 
models. The VEGF incorporated in this study was VEGF-A and it has been suggested that 
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AdVEGF-B186 produces a better response than VEGF-A. Encapsulation and release kinetics 
of this form in P(3HB) microspheres have been attempted and, in the future, its release 
kinetics will be compared with release from microspheres embedded in collagen scaffolds. 
To test whether sterilization procedures compromise the stability of the VEGF and release 
kinetics will also be investigated both before and after sterilization.  
8.1.4. Photodynamic therapy 
To understand the mechanism of drug delivery, it is important to be able to identify the 
distribution DDS. Although this study was able to observe the effect of P(3HB) microspheres 
encapsulated with porphyrin derivatives on SK-BR-3, the location of microspheres (whether 
they have penetrated the cells or not) is yet to be elucidated. To achieve this SK-BR-3 cells 
treated with microspheres prepared under the same conditions, encapsulated with 
Rhodamine will be observed using confocal microscopy.  
8.1.5. P(3HB)- HA microspheres in wound healing  
A 3D printed wound healing patch incorporated with P(3HB)-HA microspheres can be 
achieved in the future. P(3HB) can be used to form a mesh like, layered structures, 
especially when blended with a more elastomeric PHA, in between which P(3HB)- HA 
microspheres with curcumin can be incorporated. This way, P(3HB) will provide the 
necessary mechanical strength and the amphiphilic microspheres can provide the moisture 
needed at the wound site and release the antibiotics.
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